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DNA-binding proteins use a combination of the following mechanisms to find their
DNA target sites: “hopping” or “jumping” along DNA (3D diffusion), intersegment
transfer, sliding (1D diffusion), and site-specific recognition. In particular, the process
of sliding is not well understood. It has been hypothesized that while sliding, proteins
are “loosely” associated with DNA via electrostatic interactions between cationic
residues on the protein and anionic phosphate groups on the DNA backbone. To test
this hypothesis, a biomimetic model of sliding was created in which the protein was
replaced with cationic particles and the DNA with anionic “linear” molecules. The
model system utilized in this dissertation was a nanoparticle-microtubule system.
Microtubules were chosen because like DNA, they are “linear”, negatively-charged
biopolymers. Using total internal reflection fluorescence microscopy (TIRFM), it was
found that aggregated cationic particles can slide along microtubules. Accordingly,
it was hypothesized that the roughened surface of the aggregates mimics the protein
conformation complementarity occurring in the cell, and that this complementarity
xiii
and the juxtaposition of cationic residues within the protein’s DNA binding pocket
are crucial to protein sliding.
Next, specific binding site recognition was incorporated into the model based on
paclitaxel. Paclitaxel is known to bind microtubules and hyperstabilize them. For
this cytotoxic property, it is marketed as an anti-cancer drug, although it causes
detrimental side effects due to its water insolubility and promiscuity. Accordingly,
testing the microtubule binding properties of the paclitaxel-conjugated nanoparti-
cles was of interest. Using TIRFM and transmission electron microscopy (TEM), it
was found that paclitaxel-conjugated G5 PAMAM dendrimers affect microtubules by:
(1) promoting polymerization; (2) stabilizing microtubules; and (3) bundling micro-
tubules. The latter is independent of paclitaxel and due instead to a combination of
electrostatic interactions involving protonatable amines in the dendrimer core, and
hydrophobic interactions between the fluorescent labels on the dendrimer (Cy5) and
tubulin (TMR). These results warrant further investigation into the toxicity of the
cationic dendrimer core before further consideration as paclitaxel delivery platforms.
Finally, it is demonstrated that paclitaxel-conjugated gold nanoparticles also show
promise as targeted delivery platforms as they polymerize, stabilize, and bundle mi-
crotubules in a paclitaxel-dependent manner.
xiv
CHAPTER I
A Journey Towards Modeling Protein Sliding
Along DNA: A Logical Detour into Microtubules
as Drug Targets
1.1 Introduction
DNA-binding proteins play important roles in regulating and driving gene ex-
pression, a crucial cellular function. In the cell, it is often necessary for the level of
RNA or protein expression to be quickly altered, requiring DNA-binding proteins to
rapidly locate their specific binding (target) sites. However, this is no trivial task for
the protein. Consider a human cell, which packs ≈ 3 billion base pairs (≈ 1 m of
linear DNA)1 into a nucleus which is on the order of 10 µm in diameter.2 In contrast,
a protein’s DNA target site is on the scale of nanometers, which creates daunting
thermodynamic and kinetic challenges for the protein to overcome while locating its
target site.
Given that proteins are able to locate their target sites in vivo 100 times faster
than the diffusion limit predicted by theory (this prediction reflects only the time
taken to arrive at the target site, not recognize it; recognition would take even more
time), and 1000 times faster than the DNA-protein association rates measured in
vitro,3 it is apparent that DNA-binding proteins employ mechanisms other than
1
three-dimensional (3D) diffusion to locate their target sites. However, the exact
mechanisms employed by these proteins to rapidly locate their target sites are not
yet fully understood.
1.2 Target Site Search Mechanisms Employed by DNA-Binding
Proteins
DNA-binding proteins employ a combination of the following mechanisms to lo-
cate their target sites (Figure 1.1): hopping (3D diffusion: protein randomly collides
with DNA, dissociates if not at target site, and reassociates close by), jumping (3D
diffusion: same as hopping but reassociation is far from site of dissociation) interseg-
ment transfer (between segments of DNA brought close by looping, etc.), sliding (
one-dimensional (1D) diffusion), and finally, target site recognition.4–6 This disserta-
tion will focus on the mechanisms of sliding and target site recognition.
Sliding serves to increase the probability of the protein finding its target site by
restricting the normal 3D Brownian diffusion of the protein in the cytoplasm to one
dimension along the DNA. Consequently, this allows the protein to sample more
than one small area on the DNA each time it comes into contact with the DNA.
However, this 1D diffusion along DNA is not sufficiently fast for a single protein
to locate the target site quickly enough if rapid response times are required by the
cell.6 Accordingly, it has been hypothesized that the cell regulates the copy number
of proteins per cell based on the response time needed. Based on the copy number,
the proteins will either be more likely to locate their target site using 3D diffusion (if
the copy number is high), or 1D diffusion (if the copy number is low).7 This does not
imply that a protein will exclusively find its target search using one method based
on its copy number, only that the probability of the protein finding its target site











Figure 1.1: DNA target site search mechanisms employed by DNA-binding proteins
3
1D diffusion of various DNA-binding proteins has been observed using various
single-molecule microscopy techniques in vitro 8–12 as well as in vivo.13 However, it is
still not entirely understood how 1D diffusion occurs. In order for a DNA-binding
protein to diffuse in 1D along DNA, it must be associated with the DNA tightly
enough to sense the DNA bases, but loosely enough to move rapidly along the DNA.
This loose association is thought to be primarily mediated by electrostatic interactions
between cationic residues on the protein and anionic charges on the phosphates groups
of the DNA.14,15 In support of this hypothesis, it has been observed that an increase
in salt concentration correlates with a decrease in protein sliding in vitro.5,8,16,17 Once
the protein reaches its target site, it strongly interacts with the bases of the target
site that “match” residues in the protein’s DNA-binding site via hydrogen bonds,
hydrophobic interactions, and water-mediated interactions.18 By contrast to the salt
dependence of the non-specific interactions mediating sliding, target site recognition
is not significantly dependent on salt concentration.19,20
If sliding is indeed primarily mediated by electrostatics, then it should be possible
to synthetically model this process with charged components of the approximate size
and shape of the protein and DNA (Figure 1.2). If a cationic nanoparticle (acting
as the protein analog) is able to slide along an anionic nanoline (acting as the DNA
analog) at rates comparable to those observed for proteins sliding along DNA (see
for example8–12), this would be compelling evidence that the biological process of a
DNA-binding protein sliding along DNA is driven by electrostatics. Furthermore,
this would enable precise determination of the charge densities, sizes, and shapes of
the individual components required for sliding to occur. In addition, such artificial



































































Figure 1.2: Biomimetic model of DNA-binding proteins. DNA-binding proteins are
replaced with cationic nanoparticles of comparable size and DNA is re-
placed with anionic nanolines. A target site may also be engineered onto
the nanoline to study target site recognition.
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1.3 Steps Towards Modeling Protein Sliding Along DNA
While there are many examples of directed diffusion that exploit various chemical
and physical phenomena,22 no synthetic model of random diffusion driven entirely by
electrostatics has been demonstrated to date. Since developing an entirely synthetic
model is a considerable step above the entirely biological system, a logical first step
would be to replace either the protein or the DNA with a synthetic or biologic analog,
while using the natural biological form of the other component.
Nanoparticles are good candidates for protein mimics as their size, shape, charge
density, and other surface properties can be well controlled during synthesis. Both
inorganic23 and organic particles may be suitable for this function. For example,
the organic polymeric PAMAM dendrimers have already shown promise as mimics of
histones.24 While there are no known examples of electrostatically-driven nanoparticle
diffusion along DNA, there is, however, at least one demonstration in the literature of
electrostatically-driven nanoparticle diffusion along microtubules. This study shows
that polystyrene nanoparticles carrying high cationic surface charges are able to slide
along microtubules, and furthermore, the surface charge density affects the diffusion
coefficient and duration of microtuble interaction.25
Microtubules may be considered electrostatic analogs of DNA as both can be
reduced to negatively charged “linear” biopolymers (Figure 1.3). Due to their neg-
ative charge, microtubules would provide opportunities for electrostatic interactions
with cationic nanoparticles. However, as microtubules are composed of protein and
not nucleic acid, they would provide no specific DNA sequence information, making
it possible to study the effect of electrostatics on DNA-binding protein movement
independent of DNA sequence information.
Although DNA and microtubules are both approximately “linear” and negatively
charged, there are a few obvious structural and chemical differences that must be
considered. First, microtubules are much greater in diameter than DNA (Figure 1.3).
6
Therefore if cationic nanoparticles are able to slide along microtubules, they may
slide in a two-dimensional (2D) trajectory rather than a 1D trajectory. However, it
should be noted that DNA-binding proteins have also been observed to slide along
DNA in two dimensions when encountering obstacles on the DNA.26 Next, because
microtubules are cylindrical in structure and not helical, the nanoparticles will likely
not slide along the microtubules in a helical manner like proteins do along DNA.26–28
Finally, microtubules have a lower linear charge density than DNA by ≈ 24-fold.
In spite of these structural and chemical difference between microtubules and DNA,
an observation of nanoparticles (with cationic surface charge densities comparable
to DNA-binding proteins) sliding along microtubules (at rates comparable to 1D
diffusion coefficients of DNA-binding proteins sliding along DNA) would still support
the hypothesis that electrostatics play a significant role in protein sliding. While there
are many other options for biologic or synthetic analogs of both proteins and DNA,
this dissertation will focus on the utilization of nanoparticles as protein analogs, and
microtubules as DNA analogs.
1.4 Using Paclitaxel to Specifically Target Nanoparticles to
Microtubules
An important component of the search of DNA-binding proteins for their target
site on the DNA is the target site itself. Therefore, a complete model of protein
sliding would also incorporate a target site onto the DNA analog. As microtubules are
biological molecules, they contain natural target sites for other naturally occurring
molecules. Paclitaxel is one example of a naturally occurring microtubule binding
molecule. It is known to bind in a 1:1 ratio to the β-subunit of tubulin dimers in the
microtubule lumen (Figure 1.4).
Paclitaxel binding hyperstabilizes microtubules against depolymerization, which
7
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Figure 1.4: Microtubule polymerization, structure, and the paclitaxel binding sites on
β-tubulin. Paclitaxel can bind microtubules at a 1:1 ratio with tubulin
dimers, but is illustrated here at a lower concentration than the dimers.
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in vivo, arrests cell division, particularly of rapidly dividing cells.29 It is because of
these cytotoxic properties that paclitaxel is marketed as an anti-cancer drug (Taxol R©,
Bristol-Myers Squibb, New York, NY). Therefore, targeting nanoparticles to micro-
tubules with paclitaxel may also be of interest as a potential targeted drug delivery
strategy. Indeed there is great interest in developing a targeted delivery strategy for
paclitaxel. Paclitaxel has been proven a successful cancer drug on its own,29 however
it currently causes detrimental side effects in patients. This is partly due to the fact
that paclitaxel is poorly water soluble and consequentally, is currently solubilized in a
mixture of polyethoxylated castor oil and ethanol prior to injection into the patient.30
These toxic solubilizing agents, along with the promiscuous cytotoxicity of paclitaxel
and the fact that it has a high binding affinity for plasma proteins, are reasons that
paclitaxel causes detrimental side effects and decreased drug efficiency.30 Accordingly,
numerous targeted delivery strategies for paclitaxel that aim to overcome its limita-
tions are currently being explored experimentally and in clinical trials.30–32
1.5 Thesis Objectives
The overall goal that inspired this dissertation was to develop a synthetic mimic
of protein sliding along DNA, in order to learn more about the physicochemical prop-
erties driving this important biological process. The first objective of this dissertation
describes one of the initial steps taken towards this goal, in which nanoparticles were
utilized as protein analogs and microtubules as DNA analogs. As a next step, pacli-
taxel was used to specifically target the nanoparticles to the microtubules, in order to
mimic the specific interaction between DNA-binding proteins and their target sites.
Due to the cytotoxic nature of paclitaxel, this naturally lead to the second objective
of this dissertation, the investigation of the suitability of these paclitaxel-conjugated
nanoparticles as a targeted cancer drug delivery strategy. One finding from this in-
vestigation was that the core of the chosen nanoparticle, the G5 PAMAM dendrimer,
10
induces bundling of microtubules, even when it is not conjugated with paclitaxel.
This finding leads to the final two objectives of this dissertation: (1) an investiga-
tion of the suitability of paclitaxel-conjugated gold nanoparticles as a targeted cancer
drug delivery platform; and (2) an investigation of the properties of G5 PAMAM
dendrimers that induce microtubule bundling.
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CHAPTER II
Towards Developing a Biosynthetic Mimic of the
Target Site Search Employed by DNA-Binding
Proteins1
2.1 Introduction
DNA-binding proteins play many important roles in the cell, including regulating
and driving gene expression. The subset of DNA-binding proteins that bind spe-
cific (target) sites on the DNA have a daunting task in finding their site among the
vast amount of DNA compacted in the cell. An early confirmation that the cell has
some mechanism(s) to overcome the apparent thermodynamic and kinetic obstacles
involved in the protein’s target site search was the observation that one DNA-binding
protein, the lac-repressor, was able to locate its target site faster than the diffusion
limit would predict if the protein utilized three-dimensional (3D) diffusion alone.33
It has since been established that DNA-binding proteins employ a combination of
search mechanisms to increase the efficiency of their search (Figure 1.1): intradomain
association and dissociation (3D diffusion or “hopping”), intersegment transfer (hop-
ping between close DNA segments), and sliding (one-dimensional (1D) diffusion).4,5
1All tubulin was obtained from Edgar Meyhöfer. All modification and characterization of den-
drimers and polystyrene particles was done by Ming-Hsin Li. The polyacrylamide particles were
synthesized by Ming Qin. The QDs were synthesized by Seung-Ho Jung.
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Sliding increases the efficiency of the protein’s search by restricting the normal 3D
Brownian diffusion of the protein in the cytoplasm to one dimension along the DNA.
Although 1D diffusion of various DNA-binding proteins has been observed by
single-molecule techniques in vitro 8–12 and in vivo,13 it is still not entirely understood
how this process occurs. Theoretically, in order for a DNA-binding protein to locate
its target site by sliding along DNA, it must be associated loosely enough to move
rapidly, but tightly enough to sense the sequences it is passing over. This loose
association is thought to be provided by electrostatic interactions between cationic
residues on the protein and anionic charges on the phosphates groups of the DNA.14,15
Indeed, it has been observed in vitro that an increase in salt concentration correlates
with a decrease in protein sliding.5,8,16,17
The primary objective that inspired this dissertation was to confirm that sliding
is primarily mediated by electrostatics by creating a synthetic model of this process
using charged components of the approximate size and shape of the protein and
DNA. If a cationic nanoparticle (acting as the protein analog) is able to slide along
an anionic nanoline (acting as the DNA analog), this would be compelling evidence
that the biological process of a DNA-binding protein sliding along DNA is driven
by electrostatics. Furthermore, this would enable precise determination of the charge
densities, sizes, and shapes of the individual components required for sliding to occur.
While there are many examples of directed diffusion that exploit various chemical
and physical phenomena,22 no synthetic model of random diffusion driven entirely by
electrostatics has been demonstrated in the literature to date.
Since developing such a model is a considerable step above the entirely biological
system, the current study takes a preliminary step by replacing the protein with
a synthetic analog, but the DNA with a biological analog. The synthetic protein
analogs chosen for this study are nanoparticles and the biological DNA analogs chosen
are microtubules. Nanoparticles were chosen as protein mimics because their size,
13
shape, charge density, and other surface properties can be well controlled during
synthesis. Microtubules were chosen as electrostatic DNA analogs as both are “linear”
biopolymers with negative surface charges. Microtubules would provide opportunities
for van der Waals and electrostatic interactions with cationic nanoparticles, but no
specific DNA sequence information. In fact, there is already one example in the
literature of cationic nanoparticles sliding along microtubules.25
The overall aim of the current study was to characterize the contribution of
nanoparticle material, size, and charge density to nanoparticle kinetics of sliding
along microtubules. First, we tested the ability of cationic polyacrylamide parti-
cles to slide along microtubules. When it became apparent that the polyacrylamide
particles tested did not carry a high enough charge density to exhibit prolonged
association with microtubules, polystyrene particles with a higher charge density
were tested. Preliminary results show that these highly cationic polystyrene particles
are indeed able to slide along microtubules, but only when significantly aggregated
to obtain a diameter ≈ 40 times greater. Finally, in order to more closely model
the protein searching process, two different nanoparticles closer in size to DNA-
binding proteins (≈ 5 nm) were tested for the ability to slide along microtubules.
First, inorganic nanoparticles—DMAET-stabilized CdHgTe quantum dots (QDs)—
were tested.23 Like the polyacrylamide particles, these particles did not carry a high
enough charge density to exhibit any prolonged interactions with microtubules. Next,
organic nanoparticles—generation 5 (G5) polyamidoamine (PAMAM) dendrimers—
were tested. Ideally, these particles have 128 end groups which can be easily modified
through chemical reactions. This enables the charge density of the particles to be
very precisely altered, from a neutral surface charge density to a very high surface
charge density. At the time that this dissertation was written, no dendrimer slid-
ing along microtubules has been observed with the conditions and dendrimer charge
densities tested, however, many dendrimer-microtubule binding interactions were ob-
14
served with high cationic charge densities and high dendrimer concentrations.
2.2 Materials and Methods
Materials
2-(N -morpholino)ethanesulfonic acid (MES), magnesium chloride (MgCl2), and
guanosine triphosphate (GTP) were all purchased from Fisher Scientific (Waltham,
MA). Ethylene glycol tetraacetic acid (EGTA), paclitaxel, protocatechuate acid (PCA),
protocatechuate-3,4-dioxygenase (PCD), and 3-methacryloxylpropyltrimethoxysilane
from Sigma-Aldrich (St. Louis, MO); Trolox from Acros Organics (Geel, Belgium);
5-(6)-carboxytetramethylrhodamine succimidyl ester (TMR) from Molecular Probes
(Eugene, OR); and Cy5 Cyanine dye (Cy) succimidyl ester from GE Healthcare Life
Sciences (Piscataway Township, NJ).
Tubulin Purification and Polymerization
Tubulin was purified from bovine brain and fluorescently labeled with TMR by
Neha Kaul, Jenna Campbell, and Charles Chang Jiang in Edgar Meyhöfer’s lab.
Briefly, tubulin was purified from bovine brain by two cycles of microtubule polymer-
ization in the presence of a high-molarity PIPES buffer.34 Tubulin was TMR-labeled
by reacting polymerized microtubules with a 20-fold excess of TMR at room temper-
ature for 30 min. Competent, TMR-labeled tubulin was purified from this mixture
by repeated depolymerization and polymerization.35
For all experiments, microtubules were polymerized by incubating 2 mg/mL (≈ 20
µM) α/β-tubulin dimers (using a mix of TMR-labeled and unlabeled tubulin dimers
to achieve a final ratio of 1 TMR dye per 20 dimers, as determined by UV-Vis, where
noted) with 4 mM MgCl2 and 1 mM GTP in MEM806.8 buffer (80 mM MES-KOH,
pH 6.8, 1 mM EGTA, 2 mM MgCl2) at 37
◦C for 30 min. After polymerization, the
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microtubules were stabilized with 10 µM paclitaxel.
TIRFM
Imaging chambers were prepared by affixing a cover glass (No. 1.5, 24x30 mm,
VWR, Radnor, PA) to a glass slide (Fischer Scientific, Waltham, MA) with double-
sided sticky tape. After the imaging solution was flown into the imaging channel, the
channel was sealed with candle wax. Images were taken on an inverted fluorescence
microscope (model IX81, Olympus, Center Valley, PA) using a 60x objective lens.
Samples were illuminated at either 532 nm (for TMR; type Compass 315M, Coherent
Inc., Santa Clara, CA) or 635 nm (for Cy5; type Cube 640-100C, Coherent Inc.,
Santa Clara, CA) at the critical angle, using a cellˆ TIRFTM Illuminator (Olympus,
Center Valley, PA). Fluorescent emissions were split into four separate channels using
a QV2 Quad View Imaging System (Photometrics, Tuscon, AZ) and projected onto an
EMCCD camera (model Evolve 512, Photometrics, Tuscon, AZ). Fluorescent images
were viewed using MetaMorph software (Molecular Devices, Sunnyvale, CA) and
further processed using either ImageJ (NIH) and/or MATLAB (The MathWorks,
Inc., Natick, MA).
Polyacrylamide Nanoparticles
The polyacrylamide nanoparticles used in this study were synthesized, and kindly
provided by, Ming Qin, member of Raoul Kopelman’s lab at the University of Michi-
gan. Two distinct batches were provided: (1) 38 ± 10 nm particles with surface
charge density σ = 0.05 (+)/nm2; and (2) 80 nm particles (standard deviation of
diameter unknown) with σ = 0.03 (+)/nm2 as determined by Ming Qin using zeta
potential (ZP) measurement. Both batches were labeled with methylene blue to en-
able fluorescent detection.36 These particles will be referred to throughout the text
as PAA38 or PAA80, respectively, according to their diameters. When it became
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apparent that these particles were not charged enough to interact with microtubules,
an attempt was made to increase the particle charge density of PAA38. This was
done with the help of Ming-Hsin Li and Seok-Ki Choi, members of James R. Baker’s
lab, formerly of the University of Michigan, using the amination methods of Minoura
et al.25 which utilize ethylenediamine. However, zeta potential measurement showed
that the result of this amination reaction was an aggregated population of particles
(the particle diameter increased from 38 ± 5 nm to 100 ± 7 nm) with a zeta potential
measurement of -5 ± 3 mV, likely implying that particles with charge densities both
positive and negative are present, resulting in an average charge density close to 0
(neutral).
Probing for Co-localization of Polyacrylamide Nanoparticles and Micro-
tubules by TIRFM
TMR-labeled, paclitaxel-stabilized microtubules were polymerized and stabilized
as described above (see section Tubulin purification and polymerization). These mi-
crotubules were flowed into a slide imaging channel at 0.3 µM tubulin. After allowing
the microtubules 10 min to fall to the coverslip surface, the tubulin remaining in
solution was washed away using 3 flow channel volumes of MEM30 (30 mM MES, pH
6.8, 0.3 mM MgCl2, 25 mM KCl, 0.003% NP40) containing OSS and 10 µM pacli-
taxel. Then 3 fM of either (1) PAA38; or (2) PAA80 and oxygen scavenging system
(OSS; 5 mM PCA, 50 nM PCD, 2 mM Trolox) were flowed into the imaging channel
in MEM806.8 at room temperature. The mixture was then visualized by TIRFM.
All coverslips used for these experiments were spin-coated with polystyrene prior to




50 ± 5 nm, amine-terminated, polystyrene particles were purchased from Sigma-
Aldrich (St Louis, MO). The charge density of these particles, σ = 0.13 (+)/nm2,
was determined by Ming-Hsin Li, member of James R. Baker’s lab, formerly of the
University of Michigan, using zeta potential measurement. Ming-Hsin Li also labeled
these particles with, on average, 5-6 Cy5 dyes per particle to enable detection by
TIRFM. These particles will be referred to as Cy-PS throughout the text.
Co-localization of Cy-PS and Microtubules by TIRFM
TMR-labeled, paclitaxel-stabilized microtubules were polymerized and stabilized
as described above (see section Tubulin purification and polymerization). These mi-
crotubules were flowed into a slide imaging channel at 0.3 µM tubulin. After allowing
the microtubules 10 min to fall to the coverslip surface, the tubulin remaining in so-
lution was washed away using 3 flow channel volumes of MEM30 containing OSS and
10 µM paclitaxel. Then 1 nM of Cy-PS was added to the imaging channel in MEM30
containing OSS and 10 µM paclitaxel. The resulting mixture was then visualized by
TIRFM.
Particle Tracking
Particle tracking was done with the help of Anthony Manzo, former member
of Nils Walter’s lab, using his custom MATLAB scripts for FIONA (fluorescence
imaging with one nanometer accuracy) particle tracking. Briefly, the position of
a particle relative to its first detected position was extracted over time by fitting
the diffraction-limited point-spread function of the particles in a 5-min sequence of




2-dimethylaminoethanethiol (DMAET)-stabilized quantum dots (QDs) were syn-
thesized by Seung-Ho Jung, former member of Nick Kotov’s lab at the University
of Michigan. These particles were determined to be 4.3 nm in diameter (standard
deviation unknown) with a surface charge of σ = .09 (+)/nm2 by Seung-Ho using
zeta potential measurement. These particles will be referred to as DMAET-QDs
throughout the text.
Probing for Co-localization of DMAET-QDs and Microtubules by TIRFM
TMR-labeled, paclitaxel-stabilized microtubules were polymerized and stabilized
as described above (see section Tubulin purification and polymerization). These mi-
crotubules were flowed into a slide imaging channel at 0.3 µM tubulin. After allowing
the microtubules 10 min to fall to the coverslip surface, the tubulin remaining in so-
lution was washed away using 3 flow channel volumes of MEM30, MEM806.8, or 0.1-1
M Tris (pH 8.0 with HCl), where noted, containing OSS and 10 µM paclitaxel. Then
DMAET-QDs were flowed into the imaging channel in MEM30, MEM806.8, or 0.1-1
M Tris (pH 8.0 with HCl), where noted, containing OSS and 10 µM paclitaxel. The
DMAET-QDs were titrated to a final concentration of 3 pM-1.67 µM over multiple
experiments. The mixtures were visualized by TIRFM.
G5 PAMAM Dendrimers
G5 PAMAM dendrimers were purchased from Dendritech, Inc. (Midland, MI).
All modification, purification, and characterization of these dendrimers was done
by Ming-Hsin Li, member of James R. Baker’s lab, formerly at the University of
Michigan. The dendrimers were first purified using a 10 kDa molecular weight cut
off (MWCO) dialysis membrane, achieving a relatively monodisperse population
(polydispersity index (PDI) = 1.01–1.05, determined by gel permeation chromatogra-
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phy (GPC)).38 The average number of primary amine end groups was determined to
be 114 by potentiometric titration after purification by dialysis, membrane filtration,
and lyophilization.39 These dendrimers were then reacted with 5 molar equivalents of
Cy5 NHS-ester to achieve an average of 2-3 Cy5 molecules per dendrimer, as deter-
mined by 1H NMR and UV-Vis. These particles will be referred to as (NH2)114-G5
throughout the text, according to their surface chemistry and stoichiometry.
Co-localization of (NH2)114-G5 and Microtubules by TIRFM
TMR-labeled, paclitaxel-stabilized microtubules were polymerized and stabilized
as described above (see section ‘Tubulin Purification and Polymerization’). These
microtubules were flowed into a slide imaging channel at 0.3 µM tubulin. After
allowing the microtubules 10 min to fall to the coverslip surface, the tubulin remaining
in solution was washed away using 3 flow channel volumes of MEM30 containing OSS
and 10 µM paclitaxel. Then G5 PAMAM dendrimers were flowed into the imaging
channel in MEM30, or MEM806.8 where noted, containing OSS and 10 µM paclitaxel.
The dendrimers were titrated to a final concentration of 10pM-100 nM over multiple
experiments. The mixtures were visualized by TIRFM.
Alternatively, the microtubules (at 0.3 µM tubulin) and 1.67 µM dendrimers were
pre-mixed in MEM806.8 with OSS and 10 µM paclitaxel. This mixture was then
flowed into the imaging channel and visualized by TIRFM.
2.3 Results and Discussion
38 and 80 nm Polyacrylamide Particles Do Not Slide Along Microtubules
To probe for co-localization of PAA38 and PAA80 with microtubules, a similar
protocol to that reported in the literature25 was used, except that the coverslips
were spin-coated with polystyrene (done by Shi Yu, Ron Larson’s lab, Department of
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Chemical Engineering, University of Michigan) instead of treating with silane to block
particle binding to the surface. Now following the published protocol, microtubules
in MEM806.8 were flown into a slide imaging channel, incubated for 10 min to allow
the microtubules to fall to the coverslip surface, rinsed away any tubulin in solution
with MEM30, and flowed 3 fM of either PAA38 or PAA80 into the imaging channel
before visualizing by TIRFM.
Figure 2.1 shows a few particles of either PAA38 (Figure 2.1a) or PAA80 (Fig-
ure 2.1b) co-localizing with microtubules. However, many more particles of both
PAA38 and PAA80 are bound to the slide surface. Because so many more particles
are bound to the slide surface than the microtubules, it cannot be said that there
is any significant interaction observed between the polyacrylamide particles and the
microtubules. Recall that these particles had surface charge densities of 0.05 (+)/nm2
or 0.03 (+)/nm2, respectively. These charge densities may not be sufficient for in-
teraction with microtubules as it has previously been reported in the literature that
polyacrylamide particles of similar size cannot significantly interact with microtubules
until their surface charge densities reach ≈ 3.3 (+)/nm2.25 Accordingly, it was next
attempted to increase the cationic charge density of the particles using the same
amination reaction used in the aforementioned study to increase the surface cationic
charge density of polyacrylamide particles.25
In order to increase the cationic surface density of their polyacrylamide nanopat-
icles, Minoura et al.25 reacted the particles with ethylenediamine for 1.3-7 h. Using
the same protocol, PAA38 was reacted with ethylenediamine for 4.5 h.25 After this
reaction, zeta potential measurements showed that the particles had aggregated (their
diameter increased from 38 ± 10 nm to 100 ± 7 nm). This aggregated population
gave a zeta potential measurement of -5 ± 3 mV, likely implying that particles with
charge densities both positive and negative are present, resulting in an average charge
density close to 0 (neutral). After this, particles of different materials were tested.
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Figure 2.1: 3 fM of (a) PAA38 or (b) PAA80 with microtubules visualized by TIRFM.
Images from the TMR channel (green: microtubules) are overlaid onto
images from the Cy5 channel (red: polyacrylamide particles). Scale bars
shown in top images are 10 µm; those in the bottom zoomed in images
are 5 µm. The majority of particles from both populations were primarily
observed bound to the coverslip surface.
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Polystyrene Nanoparticles Slide Along Microtubules
Next, amine-terminated polystrene nanoparticles were purchased from Sigma-
Aldrich. These particles were 50 nm in diameter with a surface charge density of σ =
0.13 (+)/nm2, as determined by zeta potential measurement. After purchase, these
particles were labeled, on average, with 5-6 Cy5 dyes per particle by Ming-Hsin Li,
member of James R. Baker’s lab, formerly at the University of Michigan. According
to their fluorescent label, these particles will be referred to as Cy-PS throughout the
text. These particles do not carry the high charge density previously reported as nec-
essary for interaction between cationic polyacrylamide particles and microtubules,25
however, polystyrene is more hydrophobic than polyacrylamide (Figure 2.2) and thus
will provide additional opportunities for interactions with microtubules.
In order to probe for co-localization between Cy-PS and microtubules, the same
protocol was followed as described for the polacrylamide particles above, with the
exception that the coverslips were not treated with polystyrene or any other blocking
material, and the Cy-PS concentration used was 1 nM. A few Cy-PS particles—≈ 6%
of the population observed—not only co-localized with microtubules, but seemingly
slid along them. Figure 2.3 shows one example of an apparently sliding particle. This
particle is outlined with a white box in Figure 2.3a. The movement of this particle
was tracked using a FIONA (fluorescence imaging with one nanometer accuracy) par-
ticle tracking MATLAB routine written by Anthony Manzo.37 Figure 2.3b shows a
plot of the particle’s displacement in the y-direction vs. the x-direction relative to the
location of the microtubule axis, which was estimated in ImageJ (NIH) by tracing the
path of the microtubule with a line segment and recording the angle of the segment
with respect to the x-axis. This angle was then used to generate a line equation for
plot Figure 2.3b. This plot shows that the particle’s overall trajectory closes follows
the microtubule axis. Furthermore, while the particle’s trajectory is mostly one-
dimensional, it is also two-dimensional for some time intervals. Figure 2.3c shows a
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Polyacrylamide Polystyrene
Figure 2.2: Chemical structures of polyacrylamide and polystyrene. The polystyrene
nanoparticles used in this study were amine-terminated by Sigma-Aldrich
(St. Louis, MO); the final chemical structure is not published by the
manufacturer.
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histogram of the distances the particle traveled in 100 ms intervals. A Gaussian fit of
these data shows that the mean distance traveled by the particle while electrostatically
trapped by the microtubule is 0.44 µm/s. Figure 2.3d shows the mean square displace-
ment (MSD) of the particle’s trajectory as a function of time. Error bars represent the
standard deviation of the MSD, σ =
√
((2Di∆t)2(2i2 + 1)/3i(N − i+ 1)).10 The first
1.5 s of the trajectory were fit with the allometric equation, MSD = a + (2nD) ∗ tc,
where a = offset, D = diffusion coefficient, n = dimensionality of diffusion, t = time
lag, and c = coefficient characterizing diffusion. The coefficient of determination for
the fit was R2 = 0.98.
From the fit, many parameters can be extracted that will give information about
the particle’s trajectory. The parameter c is 1.04, indicating the particle under-
went Brownian diffusion.40–42 In addition, the coefficient of determination is equal
(R2 = 0.98) whether the parameter n is fixed at 1 (1D diffusion) or 2 (2D diffusion).
Considering the plot in Figure 2.3b, and the large diameter of microtubules which
would theoretically allow 2D diffusion, it is assumed that the particle underwent 2D
diffusion. Under this assumption, a diffusion coefficient of 2.12×10−9 cm2/s is calcu-
lated. From this diffusion coefficient, the diameter of the particle is estimated to be 2
µm using the Stokes-Einstein equation D = kBT
6πηr
, where kB is Boltzmann’s constant,
T is temperature, η is viscosity, and r is particle radius. If the particle is truly 2 µm
in diameter, it is larger than the diffraction limit of light (≈ 266 nm), and its diameter
can be measured directly from the fluorescent image. Indeed, a cross-sectional line
plot made in ImageJ (NIH) estimates the particle diameter to be ≈ 1 µm.
However, these diameter measurements are significantly greater than 50 nm, the
particle diameter stated by the manufacturer and confirmed in-house by zeta po-
tential measurement. This discrepancy could be due to either calculation error or
particle aggregation. Nevertheless, the measured diffusion coefficients are close to
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Figure 2.3: (a) 1 nM of Cy-PS with microtubules visualized by TIRFM. Images from
the TMR channel (green: microtubules) are overlaid onto images from the
Cy5 channel (red: Cy-PS). Scale bar shown is 10 µm. The particle indi-
cated by the white box was analyzed using a FIONA (fluorescence imag-
ing with one nanometer accuracy) particle tracking routine. (b) A plot of
the particle’s displacement in the y- vs. x-direction relative to the micro-
tubule axis (red dotted line). (c) A histogram of the distances the particle
traveled in 100 ms intervals overlaid by a Gaussian fit (R2 = 0.89). The
time-color scale is shown above the plot. (d) MSD of the particle’s trajec-
tory as a function of time. Error bars represent the standard deviation of
the MSD, σ =
√
((2Di∆t)2(2i2 + 1)/3i(N − i+ 1)). The first 1.5 s of the
trajectory were fit with an allometric equation (MSD = a + (2nD) ∗ tc)
with R2 = 0.98 and parameter c = 1.04.
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(57 nm): 8.9×10−9 cm2/s. Albeit, these polyacrylamide particles had a much higher
charge density than Cy-PS, 3.3 (+)/nm2 compared to 0.13 (+)/nm2.
To test if these particles were indeed aggregated, the experiment was repeated
except the Cy-PS sample was vigorously vortexed prior to addition to the imaging
channel. Figure 2.4 shows that vortexing results in particles that appear much smaller
than those observed without vortexing (Figure 2.3). In addition, a higher apparent
particle density is observed in Figure 2.4 compared to Figure 2.3 even though the
same particle concentration was used for both experiments. This is compelling evi-
dence that the Cy-PS particle observed to slide along microtubules in Figure 2.3 was
aggregated. Since there was no obvious sliding observed with the vortexed particles,
this implies that the higher number of cationic charges afforded by the aggregates
allowed the prolonged microtubule association observed.
Overall, these data suggests that a cationic charge density ≤ 0.13 (+)/nm2 is not
sufficient for prolonged interaction with microtubules. However, when the number of
charges available to interact with the microtubule is significantly increased—through
particle aggregation, for example—prolonged association is possible. In one instance,
the Brownian diffusion of a Cy-PS aggregate was confined (for 2 ± 0.1 s) to less
than three dimensions by a microtubule, likely through electrostatic attraction. The
distinction between the observed 2D diffusion of this particle, and the observed 1D
diffusion of proteins along DNA,8–12 can be explained by the larger diameter of mi-
crotubules (25 vs. 2 nm), which allows sufficient dimensionality for the particle to
undergo 2D diffusion. In order to confirm this observation, additional testing must be
done. In addition, the diameter extracted from the 3D diffusion coefficient of these




Figure 2.4: 1 nM of Cy-PS were vigorously vortexed before being introduced into an
imaging channel already containing microtubules. The resulting mixtures
were visualized by TIRFM. Images from the TMR channel (green: mi-
crotubules) are overlaid onto images from the Cy5 channel (red: Cy-PS).
Scale bar shown is 10 µm.
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DMAET-Stabilized Quantum Dots Do Not Significantly Interact with Mi-
crotubules
Next, particles with smaller diameters more comparable to those of DNA-binding
proteins were texted. Inorganic nanoparticles are theoretically good candidates for
protein mimics23 and, therefore, cationic quantum dots were tested for an ability
to slide along microtubules. To this end, 2-dimethylaminoethanethiol (DMAET)-
stabilized CdHgTe quantum dots (QDs)—hereafter referred to as DMAET-QDs—
were kindly provided by the Kotov lab at the University of Michigan, which were syn-
thesized by Seung-Ho Jung. These particles were determined to be 4.3 nm in diameter
with a charge density of 0.3 (+)/nm2 by zeta potential measurement. This charge den-
sity is slightly higher than that of the polyacrylamide (0.04 (+)/nm2) and polystyrene
(0.13 (+)/nm2) particles tested above. The chemical structure of DMAET is shown
in Figure 2.5 for comparison to that of polyacrylamide and polystyrene (Figure 2.2).
TIRFM co-localization experiments were performed exactly as those with the poly-
acrylamide or polystyrene particles, except that in addition to MEM30, MEM806.8
and 0.1-1 M Tris, were also tested as visualization buffers. DMAET-QDs were imaged
in these buffers at a final concentration of 3 pM-1.67 µM, over multiple experiments.
Although some co-localization of the particles and the microtubules was observed
(Figure 2.6), it did not appear significantly greater than the binding of the particles
to the slide surface at any concentration tested.
Considering all particles tested thus far, the only particle that exhibited potential
sliding along microtubules was Cy-PS. While all particles tested had relatively low
cationic charge densities—ranging from 0.03-0.3 (+)/nm2—compared to the minimum
particle charge density required for significant microtubule association, as determined
by Minoura et al.,25 Cy-PS aggregates did exhibit sliding along microtubules. From
the diffusion coefficient of this particle, a very large diameter was calculated using
the Stokes-Einstein equation, 1-2 µm. This would drastically increase the number
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Figure 2.5: Chemical structure of 2-dimethylaminoethanethiol (DMAET), which is




Figure 2.6: 3 pM of DMAET-stabilized CdHgTe QDs with microtubules in 500 mM
Tris (pH 8.0) visualized by TIRFM. Images from the TMR channel (green:
microtubules) are overlaid onto images from the Cy5 channel (red: QDs).
A zoomed in area of interest containing potential sites of co-localization
in the image on the right is shown on the left. Sites of co-localization are
indicated by white arrows.
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of cationic charges available for interaction with the microtubule, although the exact
number of cationic charges is not known. Since the particle aggregation was not
controlled, even if the charge density of the aggregates was determined from their zeta
potential, this would likely result in a wide distribution of particle sizes and charge
densities. Therefore, single particles with higher charge densities must be tested for
microtubule interaction in order to concisely determine, or confirm,25 charge density
limits for interaction with microtubules.
Highly Cationic G5 PAMAM Dendrimers Interact with Microtubules
The higher charged particles chosen to test were generation 5 (G5) polyami-
doamine (PAMAM) dendrimers. Due to the highly branched nature of these organic
polymers, the fifth generation particles carry 128 chemically reactive end groups per
5.4 nm particle,43,44 if formed perfectly. This large number of reaction sites on the
surface of the particle makes possible two things important for our purposes: (1) the
particle can carry a high cationic surface charge (up to 1.4 (+)/nm2); and (2) the
surface charge on the particles can be very precisely covalently altered, resulting in
a wide range of testable charge densities possible for the same particle. Considering
that the maximum cationic charge density carried by the G5 PAMAM dendrimer
is 1.4 (+)/nm2, it is a little surprising that Minoura et al.25 were able to achieve
9.4 (+)/nm2. Nevertheless, it was tested if G5 PAMAM dendrimers carried enough
cationic charge to interact, and/or slide along, microtubules.
The batch of G5 PAMAM dendrimers used in this study had 114 terminal [pri-
mary] amine groups on average, as determined by potentiometric titration. This
results in a cationic charge density of 1.2 (+)/nm2. According to their chemistry
and stoichiometry, these dendrimers will hereafter be referred to as (NH2)114-G5. To
test for co-localization between (NH2)114-G5 and microtubules, the same protocol
was used as throughout this study, using a final concentration of (NH2)114-G5 of 10
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pM-100 nM in MEM30, over multiple experiments.
Similar to all other particles tested (with the exception of the Cy-PS aggregate),
there were no significant interactions observed between the dendrimers and the mi-
crotubules. However, when the experimental conditions were changed so that the
dendrimers were first mixed with the microtubules prior to addition to the imaging
chamber, and a much higher dendrimer concentration was used (1.67 µM), significant
dendrimer binding to microtubules was observed. Figure 2.7 shows a few examples of
dendrimer-bound microtubules. This is in contrast to all other particles tested in that
no significant co-localization events were detected whether the particles and micro-
tubules were pre-mixed before introduction into the imaging chamber, or whether the
microtubules were first allowed to bind the coverslip surface before the particles were
introduced into the imaging chamber. A white box on the leftmost image outlines
a dendrimer-bound microtubule. The TMR (tubulin) fluorescence from this micro-
tubule cannot be seen, but this is likely due to fluorescence resonance energy transfer
(FRET) between the TMR label on the tubulin and the Cy5 label on the dendrimers.
In the rightmost image, some microtubules are observed with a few instances of co-
localization with the dendrimers. In the future, G5 PAMAM dendrimers with lower
charge densities should be tested for an ability to bind to microtubules, in order to
determine a lower charge density limit for microtubule binding.
Conclusions
In conclusion, particles with cationic charge densities of ≤ 1.2 (+)/nm2 do not
seem to significantly interact with microtubules, especially at sub-µM particle con-
centrations. These results are consistent with those of Minoura et al.,25 who found
that particles with cationic charge densities less than 3.3 (+)/nm2 cannot associate
with microtubules. However, aggregated polystyrene particles with a single parti-
cle charge density of 0.13 (+)/nm2 were observed to undergo 2D Brownian diffusion
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Figure 2.7: 1.67 µM of (NH2)114-G5 with microtubules in MEM806.8, visualized by
TIRFM. Images from the TMR channel (green: microtubules) are overlaid
onto images from the Cy5 channel (red: dendrimers). Scale bar shown is
10 µm. The two images are taken under the same experimental conditions.
The white box on the left image outlines a dendrimer-bound microtubule.
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along microtubules (Figure 2.3). When the same particle sample was instead vigor-
ously vortexed prior to mixing with the microtubules, no sliding along, or association
with, microtubules was observed. This implies that many more cationic charges must
be available for microtubule interaction than those supplied by particles with charge
densities of ≤ 1.2 (+)/nm2.
Considering the implication of these results for the protein-DNA system, DNA-
binding (or microtubule-binding) proteins do not have the high charge densities seem-
ingly required by synthetic nanoparticles to interact with, and slide along, micro-
tubules. For example, T7 RNA polymerase has a cationic charge density of 0.057
(+)/nm2. However, the cationic charges of DNA-binding proteins are primarily con-
centrated in their DNA-binding domains, which may serve to dramatically increase
the local cationic surface charge density of the protein. At this time, there have been
no calculations reported in the literature to determine the local surface charge den-
sity of DNA-binding proteins, to my knowledge. If the local charge densities of the
DNA-binding domains of proteins do not reach those determined to be necessary for
synthetic nanoparticles in vitro, then this may imply that other interactions in addi-
tion to electrostatics are required for non-specific binding to, and sliding of, proteins
along DNA. However, the organic nanoparticles tested in this study were actually
able to provide some of these alternative interaction opportunities with microtubules
other than electrostatic. Therefore, it may be that the shape complementarity of the
protein to the DNA, and the charge juxtaposition within the DNA binding pocket of
the protein, are very important components of the protein-DNA interactions mediat-
ing sliding.14,45,46 Indeed, it is possible that the reason that some of the polystyrene
particle aggregates were able to slide along microtubules when many were not, is that
the presumably rough surface of these aggregates may have become, by chance, com-





Figure 2.8: Model of particle aggregate shape complementarity with microtubules.
50 nm polystyrene particles, depicted as red spheres, are shown to form
an aggregate that has a pocket of the right size to fit around a micro-
tubule, depicted as a cylindrical polymer of blue and green spheres. The
shape complementarity of this pocket, randomly formed through particle





Adversely Affect Microtubule Structure through
Two Independent Modes of Action1
3.1 Introduction
Paclitaxel is a small organic molecule that is marketed as an anti-cancer drug
(Taxol R©, Bristol-Myers Squibb, New York, NY; Figure 3.1) because of its cytotoxic
properties that derive from its ability to hyperstabilize microtubules against depoly-
merization and, consequently, arrest cell division, particularly of rapidly dividing
cells.29 Since paclitaxel is poorly water soluble, it is currently solubilized in a mixture
of polyethoxylated castor oil and ethanol prior to injection into the patient.30 These
toxic solubilizing agents, the promiscuous cytotoxicity of paclitaxel, and the fact that
paclitaxel has a high binding affinity for plasma proteins, lead to detrimental side
effects and decreased drug efficiency.30 Nevertheless, paclitaxel has proven to be a
successful cancer drug,29 making the design of a targeted delivery strategy using a
water-soluble form of paclitaxel very desirable.
Numerous targeted delivery strategies for paclitaxel that aim to overcome its lim-
1Adapted with permission from Cline, E.N.; Li, M-H; Choi, S.K.; Herbstman, J.F.; Kaul, N.;
Meyhöfer, E.; Skiniotis, G.; Baker, J.R.; Larson, R.G.; Walter, N.G. Biomacromolecules 2013, 14,


















































Figure 3.1: Two-dimensional schematic of the fifth generation (G5), paclitaxel (PX)-
conjugated PAMAM dendrimer used in this study (systematically termed
PX3Cy2−3OH108-G5 by its chemical composition). The theoretical num-
ber of terminal branches per G5 dendrimer is 128, but only a fraction of
the branches (64) are shown for clarity. The batch used in this study had
114 end groups on average, as determined by potentiometric titration.
The modification of all end groups from the original primary amines is
depicted by colored circles, showing covalent attachment of 3 paclitaxel
molecules (PX: red) and 3 Cy5 molecules (Cy: blue), on average. The
remaining surface groups were neutralized by the addition of 108 hydroxyl
groups, on average (OH: dark green). The chemical structures of the hy-
droxyl end groups (OH) and paclitaxel (PX)—covalently linked to the
dendrimer at the 2’OH (red) by a linker containing an ester, disulfide
bridge, and amide bond—are shown on the right.
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itations are currently being explored experimentally and in clinical trials.30–32 One
potential strategy is to use a water-soluble drug carrier such as a PAMAM dendrimer.
PAMAM dendrimers are branched, organic nanoparticles that are highly multivalent,
allowing for the attachment of many (different) ligands (Figure 3.1).43,47 PAMAM
dendrimers have shown promise as a drug delivery platform in the treatment of many
diseases, including cancer.32,48–51 Notably, paclitaxel-conjugated generation 5 (G5)52
PAMAM dendrimers have demonstrated cytotoxicity against cancerous cells.53 The
mechanism(s) of cytotoxicity of these paclitaxel-conjugated dendrimers, however, was
not investigated. That is, it is not known if the observed cytotoxicity is due to pacli-
taxel stabilization of microtubules, or to some other mechanism(s). The dendrimers
were designed so that the paclitaxel load can be cleaved from the dendrimer carrier
inside the cell, via the hydrolysis of the ester bond at the C2’-OH of paclitaxel (Fig-
ure 3.1), and/or a second ester bond that tethers the drug-linker to the dendrimer
carrier. This mechanism has not been experimentally confirmed, although numerous
studies suggest that such paclitaxel prodrugs similarly employing a C2’-ester bond
have no in vitro activity, but gain activity in vivo, suggesting that this ester bond may
be cleaved intracellularly to release paclitaxel.54–56 The second ester bond within the
linker has now been replaced with a disulfide bridge and amide bond (Figure 3.1)57,58
to provide better chemical stability of the linker during synthesis. In addition, a
disulfide bond may provide a second mechanism for the intracellular release of the
paclitaxel load, as it can be cleaved in the reductive environment of endosomes or
lysosomes.57,58 However, the questions remain whether paclitaxel is cleaved from the
dendrimer carrier in the cell (and if so, how rapidly), and whether the still pacli-
taxel-coupled or paclitaxel-free dendrimer may contribute to cytotoxicity by binding
to microtubules.
To address the question of whether PAMAM dendrimers, with or without pacli-
taxel, bind to microtubules, a turbidity assay as well as two single microtubule mi-
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croscopy techniques, total internal reflection fluorescence microscopy (TIRFM) and
transmission electron microscopy (TEM), are used to investigate the effects of pa-
clitaxel-conjugated or unconjugated dendrimers on purified microtubules in vitro.
These assays were performed in vitro in order to directly observe the effects of the
dendrimers on microtubules, while removing the possibility of the conjugates causing
cytoxicity through non-microtubule interactions. First, it is found that the pacli-
taxel-conjugated G5 PAMAM dendrimers stabilize polymerizing microtubules against
depolymerization, in a paclitaxel-dependent manner, although much less efficiently
than free paclitaxel. Second, and more surprisingly, it is found that G5 PAMAM den-
drimers are able to bind and bundle pre-formed microtubules, even after removing
both paclitaxel and any surface charges (by addition of hydroxyl groups to the termi-
nal primary amine groups). This paclitaxel-independent mode of action is probably
induced, at least in part, by electrostatic interactions, involving protonated tertiary
amine functionalities of the interior dendrimer core (Figure 3.1). Both modes of ac-
tion result in microtubules stabilized against depolymerization, which is expected to
impair cellular mitosis. Therefore, at least at the concentrations used in this study,
our results call to attention the need to carefully consider potentially harmful molec-
ular interactions mediated even by surface-neutralized drug carriers during the design
of novel targeted drug delivery strategies.
3.2 Materials and Methods
Materials
MES, MgCl2, and GTP were all purchased from Fisher Scientific (Waltham, MA).
EGTA, paclitaxel, PCA, and PCD from Sigma-Aldrich (St. Louis, MO); Trolox from
Acros Organics (Geel, Belgium); GpCpp (GMPCPP) from Jena Biosciences (Jena,
Germany); TMR from Molecular Probes (Eugene, OR); and Cy succimidyl ester from
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GE Healthcare Life Sciences (Piscataway Township, NJ).
Tubulin purification and polymerization
Tubulin was purified from bovine brain and fluorescently labeled with TMR by
Neha Kaul, Jenna Campbell, and Charles Chang Jiang in Edgar Meyhöfer’s lab.
Briefly, tubulin was purified from bovine brain by two cycles of microtubule polymer-
ization in the presence of a high-molarity PIPES buffer.34 Tubulin was TMR-labeled
by reacting polymerized microtubules with a 20-fold excess of TMR at room temper-
ature for 30 min. Competent, TMR-labeled tubulin was purified from this mixture
by repeated depolymerization and polymerization.35
For all experiments, microtubules were polymerized by incubating 2 mg/mL (≈ 20
µM) α/β-tubulin dimers (using a mix of TMR-labeled and unlabeled tubulin dimers
to achieve a final ratio of 1 TMR dye per 20 dimers, as determined by UV-Vis, where
noted) with 4 mM MgCl2 and 1 mM GTP, or GMPCPP where noted, in MEM806.8
buffer (80 mM MES-KOH, pH 6.8, 1 mM EGTA, 2 mM MgCl2) at 37
◦C for 30 min.
After polymerization, the microtubules were stabilized with 10 µM paclitaxel, unless
otherwise noted.
Synthesis and characterization of paclitaxel-conjugated G5 PAMAM den-
drimers
G5 PAMAM dendrimers ((NH2)114-G5) were purchased from Dendritech, Inc.
(Midland, MI). The dendrimers were first purified using a 10 kDa MWCO dialysis
membrane, achieving a relatively monodisperse population (PDI = 1.01–1.05, deter-
mined by GPC).38 The average number of primary amine end groups was determined
to be 114 by potentiometric titration after purification by dialysis, membrane filtra-
tion, and lyophilization.39 These dendrimers were first reacted with 5 molar equiva-
lents of Cy5 NHS-ester to achieve an average of 2-3 Cy5 molecules per dendrimer, as
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determined by 1H NMR and UV-Vis. The Cy5 labeled PAMAM amine-terminated
dendrimer was then fully capped with carboxylic acid groups by reacting glutaric
anhydride with the primary amine end groups on the dendrimer. Finally, the Cy5-
carboxylated dendrimer was reacted with 10 molar equivalents of paclitaxel, previ-
ously conjugated to the ester-disulfide-amide linker (see Supplementary Materials),
to achieve an average of 3.2 paclitaxel molecules per dendrimer, as determined by 1H
NMR. The residual active groups were neutralized by addition of hydroxyl groups.
More details concerning the synthesis, purification, and characterization of the pa-
clitaxel-conjugated G5 dendrimer, as well as of the paclitaxel-conjugated generation
3 (G3) dendrimer and the paclitaxel linkers used for each dendrimer, are available in
the Supplementary Materials.
Turbidity Assays
Turbidity assays were conducted as described previously.59 Briefly, 2.0 mg/mL
of unlabeled tubulin (≈ 20 µM) was mixed with 4 mM MgCl2 in MEM806.8 and
incubated on ice for 30 min. Meanwhile, the following components were pre-warmed
at 37 ◦ in cuvettes: (1) no additional components; (2) 1 mM GTP; (3) 1 mM GTP and
10 µM paclitaxel; (4) 1 mM GTP and 3.33 µM PX3Cy2−3OH108-G5; or (5) 1 mM GTP
and 3.33 µM Cy2−3OH111-G5. After 30 min, the tubulin mixtures were added to the
cuvettes and the readings were begun immediately. The turbidity (polymerization)
of the reaction mixtures was monitored at 340 nm once every minute for 30 min
at 37 ◦C on a Beckman DU-640 UV-Vis Spectrometer utilizing a High Performance
Peltier Temperature Controller (Beckman Coulter, Brea, CA).
TIRFM
Imaging chambers were prepared by affixing a cover glass (No. 1.5, 24x30 mm,
VWR, Radnor, PA) to a glass slide (Fischer Scientific, Waltham, MA) with double-
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sided sticky tape. After the imaging solution was flown into the chamber, the chamber
was sealed with candle wax. Images were taken on an inverted fluorescence microscope
(model IX81, Olympus, Center Valley, PA) using a 60x objective lens. Samples were
illuminated at either 532 nm (for TMR; type Compass 315M, Coherent Inc., Santa
Clara, CA) or 635 nm (for Cy5; type Cube 640-100C, Coherent Inc., Santa Clara, CA)
at the critical angle, using a cellˆ TIRFTM Illuminator (Olympus, Center Valley, PA).
Fluorescent emissions were split into four separate channels using a QV2 Quad View
Imaging System (Photometrics, Tuscon, AZ) and projected onto an EMCCD camera
(model Evolve 512, Photometrics, Tuscon, AZ). Fluorescent images were viewed using
MetaMorph software (Molecular Devices, Sunnyvale, CA).
TIRFM Polymerization Assays
2.0 mg/mL of a mix of unlabeled and TMR-labeled (see above) tubulin (≈ 20
µM) was mixed with 4 mM MgCl2 and 1 mM GTP in MEM806.8 and either (1) no
additional components; (2) 10 µM paclitaxel; (3) 3.33 µM PX3Cy2−3OH108-G5; or (4)
3.33 µM Cy2−3OH111-G5 at 37
◦C for 30 min. The resulting tubulin mixtures were
incubated at room temperature for another 180 min to allow unstable microtubules
to depolymerize (it was first determined that no microtubules from sample (1) could
be detected by TIRFM after 180 min incubation at room temperature). Prior to vi-
sualization by TIRFM, the samples were either diluted to 4 (sample 2) or 15 (samples
1, 3, 4) µM tubulin in MEM806.8, supplemented with an oxygen scavenging system
(OSS; 5 mM PCA, 50 nM PCD, 2 mM Trolox).
Co-localization of Dendrimers and Pre-formed Microtubules Observed by
TIRFM
TMR-labeled, paclitaxel- or GMPCPP-stabilized microtubules were polymerized
and stabilized as described above (see section Tubulin purification and polymeriza-
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tion) and incubated with either (1) PX3Cy2−3OH108-G5; or (2) Cy2−3OH111-G5 and
OSS at a 7:1 ratio of dendrimers:tubulin dimers (2.1:0.29 µM) in MEM806.8 for 30,
105, or 180 min at room temperature prior to visualization by TIRFM. To deter-
mine the proportion of microtubules bound by dendrimers for each sample, a cov-
erslip area of 0.5-2 mm2 was scanned, the bound and unbound microtubules were
counted, and the number of microtubules counted were normalized to the total cov-
erslip area scanned. Statistical significance of the difference of the proportion of
dendrimer-bound microtubules counted between samples was determined using the
Fisher’s exact test at significance level α = 0.05.
TEM
Carbon-coated copper mesh TEM grids were glow-discharged using a Solarus 950
(Gatan, Inc., Pleasanton, CA). Samples were placed on the carbon-coated side of
the grid and negatively stained with a 0.75 % solution of uranyl formate.60 It was
assumed that the acidic pH of the stain would not significantly alter the pH of the
sample as the stain would fix the sample in ≤ 10 ms.61 Samples were imaged using a
Morgagni 268 transmission electron microscope (FEI, Hillsboro, OR).
Microtubule Bundling Observed by TEM
TMR-labeled microtubules were polymerized as described above (see section Tubu-
lin purification and polymerization) and pelleted from unpolymerized tubulin by cen-
trifugation (Airfuge, rotor A-100, Beckman, Fullerton, CA; 30 s at 30 psi). Af-
ter centrifugation, microtubules were resuspended in MEM806.8 to an estimated 3.2
µM, based on the microtubule recovery efficiencies determined previously (data not
shown). Microtubules (at 0.64 µM tubulin) were then incubated with either (1) 10 µM
paclitaxel; (2) 3.33 µM PX3Cy2−3OH108-G5 (which equates to 10 µM of conjugated
paclitaxel); or (3) 3.33 µM Cy2−3OH111-G5 to achieve a 1:1 ratio of dendrimer:tubulin
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dimers in MEM80 at variable pH, adjusted with KOH, for 30 min at room tempera-
ture prior to visualization by TEM.
Quantitative Analysis of Microtubule Bundling in TEM Images
The diameter of microtubule (bundles) in TEM images taken at 3,095x magnifi-
cation was measured at 10 pixel intervals and the corresponding microtubule length
was weighted according to the number of bundled microtubules determined to be in
that length. The diameter of a single, unbundled microtubule, within two standard
deviations from the mean, was assigned to the weight of 1, and this was used as a
basis to assign diameter ranges to higher weights for bundled microtubules. The frac-
tion of bundled microtubules in a sample was calculated as the fraction of bundled
microtubule length per total measured microtubule length. This analytical process
was automated using a MATLAB (MathWorks, Natick, MA) script written in-house.
Statistical Tests for Significance in Bundling
Statistical significance of the difference of mean bundled microtubule length be-
tween samples was tested using the Student’s t-test, assuming equal variances, at
significance level α = 0.05. Prior to this test, it was verified that the two samples
being compared had equal variances using the F -test at significance level α = 0.05.
All statistical tests were performed using the Statistics Toolbox in MATLAB (Math-
Works, Natick, MA).
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3.3 Results and Discussion
Probing the Interactions of Modified PAMAM Dendrimers with Micro-
tubules
The design of the paclitaxel-conjugated, generation 5 (G5) or 3 (G3), PAMAM
dendrimers used in this study, hereafter referred to by their stoichiometry as PX3Cy2−3-
OH108-G5 (Figure 3.1) and PX3Cy2−3OH26-G3, respectively, was based on the G5
paclitaxel-conjugate used in our previous cytotoxicity study.53 As the purpose of the
previously designed conjugate was for targeted cancer drug delivery, the conjugate
bore the therapeutic drug paclitaxel, the tumor targeting molecule folic acid, and
the fluorescent molecule FITC. In the current study, folic acid was not included on
the conjugates for simplicity since these the conjugated were not tested on cells, and
replaced the fluorophore FITC with Cy5 to achieve the most sensitive detection by
objective-type TIRFM.62
For increased stability during chemical conjugation, a new paclitaxel-dendrimer
linker was developed that contained an ester-disulfide-amide linker instead of the
double-ester linker used in the previous study (Figure 3.1).53 An additional benefit
to this change is that the disulfide bond may be cleaved in the reductive environment
of the endosome or lysosome, if the conjugate enters the cell via receptor-mediated
endocytosis. This mechanism has shown promise for the delivery of drug thera-
peutics linked to carriers with disulfide bonds,63 including the specific case using
paclitaxel,57,58 although the supporting results are still debated.64
Generally, the synthesis, purification, and analysis of the conjugates were per-
formed following standard methods described elsewhere (Materials and Methods and
Supplementary Materials).65 Cy5 was first conjugated to the G5, or G3, dendrimer
at a mean stoichiometric ratio of 2-3 fluorophores per dendrimer, as determined by
1H NMR and UV-Vis spectroscopy. Next, the paclitaxel-linker was conjugated to the
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G5 and G3 dendrimer core at a mean stoichiometric ratio of 3.2 and 2.8, respectively,
drug molecules per dendrimer, as determined by 1H NMR spectroscopy. Prior to
conjugation to the dendrimer, the integrity of the paclitaxel-linker was confirmed by
high resolution mass spectroscopy and 1H NMR spectroscopy. Finally, the remain-
ing surface groups on the dendrimer, initially primary amines, were neutralized by
the addition of hydroxyl groups, as previous studies have found that highly cationic
PAMAM dendrimers disrupt cellular membranes.66,67 UPLC was used to confirm
that no detectable level of free paclitaxel was present in the conjugate preparations
(see Supplementary Materials) and that the paclitaxel conjugate was stable in wa-
ter for up to 20 h, which is much greater than the time period of an experiment
(≤ 6 h). As negative controls, G5 dendrimers without paclitaxel were synthesized
in parallel with PX3Cy2−3OH108-G5, with the exemption of the paclitaxel conjuga-
tion steps. Therefore, the only chemical difference between these dendrimers and
PX3Cy2−3OH108-G5 is the presence of paclitaxel. Hereafter this dendrimer will be
referred to as Cy2−3OH111-G5.
Microtubule polymerization and all experiments were carried out in a standard,
near-physiological buffer termed “MEM806.8”, composed of 80 mM MES-KOH, pH
6.8, 1 mM ethylene glycol tetraacetic acid (EGTA), and 2 mM MgCl2 (Materials and
Methods). This buffer will be referred to as only “MEM80” when the pH is varied
from 6.8. MEM806.8 is identical in composition to BRB80, a buffer commonly used for
polymerizing microtubules in vitro,68 except the buffering agent PIPES is replaced by
MES.25 For observing dendrimer binding by TIRFM co-localization, sparsely 5-(6)-
carboxytetramethylrhodamine succimidyl ester (TMR)-labeled tubulin purified from
bovine brain, as described before,10 were used and a dendrimer:tubulin dimer ratio of
7:1. No binding events were observed by TIRFM when the dendrimer concentration
was significantly less than a 7-fold excess of the tubulin concentration. Since there
are on average three paclitaxel molecules conjugated to each dendrimer, this ratio
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would equate to achieving a cellular paclitaxel concentration of 300-400 µM, assuming
an average cellular tubulin concentration of 15-20 µM.69,70 To decrease background
signal from unbound dendrimers, TEM assays were performed at a slightly lesser
dendrimer:tubulin dimer ratio of 1:1, which corresponds to a cellular paclitaxel con-
centration of 15-20 µM. Note that although the paclitaxel concentrations used in our
experiments seem very high in this context, these concentrations are standard for in
vitro stabilization of microtubules,71 which are the focus of this study.
G5 PAMAM Dendrimers Induce Turbidities in Tubulin Solutions Compa-
rable to Paclitaxel
Turbidity assays are standard ensemble microtubule polymerization assays as the
turbidity of a tubulin solution is a reliable measure of the mass of microtubules
present.72 To determine the ability of PX3Cy2−3OH108-G5 to induce microtubule poly-
merization and stabilization compared to paclitaxel, tubulin was mixed together with
these components and monitored the turbidity of the mixtures at 37 ◦C for 30 min, as
described in the Materials and Methods section and elsewhere.59 The following con-
trols were also tested for comparison: (1) tubulin in the absence of GTP, paclitaxel,
or dendrimers; and (2) tubulin, GTP, and Cy2−3OH111-G5.
The results of these turbidity assays are summarized in Figure 3.2. During the
time course of the experiment, the turbidity of all tubulin mixtures increased in an
exponential fashion (R2 = 0.96-0.99), except for the tubulin mixture not containing
GTP, paclitaxel, or dendrimers, which increased in a linear fashion (R2 = 0.9995)
(Figure 3.2a). Notably, the turbidity limits reached by the tubulin mixtures in the
presence of paclitaxel, PX3Cy2−3OH108-G5, or Cy2−3OH111-G5 were not significantly
different (p > 0.05, Student’s t-test), on average (Figure 3.2b). However, the rate of
turbidity change was about 3-fold greater in the presence of paclitaxel, compared to




Figure 3.2: Turbidity polymerization assays. (a) The average turbidities of 2 mg/mL
tubulin (Tub) solutions in the presence of (1) no extra components (black;
n = 2); (2) GTP and paclitaxel (PX) (red; n = 3); (3) GTP and
PX3Cy2−3OH108-G5 (green; n = 3); or (4) GTP and Cy2−3OH111-G5
(blue; n = 4) was monitored at 340 nm once every minute for 30 min
at 37 ◦C. Error bars are not shown for clarity. All turbidity trends, with
the exception of tubulin alone (which was fit with a linear equation),
were fit with the exponential growth equation y = A(1-e−kt) at R2 =
0.96-0.99. (b) The average turbidity limits (parameter A from fit) from
the tubulin mixtures in the presence of GTP and (1) paclitaxel (PX);
(2) PX3Cy2−3OH108-G5 (PXG5); or (3) Cy2−3OH111-G5 (G5). (c) The
average rate of turbidity changes (parameter k from fit) from the tubulin
mixtures.
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not significantly different from each other; p > 0.05, Student’s t-test) (Figure 3.2c).
The exponential increase in turbidity of the tubulin mixtures in the presence of den-
drimers while at 37 ◦C suggests the formation of microtubules or alternatively, non-
microtubule tubulin aggregates. To distinguish between these alternatives, TIRFM
was used, which allows visualization of single microtubules.
PX3Cy2−3OH108-G5 Stabilize Polymerizing Microtubules
To determine if the dendrimers are able to induce to the formation of microtubule-
like structures, the same general procedure was followed as with the turbidity assays,
except mixing in a small fraction of TMR-labeled tubulin (5% of all tubulin dimers
carry one TMR dye, see Materials and Methods) to allow visualization by TIRFM.
To further test the ability of PX3Cy2−3OH108-G5 to not only promote polymerization
of microtubules, but to stabilize them, the tubulin mixtures were incubated at room
temperature following the 30 min incubation at 37 ◦C. Prior to the experiment, it was
determined determined how long a tubulin mixture in the presence of only GTP has
to be incubated at room temperature (180 min) before the concentration of unpoly-
merized tubulin in solution becomes so great that the fluorescence from this tubulin
obscures the fluorescence of any remaining microtubules on the slide surface.
The results of these TIRFM experiments are summarized in Figure 3.3. No mi-
crotubules were observed in the absence of paclitaxel after 180 min (Figure 3.3a);
but instead a fluorescent haze (not shown) due to the high concentration of unpoly-
merized tubulin in solution. Contrast adjustment of these images revealed unpoly-
merized tubulin on the surface (Figure 3.3a). By contrast, typical microtubules,
identified as green rods based on their TMR fluorescence, were polymerized and
stabilized by free paclitaxel, in the absence of dendrimers (Figure 3.3b). In the
presence of PX3Cy2−3OH108-G5, microtubule-like green rods (Figure 3.3c), similar to
those observed in Figure 3.3a, were co-localized with PX3Cy2−3OH108-G5, which are
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Figure 3.3: Polymerization assays imaged by TIRFM. Images from the TMR channel
(green: microtubules) are overlaid onto images from the Cy5 channel (red:
dendrimers). Scale bar shown is 10 µm. In these assays, 2 mg/mL α/β-
tubulin heterodimers are incubated with either (a) no stabilizers; (b) free
paclitaxel; (c) PX3Cy2−3OH108-G5; or (d) Cy2−3OH111-G5 in MEM806.8
supplemented with 1 mM GTP at 37 ◦C for 30 min, then at room tem-
perature for 180 min. To obtain the best image in the presence of a high
density of microtubules, the microtubule-paclitaxel sample (b) was di-
luted 4-fold (as compared to the imaging concentration in the other three
samples, which were equal) immediately prior to imaging.
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found through their red Cy5 fluorescence. With a few exceptions, PX3Cy2−3OH108-
G5 dendrimers were often observed to co-localize at the ends of the microtubule-like
rods. The apparent microtubules observed in Figure 3.3c were likely stabilized by
PX3Cy2−3OH108-G5, since microtubules polymerized at the tubulin concentrations
used in this experiment completely depolymerize after 180 min (the incubation time
used in this experiment) in the absence of dendrimers and paclitaxel (Figure 3.3a).
However, stabilization by PX3Cy2−3OH108-G5 was very inefficient compared to free
paclitaxel, as evidenced by the difference in microtubule density between Figures 3.3b
and c, made even greater by the fact that the tubulin imaging concentration in Fig-
ure 3.3c was about 4-fold greater than the concentration in Figure 3.3b. This reduc-
tion in tubulin imaging concentration for Figure 3.3b was implemented in order to
get a clear image, as the microtubules were initially too dense on the slide at the
imaging concentration of Figure 3.3a; c-d. In the presence of paclitaxel-unconjugated
Cy2−3OH111-G5, only non-cylindrical tubulin aggregates were observed, which were
seemingly bound by dendrimers, as evidenced by the co-localization of green TMR
and red Cy5 fluorescence in some areas (Figure 3.3d).
Together, these results suggest that PX3Cy2−3OH108-G5 is able to bind micro-
tubules specifically through the conjugated drug, resulting in the stabilization of mi-
crotubules polymerized in the presence of the paclitaxel-dendrimer conjugate. This
stabilization is, however, very inefficient compared to free paclitaxel. This apparent
decrease in binding affinity of the dendrimer-conjugated paclitaxel compared to free
paclitaxel may result from its conjugation to the dendrimer, as previous studies have
shown that paclitaxel prodrugs modified at the same paclitaxel functional group,
the 2’ OH (see Figure 3.1), have reduced affinity for microtubules.54–56 Additionally,
or alternatively, the size of the dendrimer (≈ 5.4 nm) may hinder the binding of a
sufficient number of paclitaxel-conjugated dendrimers to accomplish microtubule sta-
bilization. Notably, while some microtubules were bound along their entire length by
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PX3Cy2−3OH108-G5, many were only bound at the ends (Figure 3.3c). It is possible
in these cases that tubulin dimers bound by PX3Cy2−3OH108-G5 are added to the (+)
end of an existing microtubule, stabilizing the (+) end and slowing depolymerization.
It is also important to note that Cy2−3OH111-G5—and presumably PX3Cy2−3OH108-
G5 as well—binds tubulin through an interaction independent of paclitaxel, and that
this interaction does not promote stabilization of microtubules.
Interpreting these results together with the turbidity results (Figure 3.2), PX3-
Cy2−3OH108-G5 is able to induce a very low level of polymerization via the conjugated
paclitaxel. In addition, as the TIRFM image in Figure 3.3d suggests, even in the ab-
sence of conjugated paclitaxel, Cy2−3OH111-G5 is able to induce tubulin aggregation,
which may also lead to an increase in turbidity. Presumably, since PX3Cy2−3OH108-
G5 is identical in structure to Cy2−3OH111-G5 with the exception of three molecules
of paclitaxel, PX3Cy2−3OH108-G5 can also induce tubulin aggregation. These inter-
pretations may explain the observation that the dendrimers increase the turbidity of
a tubulin solution to a level comparable with paclitaxel (Figure 3.2).
PX3Cy2−3OH108-G5 Binds Paclitaxel- but Not GMPCPP-stabilized Micro-
tubules
It was next sought to determine if PX3Cy2−3OH108-G5 could bind and stabi-
lize pre-assembled microtubules, which it would also encounter in the cell. To test
this idea, co-localization of PX3Cy2−3OH108-G5 with pre-assembled microtubules was
probed for by TIRFM. Tubulin dimers were pre-assembled into microtubules and
these microtubules were stabilized with an equimolar concentration of free paclitaxel
(Materials and Methods), the concentration of which was subsequently reduced by
4-fold dilution upon incubation for 30, 105, or 180 min at room temperature with
PX3Cy2−3OH108-G5 or Cy2−3OH111-G5 in MEM806.8, which did not contain any ad-
ditional free paclitaxel, at a 7:1 ratio of dendrimers:tubulin dimers. The number
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of microtubules bound or unbound by dendrimers was counted for each sample and
normalized by the total coverslip surface area scanned.
When incubated with PX3Cy2−3OH108-G5, two distinct populations of micro-
tubules were observed (Figure 3.4a): (1) those that only fluoresced in the TMR
emission channel (green in images, corresponding to tubulin); and (2) those that flu-
oresced in the Cy5 channel (corresponding to PX3Cy2−3OH108-G5 fluorescence) only
(red in images) or in addition to the TMR channel (yellow in images). Population 1
appears entirely free of PX3Cy2−3OH108-G5 whereas population 2 is bound through-
out by PX3Cy2−3OH108-G5, sometimes so extensively that the TMR signal is not
observed, likely due to fluorescence resonance energy transfer (FRET) from TMR on
the tubulin to Cy5 on the dendrimer (top left image in Figure 3.4a). Note that no
microtubules that are only bound by dendrimers at the microtubules ends are ob-
served in the present experiment as they were in Figure 3.3c, and that few uniformly
bound microtubules are observed in Figure 3.3c compared to the present experiment.
This apparent discrepancy may be due to limited sampling.
Different structural populations of PX3Cy2−3OH108-G5-bound microtubules were
also observed. Some appeared similar to unbound microtubules (top two images
in Figure 3.4a), but some had a distinctly larger diameter (bottom left image in
Figure 3.4a) whereas others seemed to be bundled microtubules, as represented by
the microtubule(s) in the bottom right image of Figure 3.4a, which appears to have
a split tail.
Overall, the fraction of the total microtubule population that was bound by PX3-
Cy2−3OH108-G5 was initially very small—only 3.4% at the 30 min time point. The
bound fraction increased over time, but this partially coincided with a drastic de-
crease in the total microtubule population (Figure 3.4e). This population decrease
was likely due to inadequate stabilization by PX3Cy2−3OH108-G5. The very few mi-















Figure 3.4: Co-localization assays between dendrimers and pre-formed microtubules
visualized by TIRFM. Images from the TMR channel (green: micro-
tubules) and Cy5 channel (red: dendrimers) are overlaid. Scale bar
shown is 10 µm. Microtubules were polymerized, stabilized with ei-
ther free paclitaxel (a-b) or GMPCPP (c-d), then incubated with either
PX3Cy2−3OH108-G5 (a,c) or Cy2−3OH111-G5 (b,d) for 30, 105, or 180 min
at room temperature. All images shown are from the 30 min time point,
and each 2 x 2 grid of images are from the same sample. The number of
microtubules bound or unbound by dendrimers was counted for each sam-
ple and normalized by the total coverslip surface area scanned. The plot
in (e) shows these normalized data for the GTP-stabilized microtubules
and the PX3Cy2−3OH108-G5 samples over time.
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presumably stabilized, by PX3Cy2−3OH108-G5. Recall that PX3Cy2−3OH108-G5 was
observed to stabilize microtubules in Figure 3.3c, and that this stabilization seemed
much less efficient than that induced by free paclitaxel. However, the extent of stabi-
lization in this latter experiment can not be quantitatively compared with the current
experiment as the former provided only qualitative observations. The negative con-
trol dendrimer, Cy2−3OH111-G5, showed an even smaller incidence of binding: only
2.2% of paclitaxel-microtubules after 105 min. No binding was observed at the 30
and 180 min time points. As found with PX3Cy2−3OH108-G5, all bound microtubules
observed were bound by Cy2−3OH111-G5 along their entire length (Figure 3.4b).
Because so few microtubules bound by PX3Cy2−3OH108-G5 were observed, it was
next asked whether PX3Cy2−3OH108-G5 may still be competing for paclitaxel binding
sites with the free paclitaxel used to initially stabilize the microtubules immediately
after polymerization, even though its concentration was reduced 20-fold by buffer ex-
change upon incubation with PX3Cy2−3OH108-G5. To this end, stable microtubules
were polymerized in the presence of GMPCPP (a slowly hydrolyzable analogue of
GTP)73 instead of GTP and paclitaxel. Hereafter, these populations will be re-
ferred to as GMPCPP-microtubules and GTP-microtubules, respectively. The results
of this experiment are shown in Figure 3.4c-d. The fraction of PX3Cy2−3OH108-
G5-bound GTP-microtubules observed was significantly greater (p < 0.05) than
PX3Cy2−3OH108-G5-bound GMPCPP-microtubules at all time points. With Cy2−3-
OH111-G5, this difference was significantly greater only at the 105 min time point.
These observations suggest that PX3Cy2−3OH108-G5 can either associate more
readily with GTP-microtubules or dissociate more readily from GMPCPP-micro-
tubules, and that this observation is specifically caused by the paclitaxel on the den-
drimer. As these observations directly oppose those obtained with free paclitaxel,74
the paclitaxel-dependent binding mechanism of PX3Cy2−3OH108-G5 does not likely
include access an interior paclitaxel binding site through the microtubule walls.74
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Since the dendrimers often bind the entire microtubule length, and it is not likely
that PX3Cy2−3OH108G5 is able to diffuse along the microtubule length while inside
the microtubule within the time frame of the experiments,75 PX3Cy2−3OH108-G5 is
also not likely binding an interior paclitaxel binding site by entering through its
ends. Therefore, it is possible that PX3Cy2−3OH108-G5 is either: (1) not binding pre-
assembled microtubules, but assembling microtubules that have luminal paclitaxel
binding sites exposed to solution, and remaining associated with these microtubules
as they complete assembly; or (2) binding an exterior paclitaxel binding site.
The first mechanism is supported by the fact that GTP-microtubules depolymer-
ize faster than GMPCPP-microtubules,73 which is consistent with the observation
of more dendrimer bound GTP-microtubules than GMPCPP-microtubules. Further-
more, this may be the binding mechanism utilized by PX3Cy2−3OH108-G5 in the
experiments shown in Figure 3.3 since in these experiments, PX3Cy2−3OH108-G5 was
included from the start of the polymerization reaction. The second mechanism is
supported by published biochemical and computational data that provides evidence
for an exterior paclitaxel binding site.76–78 If the latter mechanism were occurring in
our experiments, it would not disprove the idea that an interior paclitaxel binding
site exits,79 but merely support the hypothesis that there is an additional exterior
paclitaxel binding site. It is therefore concluded that the low binding incidence of
PX3Cy2−3OH108-G5 is unlikely due to competition with the free paclitaxel used to
stabilize the microtubules in the previous experiment.
In addition to G5 paclitaxel-conjugated dendrimers, the ability of a G3 paclitaxel-
conjugated dendrimer to bind microtubules was also tested. G3 PAMAM dendrimers
are smaller than G5 PAMAM dendrimers, ≈ 3.6 nm vs. 5.4 nm.43,44 Our G3 conju-
gate (see Supplementary Materials for structural details), named PX3Cy2−3OH26-G3
according to its stoichiometry, has the same number of conjugated paclitaxel and
Cy5 molecules per dendrimer as our G5 conjugates, and the same neutral hydroxyl
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structure on the remaining end groups. When PX3Cy2−3OH26-G3 was incubated with
either paclitaxel- or GMPCPP-stabilized microtubules for 30, 105, or 180 min, under
the same conditions used for the G5 conjugates (see above), no binding events were
observed (data not shown). The fact that our G3 paclitaxel-conjugates cannot bind
microtubules, but our G5 paclitaxel-conjugates can, may be due to the lower density
of protonatable amines in the G3 vs. G5 dendrimer core (10 vs. 40 at pH 6.8; see
results in subsequent sections).80
Taking these observations together, it is proposed that PX3Cy2−3OH108-G5 is able
to bind microtubules by two mechanisms: (1) binding and stabilizing polymerizing
microtubules in a paclitaxel-dependent manner; and (2) binding pre-formed micro-
tubules in a paclitaxel-independent manner, potentially mediating bundling of these
microtubules. The first mechanism is supported by the polymerization experiments
described above (see Figure 3.3). The second mechanism is supported by the fact
that high concentrations of paclitaxel (≥33 nM),81 and certain microtubule binding
proteins,82 are known to induce bundling of microtubules, as well as by the two lower
images of Figure 3.4a.
It is important to note that while the experiments described thus far suggest
these two mechanisms, the ability of PX3Cy2−3OH108-G5 to bind and stabilize mi-
crotubules appears by TIRFM to be very low and inefficient, as compared to free
paclitaxel. This may be due to a decreased ability, compared to free paclitaxel, of
the conjugated paclitaxel to access its binding site in the microtubule lumen. It has
been proposed that in vivo small molecules such as paclitaxel are able to access the
microtubule lumen through ≈ 1 nm pores in the microtubule wall,74,83 whereas large
molecules, such as the enzyme tubulin acetyltransferase, are able to access the mi-
crotubule lumen either through large transient openings in the microtubule wall or
by copolymerization.84,85 The size of PX3Cy2−3OH108-G5 is on the order of tubulin
acetyltransferase, and indeed it have been observed that PX3Cy2−3OH108-G5 is able
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to bind and stabilize polymerizing microtubules to some degree, however, it is possible
that the entry mechanism utilized by large molecules such as tubulin acetyltransferase
in vivo is not readily available to PX3Cy2−3OH108-G5 in vitro. It is also possible that
PX3Cy2−3OH108-G5 may be able to access the microtubule lumen via the ≈ 17 nm
diameter openings at the microtubule ends (Figure 3.3c). However, modeling studies
have predicted that paclitaxel would take days to reach half equilibrium concentra-
tion in the center of a 40 µm microtubule (typical microtubule lengths are 1-100 µm),
and an antibody would take years.75 The paclitaxel-conjugated dendrimer, which has
a molecular weight far greater than that of paclitaxel alone, but lower than that
of an antibody, would also likely take days to years. Therefore, it is unlikely that
PX3Cy2−3OH108-G5 is accessing its luminal binding site via this mechanism on the
microtubules that are observed to be bound by PX3Cy2−3OH108-G5 along their entire
length (Figure 3.4), and may be binding the outside wall of the microtubule in these
instances.
Surface Neutralized G5 PAMAM Dendrimers Bundle Microtubules in a
Paclitaxel-Independent Manner
The bundling mechanism discussed above is indirectly supported by the observa-
tion that some dendrimer-bound microtubules seem to have a greater diameter than
unbound microtubules. Figures 3.4a-b (microtubules in the presence of PX3Cy2−3-
OH108-G5 or Cy2−3OH111-G5, respectively) show this qualitatively. In addition, the
results of Figure 3.2 in conjunction with those of Figure 3.3 suggest that the den-
drimers induce the formation of large tubulin aggregates. In order to directly ob-
serve the structure of these PX3Cy2−3OH108-G5-bound microtubules and determine
whether they are bundled, an imaging technique with greater spatial resolution than
TIRFM, electron microscopy, was used next.
Electron microscopy is routinely used to measure the diameter of microtubules.76,86–88
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Employing the same reagents that were used for the TIRFM experiments, and the
same protocol—with the additional step of separating polymerized microtubules from
unpolymerized tubulin via centrifugation to decrease tubulin background (Materials
and Methods)—it was sought to examine dendrimer-bound microtubules via negative-
stain TEM. Negative staining enables single microtubules to be observed, which is
advantageous since dendrimers may have multiple effects on microtubules. Using
TEM, microtubule diameter cannot be precisely measured due to the requirement
that the sample be dried, thereby collapsing the microtubules. Nonetheless, bundled
microtubules will be easily distinguished from unbundled microtubules.
To determine if PX3Cy2−3OH108-G5 induces microtubule bundling, the same as-
says were performed as for the TIRFM imaging above (Figure 3.4). That is, pre-
assembled microtubules were incubated with either paclitaxel, PX3Cy2−3OH108-G5,
or Cy2−3OH111-G5 for 30 min at room temperature, and then imaged the samples
via TEM. To obtain a rough estimate of the degree of bundling in each sample (Fig-
ure 3.5g), the diameter of a microtubule (bundle) was measured at 10 pixel intervals
and weighted according to the estimated number of bundled microtubules present in
that interval, where the mean diameter of a single, unbundled microtubule within
two standard deviations was assigned a weight equal to one. This measurement re-
sults in a set of bundled or unbundled microtubule lengths, which are then summed
and used to calculate the fraction of bundled microtubule lengths for each sample.
This analytic method only provides a rough estimate of the degree of bundling, as
the thickness of the microtubule bundle cannot be measured in the z-direction from
the TEM images. However, using the planar thickness of the bundles to estimate
the number of microtubules present should be sufficient to compare the degree of
bundling among the samples tested.
Figures 3.5a and 3.5d show the typical structure of paclitaxel-stabilized micro-











Figure 3.5: Negative-stain TEM images obtained at 3,095x (a-c; scale bar = 1 µm)
or 24,628x magnification (d-f; scale bar = 100 nm). Microtubules are
incubated in MEM806.8 at room temperature for 30 min with either: pa-
clitaxel (a,d); PX3Cy2−3OH108-G5 (b,e); or Cy2−3OH111-G5 (c,f). The
amount of bundling in a population is represented as the fraction of bun-
dled microtubule length (g).
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ison, Figures 3.5b and 3.5e show microtubules in the presence of PX3Cy2−3OH108-G5,
revealing that PX3Cy2−3OH108-G5 induces formation of microtubule bundles of vari-
ous sizes. The PAMAM dendrimers are not easily resolved in these images due to their
small size, low electron mass compared to the carbon imaging grid, and high back-
ground from dendrimers and unpolymerized tubulin. Small bundles, containing 2-3
microtubules, were observed in the absence of dendrimers, but the fraction of the total
population represented by these bundles was significantly smaller (p < 0.05) than the
fraction observed in the presence of PX3Cy2−3OH108-G5, as quantified in Figure 3.5g.
Intriguingly, a large amount of microtubule bundles was also observed in the presence
of Cy2−3OH111-G5 (Figure 3.5c,f), and this bundled fraction was not significantly
different from the bundling fraction measured in the presence of PX3Cy2−3OH108-G5
(p > 0.05) (Figure 3.5g).
Surface Neutralized G5 PAMAM Dendrimers Bundle Microtubules via
Electrostatic Interactions
It was next sought to identify the properties of PX3Cy2−3OH108-G5 and Cy2−3OH108-
G5 that induce microtubule bundling. Microtubule bundles have been observed
both in vitro and in vivo, induced by paclitaxel,81 microtubule-associated proteins
(MAPs),82 or polyamines.89 The mechanism of action for these microtubule bundling
agents has been postulated to be cross-linking and/or charge shielding (i.e., binding
the C-terminal tails of the microtubules where the majority of the negative charge
is located, thereby reducing electrostatic repulsion between microtubules and allow-
ing them to associate laterally). The fact that there is no significant difference in
the amount of bundling induced by PX3Cy2−3OH108-G5 as compared to Cy2−3OH111-
G5 (see Figure 3.5) precludes the contribution of paclitaxel. The commonalities in
the chemical structures of PX3Cy2−3OH108-G5 and Cy2−3OH111-G5 (Figure 3.1)—
the fluorescent dye Cy5 and the dendrimer core itself—were therefore considered to
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determine if either of these components contribute to the observed bundling.
First, considering the dendrimer core structure, it was realized that it contains
interior tertiary amines with pKa equal to 6.5 ± 0.2 (derived from potentiometric
titration; see Supplementary Materials), and therefore a fraction of these will be pos-
itively charged at neutral pH. It is feasible that the interior amines of the dendrimer
core could encounter the microtubule surface, as the branched structure of the core
is highly flexible and has been predicted by molecular dynamics simulations, and
demonstrated by atomic force microscopy, to flatten into a disc-like structure upon
encountering a surface.90 Therefore, it is hypothesized that these protonated tertiary
amines contact the microtubule surface and induce microtubule bundling through
cross-linking and/or charge shielding. In support of this hypothesis, it is found that
unmodified G5 PAMAM dendrimers, hereafter referred to as (NH2)114-G5, carrying
114 protonatable primary amines on the surface, but no paclitaxel or Cy5, are also
able to bundle microtubules to a significant degree compared to microtubules alone
(p < 0.05) (Figure 3.6), although its bundling ability is seemingly lesser than that
of PX3Cy2−3OH108-G5 (or by extension, Cy2−3OH111-G5). This difference is possibly
attributed to the fact that (NH2)114-G5 dendrimers would be highly electrostatically
repulsed from each other as they are highly cationic, and therefore fewer (NH2)114-
G5 might bind a microtubule than the surface neutralized PX3Cy2−3OH108-G5 or
Cy2−3OH111-G5. Because the cationic (NH2)114-G5 was able to bundle microtubules,
it was therefore sought to test the impact of the positive charges from the interior
tertiary amines of PX3Cy2−3OH108-G5 on the ability of these dendrimers to bundle
microtubules.
To test the hypothesis that the cationic amines of the dendrimer core interior
contribute to the microtubule bundling observed by TIRFM and TEM, the pH of the
MEM80 incubation buffer was incrementally increased from 6.5 to 8.3 using KOH,







Figure 3.6: Microtubules are incubated with (NH2)114-G5 for 30 min in MEM806.8
and visualized by negative-stain TEM at 3,095x (a; scale bar = 1 µm) or
24,628x (b; scale bar = 100 nm). The amount of bundling in each sample
was quantified as before (c), from ten 25.38 µm2 images from each of
three trials. The data from microtubules in the absence of dendrimers
(sample 2 in c) was introduced previously (Figure 3.5), but is shown here
for reference.
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increases, the fraction of tertiary amines in the dendrimer core that are protonated,
and therefore positively charged, decreases (Figure 3.7g). If the observed dendrimer-
induced bundling is mediated by electrostatics, microtubule bundling will decrease
with increasing pH. Only PX3Cy2−3OH108-G5 dendrimers were used for these exper-
iments.
The images of Figure 3.7a-f show qualitatively that the amount of bundling does
indeed decrease as the pH increases. The degree of bundling in each sample is roughly
estimated as before (Figure 3.7g), and a pH titration curve is fit to the data with an
excellent correlation coefficient, R2 = 0.94, suggesting that the observed bundling is
indeed pH dependent. From the titration curve, a pKa of bundling equal to 7.6 ±
0.1 is extracted.
The source of the bundling pH dependence could be one or both of the following:
(1) electrostatic interactions between the cationic amines in the dendrimer core and
the anionic C-terminal tubulin tails on the microtubule surface; or (2) the instability
of microtubules at alkaline pH.91 Considering the first mechanism, the pH increase
would cause both a decrease in the number of protonated, cationic amines in the
dendrimer core, as well as an increase in the number of deprotonated, anionic C-
terminal tubulin tails on the microtubule surface. These changes would decrease any
electrostatic attraction between the dendrimers and the microtubules, as well as in-
crease the electrostatic repulsion between microtubules that do not have the negative
charges on their C-terminal tubulin tails shielded by bound dendrimers. Consider-
ing the second mechanism, it is known that microtubule disassembly increases with
increasing pH.91 Therefore, observing a decrease in microtubule bundling with in-
creasing pH my be observed simply due to increased microtubule disassembly. To
distinguish between these two possibilities, additional experiments, such as quantifi-
cation of microtubule bundling in the presence of PAMAM dendrimers after cleavage











Figure 3.7: Negative stain TEM images obtained at 3,095x magnification (scale
bar = 1 µm). Microtubules are incubated at room temperature with
PX3Cy2−3OH108-G5 for 30 min in MEM80, in which the pH has been
adjusted with KOH to: (a) 6.5; (b) 7.0; (c) 7.2; (d) 7.4; (e) 8.0; or
(f) 8.3. Bundling in each sample was estimated as before (g), from ten





) was fit to the data (R2 = 0.94). The
amount of bundling in the absence of dendrimers is shown for reference
(solid square labeled ‘MTs only’). The Henderson-Hasselbalch equation
(y = 126
1+10pH−6.5
) is used to determine the theoretical number of protonated
amines in the dendrimer core at the tested pH values (h).
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Implications of Dendrimer-Induced Microtubule Structural Changes for
Cancer Treatment
Both dendrimer-induced microtubule structural changes observed in this paper—
stabilization of polymerizing microtubules and bundling of pre-formed microtubules—
have the potential to stall mitosis in a dividing cell. In this respect, paclitaxel-
conjugated dendrimers show promise for use as cancer therapeutics, even without, or
upon slow, cleavage of the drug from the carrier. However, one of these structural
changes was not specific to the cancer drug paclitaxel, but rather the dendrimer core
itself.
Our previous study demonstrated that untargeted, surface neutralized G5 PAMAM
dendrimers are not cytotoxic,53,93 implying that paclitaxel, and less the dendrimer
core, induces cytotoxicity. While differences in dendrimer concentration between the
current study utilizing purified proteins and the prior study utilizing cultured cells
may explain this difference, or the possibility that paclitaxel was cleaved from the
dendrimer carrier intracellularly in the prior study, the current study underscores the
need for exercising caution when designing dendrimer-conjugates for the treatment
of diseases both responsive and non-responsive to paclitaxel, as the dendrimers may
have unintended cytotoxic effects not specific to paclitaxel due to their potential di-
rect electrostatic interactions with microtubules. More broadly, the current study
highlights the need for careful toxicity studies to be performed and target cell speci-
ficity to be achieved to control for and avoid such side effects; not only when using
PAMAM dendrimers as a carrier, but any other carrier molecules as well.
Nanoparticle toxicity is a topic that is very important to everyday life, as nanoma-
terials are being incorporated into a wide array of consumer products in addition to
therapeutics.94–96 Although it is recognized that nanoparticle toxicity stems from the
ability of nanoparticles to cross cellular membranes, and that this ability derives from
their small size97 and surface charge,66,98 it is not completely understood what the
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molecular basis of the toxicity is, or what physicochemical properties of nanoparticles
contribute to this toxicity.96–98 The present study further emphasizes the need for ad-
ditional studies addressing these questions, and advances a mechanism of cytotoxicity
for flexible cationic nanoparticles involving interior, cationic tertiary amines.
Conclusions
In the present study, it is found that paclitaxel-conjugated, fifth generation,
PAMAM dendrimers are able to affect microtubule structure via two mechanisms:
(1) by stabilizing polymerizing microtubules; and (2) by bundling pre-formed micro-
tubules. The latter mode of action is not specific to the activity of paclitaxel, as
surface neutralized G5 PAMAM dendrimers that are not conjugated with paclitaxel
are also able to bundle pre-formed microtubules to the same degree as paclitaxel-
conjugated dendrimers. The mechanism for this bundling is at least partially electro-
statically driven, mediated by tertiary amines located in the interior of the polyvalent
dendrimer core that cannot be neutralized through chemical modifications. The re-
sults of this study, therefore, demonstrate both the promise of paclitaxel-conjugated
dendrimers in the treatment of cancer and the necessity for further careful toxicity
studies of these and other cationic nanoparticles.
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CHAPTER IV
The Fluorescent Dyes Cy5 and TMR Induce
Microtubule Bundling Through Hydrophobic
Interactions1
4.1 Introduction
Nanoparticles are being increasingly incorporated into a wide array of consumer
products,94–96 making the study of their toxicity very important. Recently, nanopar-
ticles have been considered for use as targeted drug delivery platforms32,48,50 as they
may allow attachment of many different molecules, including the drug, targeting
molecules, and tracking/imaging molecules. In addition, nanoparticle attachment
may improve the water solubility, membrane permeability, and release timing of a
drug.31
Despite the increased utilization of nanoparticle technology, little is understood
concerning any associated toxicity. It has been established, however, that the nanome-
ter size of the particles increases toxicity as it: (1) increases their surface area, expos-
ing more reactive sites of the particles; (2) facilitates movement of the particles across
cellular and other internal barriers; and (3) enables their interaction with subcellular
1All tubulin was obtained from Edgar Meyhöfer. All modification and characterization of den-
drimers was done by Ming-Hsin Li. All TEM images were taken using the microcope in the lab of
Georgios Skiniotis.
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structures, such as DNA and microtubules.96 Besides their size, it is not completely
understood what physicochemical properties of these nanoparticles may contribute
to these toxic behaviors,96–98 and if these properties may be altered or controlled so
that their size is no longer a toxicity concern.
In addition to nanosize, nanoparticle charge has been implicated in nanotoxic-
ity.66,98 Indeed, the results of Chapter III in this dissertation shed light on one po-
tential reason why charge may contribute to nanotoxicity. The results of this earlier
chapter show that generation 5 (G5) polyamidoamine (PAMAM) dendrimers carry-
ing no microtubule-targeting molecules are able to bundle microtubules to a very
high degree in vitro.99 It was determined that this bundling was electrostatically-
driven, mediated by protonable tertiary amines in the dendrimer core that cannot be
neutralized.
Formation of microtubule bundles in vivo is necessary for proper assembly of
the mitotic machinery.100 These bundles consist of only a few microtubules and are
formed through cross-linking by various microtubule-associated proteins (MAPs).82
Thick microtubule bundles, such as those observed in Chapter III of this dissertation,
have also been observed to form in vivo when the neuronal microtubule binding
protein, tau, is expressed in non-neuronal cells in high concentrations.101 Tau was
found to bundle microtubules by forming cross-bridges between them. Furthermore,
this study found that cells with significant microtubule bundling could not proliferate.
One non-protein molecule has been reported to induce micotubule bundling. Sper-
mine, a polyamine naturally present at high concentrations in all eukaryotic cells, was
shown to bundle microtubules in vitro, but not aggregate or sequester free tubulin.89
This is in contrast to the observed activity of tau in non-neuronal cells, which has
been found to promote participation of free tubulin in the formation of thick micro-
tubule bundles.101 This phenomenon inhibits the degradation of β-tubulin mRNA,
causing tubulin production to increase, which in turn promotes the formation of even
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larger bundles.
Clearly, unregulated bundling and free tubulin aggregation—both observed to oc-
cur in the presence of G5 PAMAM dendrimers in Chapter III—would have drastic
consequences for the cell, as strict regulation of microtubule dynamics is essential for
proper chromosome movement during mitosis. Therefore, the results of Chapter III
warrant investigation of the following: (1) whether other cationic nanoparticles can
induce bundling; (2) what nanoparticle sizes, charge densities, and concentrations
are required for the induction of bundling; and (3) whether nanoparticles can induce
bundling in vivo. In the current study, these questions are addressed using various
G5 PAMAM dendrimers. In doing so, convincing evidence is found that the fluores-
cent dyes, Cy5 and TMR, can enhance microtubule bundling through hydrophobic
interactions.
4.2 Materials and Methods
Materials
MES, MgCl2, and GTP were all purchased from Fisher Scientific (Waltham, MA).
EGTA, paclitaxel, PCA, and PCD from Sigma-Aldrich (St. Louis, MO); Trolox from
Acros Organics (Geel, Belgium); GMPCPP from Jena Biosciences (Jena, Germany);
TMR from Molecular Probes (Eugene, OR); Cy succimidyl ester from GE Healthcare
Life Sciences (Piscataway Township, NJ) and Cy5 analog (CyA; 2-[(1E,3E)-5-(3,3-
Dimethyl-1-propyl-1,3-dihydro-2H-indol-2-ylidene)-1,3-pentadienyl]-3,3-dimethyl-1-propyl-
3H-indolium iodide; CAS # 53213-98-2) from H.W. Sand Corp. (Jupiter, FL).
Tubulin Purification and Polymerization
Tubulin was purified from bovine brain and fluorescently labeled with TMR by
Neha Kaul, Jenna Campbell, and Charles Chang Jiang in Edgar Meyhöfer’s lab.
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Briefly, tubulin was purified from bovine brain by two cycles of microtubule polymer-
ization in the presence of a high-molarity PIPES buffer.34 Tubulin was TMR-labeled
by reacting polymerized microtubules with a 20-fold excess of TMR at room temper-
ature for 30 min. Competent, TMR-labeled tubulin was purified from this mixture
by repeated depolymerization and polymerization.35
For all experiments, microtubules were polymerized by incubating 2 mg/mL (≈ 20
µM) α/β-tubulin dimers (using a mix of TMR-labeled and unlabeled tubulin dimers
to achieve a final ratio of 1 TMR dye per 20 dimers, as determined by UV-Vis, where
noted) with 4 mM MgCl2 and 1 mM GTP in MEM806.8 buffer (80 mM MES-KOH,
pH 6.8, 1 mM EGTA, 2 mM MgCl2) at 37
◦C for 30 min. After polymerization, the
microtubules were stabilized with 10 µM paclitaxel.
G5 PAMAM Dendrimers
G5 PAMAM dendrimers were purchased from Dendritech, Inc. (Midland, MI).
All modification, purification, and characterization of these dendrimers was done by
Ming-Hsin Li, member of James R. Baker’s lab, formerly at the University of Michi-
gan. The dendrimers were first purified using a 10 kDa MWCO dialysis membrane,
achieving a relatively monodisperse population (PDI = 1.01–1.05, determined by
GPC).38 The average number of primary amine end groups was determined to be 114
by potentiometric titration after purification by dialysis, membrane filtration, and
lyophilization.39 These dendrimers were then reacted with 5 molar equivalents of Cy5
NHS-ester to achieve an average of 2-3 Cy5 molecules per dendrimer, as determined
by 1H NMR and UV-Vis. The original terminal amine groups of the dendrimers were
either neutralized by the addition of acetyl groups, or made negatively charged by
the addition of carboxylic acid groups. A non-Cy5 control dendrimer was also identi-
cally synthesized, except it was not conjugated with Cy5, and its surface groups were
neutralized by the addition of acetyl group. According to their surface chemistry and
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stoichiometry, the G5 PAMAM dendrimers in this study will be referred to as: (1)
Cy2−3(COOH)111-G5 (negative surface charge); (2) Cy2−3(OH)111-G5 (neutral surface
charge); and (3) (OH)114-G5 (neutral surface charge).
TIRFM
Imaging chambers were prepared by affixing a cover glass (No. 1.5, 24x30 mm,
VWR, Radnor, PA) to a glass slide (Fischer Scientific, Waltham, MA) with double-
sided sticky tape. After the imaging solution was flown into the imaging channel, the
channel was sealed with candle wax. Images were taken on an inverted fluorescence
microscope (model IX81, Olympus, Center Valley, PA) using a 60x objective lens.
Samples were illuminated at either 532 nm (for TMR; type Compass 315M, Coherent
Inc., Santa Clara, CA) or 635 nm (for Cy5; type Cube 640-100C, Coherent Inc.,
Santa Clara, CA) at the critical angle, using a cellˆ TIRFTM Illuminator (Olympus,
Center Valley, PA). Fluorescent emissions were split into four separate channels using
a QV2 Quad View Imaging System (Photometrics, Tuscon, AZ) and projected onto an
EMCCD camera (model Evolve 512, Photometrics, Tuscon, AZ). Fluorescent images
were viewed using MetaMorph software (Molecular Devices, Sunnyvale, CA) and
further processed using either ImageJ (NIH) and/or MATLAB (The MathWorks,
Inc., Natick, MA).
TIRFM Bundling Assays
TMR-labeled, paclitaxel-stabilized microtubules were polymerized and stabilized
as described above (see section Tubulin purification and polymerization) and incu-
bated with either: (1) no additional components; (2) Cy2−3(COOH)111-G5; (3) PEG
600; (4) T7 RNA polymerase; or (5) Cy-PS at a 1:1 ratio (particle:tubulin dimers;
both at ≈ 0.5 µM) in MEM806.8 with oxygen scavenging system (OSS; 5 mM PCA,
50 nM PCD, 2 mM Trolox) and 10µM paclitaxel for 30 min at room temperature
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prior to visualization by TIRFM.
Quantifying Microtubule Bundling from TIRFM Images
The fraction of bundled microtubles in a sample was quantified using a custom
script written in MATLAB (MathWorks, Natick, MA) (see Appendix D of this dis-
sertation for code). Briefly, this script measures the intensity profile of a microtubule
by taking cross-sectional line scans, perpendicular to the microtubule axis, at 5 pixel
intervals. A Gaussian distribution is fit to each line scan and integrated to find the
area under the curve, which corresponds to the total fluorescence intensity at that
cross-section. The fluorescent intensity per unit length of a single, unbundled micro-
tubule was assumed to be within two standard deviations of the mean, as extracted
from the Gaussian fit, of the population distribution of microtubules measured in the
absence of dendrimers. This intensity range was assigned a weight of 1. Additional
weights for bundled microtubules were assigned as multiples of this range (dimers:
weight = 2, trimers: weight = 3, etc.). Using this weighting system, each measured
microtubule length was accordingly weighted and summed to determine the total
fraction of bundled microtubules in the sample.
TEM
Carbon-coated copper mesh TEM grids were glow-discharged using a Solarus 950
(Gatan, Inc., Pleasanton, CA). Samples were placed on the carbon-coated side of
the grid and negatively stained with a 0.75 % solution of uranyl formate.60 It was
assumed that the acidic pH of the stain would not significantly alter the pH of the
sample as the stain would fix the sample in ≤ 10 ms.61 Samples were imaged using
a Morgagni 268 transmission electron microscope (FEI, Hillsboro, OR) in the lab of
Georgios Skiniotis at the University of Michigan.
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TEM Bundling Assays
TMR-labeled—or unlabeled, where indicated—microtubules were polymerized as
described above (see section Tubulin purification and polymerization) and pelleted
from unpolymerized tubulin by centrifugation (Airfuge, rotor A-100, Beckman, Fuller-
ton, CA; 30 s at 30 psi). After centrifugation, microtubules were resuspended in
MEM806.8 to an estimated 3.2 µM, based on the microtubule recovery efficiencies
determined previously (data not shown). Microtubules (at 0.64 µM tubulin) were
then incubated with either (1) 10 µM paclitaxel; (2) 0.64 µM Cy2−3(OH)111-G5; (3)
0.64 µM (OH)114-G5; or (4) CyA (unconjugated Cy5 analog) in MEM806.8 for 30 min
at room temperature prior to visualization by TEM.
For all salt bundling assays, 0.64 µM of PX3Cy2−3OH108-G5 was used in the same
protocol as above. MgCl2 or KCl was added to MEM806.8 to a final concentration of
2-50 mM in excess of the salt already present in the buffer.
Quantifying Microtubule Bundling from TEM Images
The diameter of microtubule (bundles) in TEM images taken at 3,095x magnifi-
cation was measured at 10 pixel intervals and the corresponding microtubule length
was weighted according to the number of bundled microtubules determined to be in
that length. The diameter of a single, unbundled microtubule, within two standard
deviations from the mean, was assigned to the weight of 1, and this was used as a
basis to assign diameter ranges to higher weights for bundled microtubules. The frac-
tion of bundled microtubules in a sample was calculated as the fraction of bundled
microtubule length per total measured microtubule length. This analytical process
was automated using a MATLAB (MathWorks, Natick, MA) script written in-house.
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Statistical Tests for Significance in Bundling
Statistical significance of the difference of mean bundled microtubule length be-
tween samples was tested using the Student’s t-test, assuming equal variances, at
significance level α = 0.05. Prior to this test, it was verified that the two samples
being compared had equal variances using the F -test at significance level α = 0.05.
All statistical tests were performed using the Statistics Toolbox in MATLAB (Math-
Works, Natick, MA).
4.3 Results and Discussion
Implications of G5 PAMAM Dendrimer Cytotoxicity
From the advent of their design, G5 PAMAM dendrimers have been of interest to
the drug development field as potential drug carriers for targeted delivery due to their
water solubility and high multi-valency.44,48 In their native state, PAMAM dendrimers
are terminated by primary amines, which are positively charged at a neutral pH. It
has been found that the high cationic surface charge of these dendrimers makes them
cytotoxic as it allows them to poke holes in cellular membranes.66,93 These previous
studies showed that neutralizing > 80% of the dendrimer’s terminal amine groups
eradicates their cytotoxicity. However, the results in Chapter III of this dissertation
show that high concentrations of G5 PAMAM dendrimers will induce microtubule
bundling in vitro, even when 100 % of the terminal amine groups are neutralized.
These dendrimers were found to bundle microtubules via electrostatic interactions
between internal protonable amines in their core—which cannot be neutralized—
and the microtubule surface.99 Therefore, the cytotoxicity of PAMAM dendrimers
warrants additional investigation.
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Increases in Ionic Strength Correspond to Decreases in Microtubule
Bundling
To better understand dendrimer-induced microtubule bundling (Chapter III), the
effects of buffer ionic strength were first tested. If dendrimer-induced bundling is
mediated by electrostatics, then an increase in buffer ionic strength will correspond
with a decrease in bundling. To test this hypothesis, TEM bundling assays were used
as before (Chapter III), except that 2-50 mM MgCl2 or KCl were added to MEM806.8
(80 mM MES-KOH, pH 6.8, 1 mM EGTA, 2 mM MgCl2). Note that the condition
“2 mM MgCl2” corresponds to MEM806.8 with no additional salt. The paclitaxel-
conjugated, Cy5-labeled, surface-neutralized dendrimers, PX3Cy2−3OH108-G5, were
used for all experiments (see Chapter III).
Figure 4.1 shows the fraction of unbundled microtubules (represented as unbun-
dled length) measured at each salt concentration. An increase in salt concentration
(buffer ionic strength) does indeed correlate with a decrease in bundling. The Hill
equation, (y = y0 + (1 +
KA
[salt]
)−1), was fit to each data set with R2 = 0.93 for MgCl2
and R2 = 0.83 for KCl. From the fits, half-saturation concentrations (KA) of 3.9
mM MgCl2 and 0.72 mM KCl were extracted. Note that the tubulin and dendrimer
concentration used in these experiments was 0.64 µM. This bundling salt-dependence
supports our earlier hypothesis that bundling is mediated by electrostatics.
The Fluorescent Dyes TMR and Cy5 Contribute to Microtubule Bundling
To complete our exploration of the mechanisms of dendrimer-induced microtubules
bundling, the contribution of the fluorescent labels used in these experiments—Cy5
(dendrimers) and TMR (tubulin) was examined next. Both dyes are hydrophobic with
multiple aromatic rings (Figure 4.2), creating the possibility for dye-dye hydrophobic
interactions that may mediate microtubule bundling. If these dyes are found to con-
tribute to bundling, it will underscore a need for caution to be used when considering
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Figure 4.1: Microtubules were incubated with PX3Cy2−3OH108-G5 at a 1:1 ratio of
dendrimers:tubulin dimers in MEM806.8 with 2-50 mM MgCl2 or KCl.
Note that the condition “2 mM MgCl2” represents MEM806.8 without
any additional salt. The mixtures were incubated together for 30 min at
room temperature and then visualized by TEM. The Hill equation (y =
y0 + (1 +
KA
[salt]
)−1) was fit to each data set with the following parameters:
(1) KA = 3.9 mM MgCl2, R









Figure 4.2: Chemical structures of (a) TMR (5-(6)-carboxytetramethylrhodamine
succimidyl ester); (b) Cy5; and (c) CyA (unconjugated Cy5 analog) show-
ing dendrimer attachment points.
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attachment of aromatic molecules to drug delivery platforms (e.g., dendrimers).
The contribution of Cy5 to dendrimer-induced bundling was tested using TEM
bundling assays with either: (1) (OH)114-G5 at a 1:1 ratio of dendrimers:tubulin
dimers; or (2) CyA at a 3:1 ratio. CyA is a Cy5 analog, chosen for its lack of chemical
reactivity and functionality (Figure 4.2c). CyA was tested at a 3:1 ratio with tubulin
in order to correspond to the Cy5 concentration contributed by the dendrimers (the
dendrimers are labeled with 2-3 Cy5 each). Bundling was quantified as in Chapter III,
from 30 x (4.9 µm)2 TEM images.
For reference, the levels of TMR-labeled microtubule bundling found in the ab-
sence or presence of Cy2−3(OH)111-G5 in Chapter III are shown in columns 1 and 2,
respectively, of Figure 4.3. To determine the contribution of the conjugated Cy5 to
the high levels of observed bundling in the presence of Cy2−3(OH)111-G5, (OH)114-G5
were next tested. This dendrimer is chemically identical to Cy2−3(OH)111-G5, except
that it does not have Cy5 conjugated to its surface. As seen in Figure 4.3, removing
Cy5 from the dendrimer eradicates its ability to bundle microtubules. Furthermore,
when CyA, a Cy5 analog (Figure 4.2c), was incubated with microtubules, the level of
microtubule bundling again increased (Figure 4.3). This level of bundling was signif-
icantly greater than that measured in the presence of (OH)114-G5 (p < 0.05), but not
significantly different from that measured in the presence of Cy2−3(OH)111-G5. This
suggests that Cy5, conjugated to dendrimers or not (as CyA), induces high levels of
microtubule bundling.
Cy5 Induces Microtubule Bundling Even When Conjugated to Highly An-
ionic Dendrimers
To further test this observation that Cy5 makes a large contribution to dend-
rimer-induced bundling, Cy2−3(COOH)111-G5 were tested for an ability to bundle
microtubules. These dendrimers are labeled with Cy5 and carry a high anionic surface
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Figure 4.3: Quantification of TMR-labeled (TMR-MTs), or unlabeled (MTs), micro-
tubule bundling from TEM images in the presence of various dendrimers
or CyA (unconjugated Cy5 analog).
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charge (1.4 (-)/nm2) from carboxylate groups. The high anionic surface charge density
of these dendrimers should cause them to be electrostatically repelled from the anionic
microtubule surface. This experiment was visualized by TIRFM instead of TEM, but
all experimental conditions were the same (with the exception of the addition of OSS).
The method used for quantifying bundling from TIRFM images (see Appendix E)
is very similar to that used previously for TEM images (see Appendix D). Briefly,
the fluorescence intensity profile is measured at cross-sections of the microtubules at
5 px intervals. Each profile is fit with a Gaussian distribution, and the area under
the curve (corresponding to the total fluorescence intensity at that cross-section) is
determined. The fluorescent intensity per unit length of a single, unbundled micro-
tubule is assumed to be within two standard deviations of the mean of the population
distribution of microtubules measured in the absence of dendrimers. This intensity
range is assigned a “weight” of 1. Additional weights for bundled microtubules are
assigned as multiples of this range (i.e. dimers: weight = 2, trimers: weight = 3,
etc.). Using this weighting system, each measured microtubule length is weighted
accordingly, and summed to determine the total fraction of bundled microtubules in
the sample.
Figure 4.4a shows microtubules in the absence of dendrimers, identified as “green
rods.” When microtubules are incubated with Cy2−3(COOH)111-G5 (Figure 4.4b),
some green rods—one example in this image is indicated by an arrow—appear to
have a greater width, as if they might be bundles of microtubules. The other mi-
crotubules may be either unbundled, or smaller bundles that are not thick enough
to distinguish from unbundled microtubules by eye, due to the resolution of light
microscopy. Indeed, upon quantification of bundling (Figure 4.4c) it is found that
Cy2−3(COOH)111-G5 bundles microtubules to a significant degree (p < 0.05). Fur-
thermore, this level of bundling is not significantly different than that measured in the





Figure 4.4: Microtubules were incubated with either (a) no additional components
or (b) Cy2−3(COOH)111-G5 at a 1:1 ratio of dendrimers:tubulin dimers
in MEM806.8 for 30 min at room temperature prior to visualization by
TIRFM. The white arrow indicates a potential [large] bundle of micro-
tubules. The other microtubules may be either unbundled, or smaller
bundles that are not thick enough to distinguish from unbundled micro-
tubules by eye, due to the resolution of light microscopy. Only the image
from the TMR channel (green: microtubules) is shown. Scale bar repre-
sents 10 µm. (c) The amount of bundling in each sample was measured
from the quantity of microtubules observed on ≥ 14 m2 of coverslip sur-
face, and represented as the fraction of total microtubule length bundled.
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(p > 0.05).
Together these observations imply that Cy5 significantly contributes to the dendrimer-
induced bundling. This raises the question of whether there is free dye present in the
dendrimer preparation. However, this is not likely as following the Cy5 conjugation
reaction, the dendrimers were purified by MWCO 10 kD ultrafiltration and six runs
of 10 kD dialysis (see Appendix A). Therefore, any elevated bundling observed in the
presence of Cy5-conjugated dendrimers is likely due to the conjugated Cy5 and not
contaminating free Cy5.
Next, to determine the contribution of the TMR label on the tubulin to dendrimer-
induced bundling, TEM bundling assays were performed with (OH)114-G5 exactly as
before except without the TMR label on the tubulin. As can be seen in column 5
of Figure 4.3, in the absence of Cy5 and TMR, only 2 % of the total population is
bundled. This amount of bundling is significantly different from that measured with
TMR-labeled microtubules, both in the presence or absence of (OH)114-G5 (p < 0.05).
Therefore, it can be concluded from all of the above data that Cy5 (whether free
or coupled to dendrimers) and TMR (while coupled to tubulin) are able to induce
bundling of microtubules, likely through hydrophobic interactions with each other.
Conclusions
G5 PAMAM dendrimer-induced microtubule bundling is likely induced by a com-
bination of: (1) electrostatic interactions involving protonatable tertiary amines in
the dendrimer core (Figure 3.1); and (2) hydrophobic interactions involving aromatic
dyes conjugated to the dendrimer (Cy5) and tubulin (TMR). The hydrophobic dye
interactions appear to have an overall greater contribution to bundling than electro-
static interactions (Figure 4.3). This suggests that the pH-dependence of bundling
(Figure 3.7) may also be due to microtubule instability at alkaline pH,91 in addition
to electrostatic interactions.
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The large contribution of dendrimer-coupled Cy5 to microtubule bundling is likely
a function of its concentration in these experiments. It is possible that lower Cy5
concentrations may reduce bundling. Indeed, this study found that TMR coupled to
microtubules, which was present in the experiments in concentrations 40-60 fold less
than Cy5, induced a lower level of bundling than Cy5. Therefore, the concentration
limit of bundling induced by Cy5, or any other aromatic, hydrophobic compound such
as a drug, must first be precisely determined before such molecules are considered for
use in imaging and therapeutic nanomedicines.
Overall, the conclusions of this chapter suggest that the bundling observed in
Chapter III may not be clinically relevant as it is dependent on dendrimer and
dye concentrations that may be too high to be clinically relevant. Nevertheless,
the paclitaxel-conjugated G5 PAMAM dendrimers studied were still able promote
microtubule polymerization and stabilization in a paclitaxel-dependent manner, al-
though not as efficiently as free paclitaxel. These data motivate further development
of paclitaxel-nanoparticle conjugates that can polymerize and stabilize (and possibly
bundle) microtubules as effectively as free paclitaxel, and/or effectively release their
paclitaxel cargo in the cell. Finally, these nanoparticle carriers, and any conjugated




Paclitaxel-Conjugated Gold Nanoparticles Show
Promise as a Targeted Cancer Drug Delivery
Strategy1
5.1 Introduction
Paclitaxel is a small organic molecule originally isolated from the Pacific yew tree
in 1962. Its cytotoxicity was demonstrated subsequently in several experimental sys-
tems, thereby initiating interest in its potential as an anti-cancer therapeutic.102,103 In
1979, Schiff et al.104 discovered the mechanism of paclitaxel cytotoxicity: promotion
of microtubule polymerization and stabilization of microtubules against depolymer-
ization. Soon after, Bristol-Myers Squibb (New York, NY) began clinical trials on
paclitaxel, and now markets the molecule as the anti-cancer drug Taxol R©, indicated
for various types of cancer, including ovarian, breast, lung and AIDS-related Kaposi’s
sarcoma.
Even though paclitaxel is a very effective anti-tumor agent,29 like many chemother-
apeutic agents, its use is accompanied by detrimental side effects primarily arising
from its poor water solubility and promiscuous cytotoxicity.30 For example, in order
1TMR-tubulin was obtained from Edgar Meyhöfer. All AuNPs were synthesized by Seok Ki Choi.
All TEM images were taken using the microcope in the lab of Georgios Skiniotis.
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to compensate for its poor water solubility, Taxol R© is currently solubilized in a very
toxic mixture of polyethoxylated castor oil and ethanol prior to injection into the
patient.30 Given the detrimental side effects associated with this preparation, it is
very desirable to develop a water-soluble, targeted delivery strategy for paclitaxel.
Nanoparticles have been of great interest to the targeted drug delivery field in
recent decades due to their inherent properties such as their capacity for multivalent
attachments, ability to cross cellular membranes, and imaging capabilities.105 Accord-
ingly, at least two examples of paclitaxel-conjugated nanoparticles are currently on
the market, attempting to increase the efficacy, and decrease the side effects, of pacli-
taxel for treatment. AbraxaneTM, marketed in the US by Celgene (Summit, NJ), uti-
lizes albumin as a nanoparticle delivery vehicle for paclitaxel. NanoxelTM, marketed
in India by Dabur Pharma (India), utilizes another type of polymeric nanoparticle
delivery vehicle (a co-polymer of N-isopropyl acrylamide and vinyl pyrrolidone).106
Although both treatments are an improvement upon Taxol R© because they are more
water soluble and increase the amount of paclitaxel delivery to the tumor sites, they
nevertheless still cause harmful side effects in patients,107 potentially due, at least
in part, to the fact that neither formulation contains any molecules to specifically
target delivery of paclitaxel to cancerous cells. Therefore, further improvement upon
paclitaxel delivery methods is warranted.
Gold nanoparticles (AuNPs) have a unique set of physical, chemical, and pho-
tonic properties among nanoparticles that makes them attractive for use in targeted
drug delivery applications.108,109 For example, AuNPs provide good radiation ther-
apy contrast, photo-imaging contrast, and spectrochemical diagnostic contrast.110
Already, there have been a few reported examples of paclitaxel-conjugated AuNPs
synthesized.106 One of these conjugates has severn increased cytotoxcity compared to
paclitaxel in vitro, however further testing of these conjugates is necessary.
AuNPs provide multiple options for carrying and releasing drugs to the target
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site. For example, one method takes advantage of the strong Au-S bond to conjugate
thiolated drugs to the AuNP surface. Once the conjugated AuNPs are internalized
into a cell, the reductive peptide glutathione (GSH), present in high concentrations
inside the cell, exchanges with the drug, freeing the drug for therapeutic action. The
intracellular concentrations of GSH are much higher than extracellular concentrations,
promoting the selective release of the drug inside the cell, rather than outside.111
In the current study, AuNPs of multiple diameters are tested, to which paclitaxel
has been conjugated via thiol bonds (Figure 5.1), for their microtubule stabilizing
capabilities in vitro using total internal reflection fluorescence microscopy (TIRFM)
and transmission electron microscopy (TEM). Preliminary evidence is presented that
these AuNPs are capable of: (1) promoting microtubule polymerization; (2) stabi-
lizing microtubules; and (3) bundling microtubules. Therefore, further testing of
these paclitaxel-conjugated AuNPs as drug delivery vehicles with the attachment of
tumor-targeting ligands is warranted.
5.2 Materials and Methods
Materials
MES, MgCl2, and GTP were all purchased from Fisher Scientific (Waltham, MA).
EGTA, paclitaxel, PCA, and PCD from Sigma-Aldrich (St. Louis, MO); Trolox from
Acros Organics (Geel, Belgium); TMR from Molecular Probes (Eugene, OR); and
HiLyte488 and unlabeled tubulin from porcine brain from Cytoskeleton, Inc. (Denver,
CO).
Tubulin Purification and Polymerization
Tubulin was purified from bovine brain and fluorescently labeled with TMR by

























Figure 5.1: General two-dimensional schematic of the paclitaxel-conjugated gold
nanoparticles (AuNPs) used in this study, showing citrate stabilization
and paclitaxel conjugation via Au-S bonds.
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Briefly, tubulin was purified from bovine brain by two cycles of microtubule polymer-
ization in the presence of a high-molarity PIPES buffer.34 Tubulin was TMR-labeled
by reacting polymerized microtubules with a 20-fold excess of TMR at room temper-
ature for 30 min. Competent, TMR-labeled tubulin was purified from this mixture
by repeated depolymerization and polymerization.35
For all experiments, microtubules were polymerized by incubating 2 mg/mL (≈ 20
µM) α/β-tubulin dimers (using a mix of TMR-labeled and unlabeled tubulin dimers
to achieve a final ratio of 1 TMR dye per 20 dimers, as determined by UV-Vis, where
noted) with 4 mM MgCl2 and 1 mM GTP in MEM806.8 buffer (80 mM MES-KOH,
pH 6.8, 1 mM EGTA, 2 mM MgCl2) at 37
◦C for 30 min. After polymerization, the
microtubules were stabilized with 10 µM paclitaxel.
Paclitaxel-Conjugated Gold Nanoparticles
Paclitaxel-conjugated gold nanoparticles were synthesized by Seok Ki Choi, mem-
ber of James R. Baker’s lab, formerly of the University of Michigan. The particles
were citrate-stabilized and conjugated to the fullest extent possible with paclitaxel via
thiol bonds. The number of paclitaxel molecules per particle has not yet been char-
acterized. Four different samples of paclitaxel-conjugated particles were prepared, of
the following sizes: 48 nm, 20 nm, and two different samples with sizes distributed
between 10-20 nm. These particles will referred to throughout the manuscript as
PX-cit-Au48, PX-cit-Au20, PX-cit-Au10a, and PX-cit-Au10b, according to their di-
ameters. As a negative control, 48 nm citrate-stabilized gold nanoparticles were
synthesized in parallel with PX-cit-Au48, except that paclitaxel was not attached.
This particle will be referred to as cit-Au48 throughout the manuscript. At this time,




Imaging chambers were prepared by affixing a cover glass (No. 1.5, 24x30 mm,
VWR, Radnor, PA) to a glass slide (Fischer Scientific, Waltham, MA) with double-
sided sticky tape. After the imaging solution was flown into the chamber, the chamber
was sealed with candle wax. Images were taken on an inverted fluorescence microscope
(model IX81, Olympus, Center Valley, PA) using a 60x objective lens. Samples were
illuminated at either 532 nm (for TMR; type Compass 315M, Coherent Inc., Santa
Clara, CA) or 635 nm (for Cy5; type Cube 640-100C, Coherent Inc., Santa Clara, CA)
at the critical angle, using a cellˆ TIRFTM Illuminator (Olympus, Center Valley, PA).
Fluorescent emissions were split into four separate channels using a QV2 Quad View
Imaging System (Photometrics, Tuscon, AZ) and projected onto an EMCCD camera
(model Evolve 512, Photometrics, Tuscon, AZ). Fluorescent images were viewed using
MetaMorph software (Molecular Devices, Sunnyvale, CA).
TIRFM Bundling Assays
HiLyte488-labeled, paclitaxel-stabilized microtubules were polymerized and sta-
bilized as described above (see section Tubulin purification and polymerization) and
incubated with either: (1) no additional components; (2) PX-cit-Au10a; (3) PX-
cit-Au10b; (4) PX-cit-Au20; (5) PX-cit-Au48; or (6) cit-Au48 at a 1:1 ratio (parti-
cle:tubulin dimers; both at ≈ 60 nM) in MEM806.8 with oxygen scavenging system
(OSS; 5 mM PCA, 50 nM PCD, 2 mM Trolox) and 10µM paclitaxel for 30 min at
room temperature prior to visualization by TIRFM.
Quantifying Microtubule Bundling from TIRFM Images
The fraction of bundled microtubles in a sample was quantified using a custom
script written in MATLAB (MathWorks, Natick, MA) (see Appendix D of this dis-
sertation for code). Briefly, this script measures the intensity profile of a microtubule
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by taking cross-sectional line scans, perpendicular to the microtubule axis, at 5 pixel
intervals. A Gaussian distribution is fit to each line scan and integrated to find the
area under the curve, which corresponds to the total fluorescence intensity at that
cross-section. The fluorescent intensity per unit length of a single, unbundled micro-
tubule was assumed to be within two standard deviations of the mean, as extracted
from the Gaussian fit, of the population distribution of microtubules measured in the
absence of dendrimers. This intensity range was assigned a weight of 1. Additional
weights for bundled microtubules were assigned as multiples of this range (dimers:
weight = 2, trimers: weight = 3, etc.). Using this weighting system, each measured
microtubule length was accordingly weighted and summed to determine the total
fraction of bundled microtubules in the sample.
TEM
Carbon-coated copper mesh TEM grids were glow-discharged using a Solarus 950
(Gatan, Inc., Pleasanton, CA). Samples were placed on the carbon-coated side of
the grid and negatively stained with a 0.75 % solution of uranyl formate.60 It was
assumed that the acidic pH of the stain would not significantly alter the pH of the
sample as the stain would fix the sample in ≤ 10 ms.61 Samples were imaged using a
Morgagni 268 transmission electron microscope (FEI, Hillsboro, OR).
TEM Polymerization Assays
2.0 mg/mL of a mix of unlabeled and TMR-labeled (see Tubulin Purification and
Polymerization above) tubulin (≈ 20 µM) was mixed with 4 mM MgCl2 and either
(1) no additional components; (2) 20 µM paclitaxel; (3) 10 nM PX-cit-Au20; (4) 10
nM PX-cit-Au48; or (5) 10 nM cit-Au48 in MEM806.8 at 37
◦C for 20 min, then room
temperature for 90 min. The resulting mixtures were then imaged by TEM.
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Quantitative Analysis of Microtubule Bundling in TEM Images
The diameter of microtubule (bundles) in TEM images taken at 3,095x magnifi-
cation was measured at 10 pixel intervals and the corresponding microtubule length
was weighted according to the number of bundled microtubules determined to be in
that length. The diameter of a single, unbundled microtubule, within two standard
deviations from the mean, was assigned to the weight of 1, and this was used as a
basis to assign diameter ranges to higher weights for bundled microtubules. The frac-
tion of bundled microtubules in a sample was calculated as the fraction of bundled
microtubule length per total measured microtubule length. This analytical process
was automated using a MATLAB (MathWorks, Natick, MA) script written in-house.
Statistical Tests for Significance in Bundling
Statistical significance of the difference of mean bundled microtubule length be-
tween samples was tested using the Student’s t-test, assuming equal variances, at
significance level α = 0.05. Prior to this test, it was verified that the two samples
being compared had equal variances using the F -test at significance level α = 0.05.
All statistical tests were performed using the Statistics Toolbox in MATLAB (Math-
Works, Natick, MA).
5.3 Results and Discussion
Paclitaxel-Conjugated Nanoparticles May Promote Microtubule Polymer-
ization in the Absence of GTP
One of the cytotoxic properties of paclitaxel is its ability to promote microtubule
polymerization in the absence of GTP or microtubule-associated proteins (MAPs).104
In the cell, abnormal microtubule polymerization would disrupt the normal cellular
functions, as strict regulation of microtubule dynamics is essential for proper chro-
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mosome movement during mitosis. Therefore, it was first tested if conjugation to the
gold nanoparticle (AuNP) disrupts the ability of paclitaxel to promote microtubule
polymerization in vitro. To test the ability of the paclitaxel-conjugated AuNPs to
promote microtubule polymerization, 2 mg/mL tubulin was incubated with 4 mM
MgCl2 and either (1) no additional components; (2) 20 µM paclitaxel; (3) 10 nM
PX-cit-Au20; (4) 10 nM PX-cit-Au48; or (5) 10 nM cit-Au48 in MEM806.8 at 37
◦C
for 20 min to encourage polymerization, then room temperature for 90 min to test
stability of any polymerized microtubules.
Figure 5.2 shows the results of these experiments. Figure 5.2a shows microtubules
formed in the presence of free paclitaxel, in a 1:1 ratio of paclitaxel:tubulin dimers. If
no paclitaxel is present, only tubulin aggregates are observed. Some of these tubulin
aggregates appeared to be roughly the same shape as microtubules (Figure 5.2b).
However, visualization at high magnification (24,628x; bottom row of Figure 5.2b)
shows that these stalk-like aggregates do not show the characteristic tubulin patterns
of a well-formed microtubules. Only a few of these stalk-like aggregates were ob-
served over more than (5 µm)2 of grid area searched. In the presence of PX-cit-Au20,
in a 1:2,000 ratio of AuNPs:tubulin dimers, well-formed microtubules were observed
(Figure 5.2c). In the presence of PX-cit-Au48, in a 1:2,000 ratio of AuNPs:tubulin
dimers, microtubules were observed with normal tubulin patterning, but apparently
more protofilaments than usual (Figure 5.2d). In contrast, in the presence of cit-Au48,
in a 1:2,000 ratio of AuNPs:tubulin dimers, only tubulin aggregates were observed
(Figure 5.2e), although none of the stalk-like aggregates were observed as in Fig-
ure 5.2b.
As expected, no well-formed microtubules are formed in the absence of paclitaxel
(Figure 5.2b). Therefore, if any microtubules are observed in the presence of PX-
cit-Au20 or PX-cit-Au48, this would suggest that the conjugated paclitaxel retains




Figure 5.2: Negative-stain TEM images obtained at 3,095x (top row; scale bar =
1 µm) or 24,628x magnification (bottom row; scale bar = 100 nm). 2
mg/mL tubulin was incubated with 4 mM MgCl2 and either (a) no ad-
ditional components; (b) 20 µM paclitaxel; (c) 10 nM PX-cit-Au20; (d)
10 nM PX-cit-Au48; or (e) 10 nM cit-Au48 in MEM806.8 at 37
◦C for 20
min, then room temperature for 90 min. The black arrow in (e) indicates
a AuNP.
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crotubules are observed in the presence of both of these AuNPs (Figures 5.2c-d).
Strikingly, the microtubules observed in the presence of PX-cit-Au48 appeared to
have more protofilaments than normally observed under the conditions used in vitro.
This may be explained by the larger diameter of PX-cit-Au48. At least one location
of the paclitaxel binding site is thought to be in the microtubule lumen,78,79 and
therefore if PX-cit-Au48 were bound to the lumen of the microtubule during poly-
merization, it is conceivable that more protofilaments would have to assemble in order
to form a closed cylindrical structure as the normal inner diameter of a microtubule
is ≈ 17 nm (Figure 1.4). The fact that no microtubules were observed in the presence
of cit-Au48 (Figure 5.2e) suggests that the formation of microtubules in the presence
of PX-cit-Au48 (Figure 5.2d) is due to the presence of paclitaxel.
However, even though microtubules were observed in the presence of PX-cit-Au20
and PX-cit-Au48, no AuNPs were observed bound to these microtubules. Due to
the much greater electron density of Au compared to the other atoms present in the
sample (C, N, O, H), the AuNPs should show up as very dark spheres, as indicated
in Figure 5.2e by a black arrow. Therefore, this suggests that either the paclitaxel
has become detached from the AuNPs, or the PX-cit-AuNPs were displaced from the
microtubules during the negative staining protocol performed prior to TEM imag-
ing. Therefore, further testing must be done to better understand the mechanism of
microtubule formation in the presence these nanoparticle samples.
PX-cit-Au48 May Bundle Microtubules
Another known cytotoxic effect of paclitaxel is its ability to promote the abnor-
mal formation of microtubule bundles.81,112 Accordingly, it was next tested if these
paclitaxel-conjugated AuNPs induced the formation of microtubule bundles in vitro.
To test this, HiLyte488-labeled microtubules were pre-polymerized and stabilized
them with free paclitaxel. Then they were incubated with either (1) no additional
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components; (2) PX-cit-Au10a; (3) PX-cit-Au10b; (4) PX-cit-Au20; (5) PX-cit-Au48;
or (6) cit-Au48 at a 1:1 ratio in MEM806.8 with 10µM paclitaxel for 30 min at room
temperature prior to visualization by TIRFM.
Figure 5.3 shows the results of experiments: microtubules in the presence of (a)
no additional components; (b) PX-cit-Au10a; (c) PX-cit-Au10b; (d) PX-cit-Au20; (e)
PX-cit-Au48; or (f) cit-Au48. No obvious bundling or differences between samples
are observable by eye. The amount of bundling in each sample was quantified using a
custom MALTLAB script by first measuring the fluorescence intensity profile at cross-
sections of the microtubule at 5 px intervals. Each profile was fit with a Gaussian
distribution and the area under the curve, corresponding to the total fluorescence in-
tensity at that cross-section, was calculated. The fluorescent intensity per unit length
of a single, unbundled microtubule was assumed to be within two standard deviations
of the mean, as extracted from the Gaussian fit, of the population distribution of mi-
crotubules measured in the absence of dendrimers. This intensity range was assigned
a weight of 1. Additional weights for bundled microtubules were assigned as multiples
of this range (dimers: weight = 2, trimers: weight = 3, etc.). Using this weighting
system, each measured microtubule length was accordingly weighted and summed to
determine the total fraction of bundled microtubules in the sample (Figure 5.3g).
The plot in Figure 5.3g shows the fraction of total microtubule length bundled in
each sample. The amount of microtubule bundling in the absence of nanoparticles
seems high compared to previous bundling levels measured by TEM (see Chapter III).
However, this is the first experiment performed with HiLyte488-tubulin, as opposed
to all other experiments in this dissertation which were performed with TMR-labeled
tubulin, therefore these elevated bundling levels may be due to an increased ability
of HiLyte488 to induce bundling compared to TMR (see conclusions in Chapter IV).
Since the chemical structure of HiLyte488 is proprietary, a structural comparison






Figure 5.3: Microtubules (MTs) were incubated with either (a) no additional compo-
nents; (b) PX-cit-Au10a; (c) PX-cit-Au10b; (d) PX-cit-Au20; (e) PX-cit-
Au48; or (f) cit-Au48 at a 1:1 ratio in MEM806.8 with 10µM paclitaxel
for 30 min at room temperature prior to visualization by TIRFM. Only
the image from the TMR channel (green: microtubules) is shown. No
obvious bundling can be seen by eye. (g) The amount of bundling in
each sample was estimated from the cross-sectional fluorescent intensity
profile of microtubules observed on ≥ (2 m)2 of coverslip surface area,
using a custom MATLAB script, and represented as the fraction of total
microtubule length bundled.
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Statistical significance between samples was tested using the Student’s t-test with
significance level α = 0.05. This statistical test showed that there was no significant
difference in bundling levels between any of the AuNPs compared to the free pacli-
taxel control, with two exceptions. PX-cit-Au48 was found to bundle microtubules
significantly more than free paclitaxel, while cit-Au48 was found to bundle micro-
tubules signficantly less than free paclitaxel (p < 0.05). The fact that the smaller
AuNP conjugates do not seem capable of bundling microtubules implies that only
PX-cit-Au48 supplies enough paclitaxel molecules per particle due to its large size
to induce bundling. The decreased bundling levels measured in the presence of cit-
Au48 are likely a result of the high anionic surface charge of the citrate, which is not
shielded by conjugated paclitaxel on these nanoparticles. This high anionic surface
charge would create electrostatic repulsion between particles, and possibly between
the particles and the microtubule surface, blocking most, or all, cit-Au48 from binding
microtubules.
Conclusions
In this study, preliminary evidence was presented showing that 20 nm and 48 nm
paclitaxel-conjugated AuNPs were able to promote polymerization of microtubules in
vitro, in the absence of GTP or MAPs. In addition, the 48 nm paclitaxel-conjugated
AuNPs were found to promote abnormal microtubule bundling in vitro, but not any
AuNP sample with a smaller diameter. This difference is likely explained by the
ability of the 48 nm particles to carry higher numbers of paclitaxel particles compared
to the smaller particles. Both of these cytotoxic activities could be attributed to the
presence of paclitaxel, showing that the AuNP core is not cytotoxic with respect
to alterations of microtubule dynamics or structure. However, AuNPs could not
be seen by TEM bound to microtubules polymerized in the presence of paclitaxel-
conjugate AuNPs, so it is not yet clear whether the paclitaxel bound the microtubules
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while conjugated to the AuNPs or not. It should be noted that the ability of the
conjugated paclitaxel to affect microtubule dynamics or structure is not absolutely
required for these AuNPs to be effective drug delivery platforms, as they may release
their paclitaxel load intracellulary. Therefore, in vitro testing with cultured cells is
necessary to confirm the promise of these conjugates as drug delivery platforms.
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CHAPTER VI
Summary and Future Directions
6.1 Summary
DNA-protein interactions are at the heart of many cellular functions in all organ-
isms. A more in-depth understanding of these interactions would not only increase
our understanding of these basic biological interactions, but better inform therapeutic
design, and enable engineering applications such as the design of nanomotors capable
of delivering cargo to a specific location in our genome.
In order to find a specific DNA-binding (target) site on the DNA, DNA-binding
proteins employ a combination of: intradomain association and dissociation (3D dif-
fusion or “hopping”), intersegment transfer (hopping between close DNA segments),
sliding (1D diffusion), and site-specific recognition (Figure 1.1).4,5 The question of
how proteins slide along DNA is one that inspired this dissertation. It is thought
that during sliding, proteins are “loosely” associated with DNA through electrostatic
interactions.14,15 This hypothesis is tested by creating a reductionist model in which
the protein is modeled by a cationic particle and the DNA with an anionic “line”.
The model employed in this dissertation was a nanoparticle-microtubule system. The
development and study of this model system led us to not only modify our hypothesis
concerning protein sliding, but to characterize cytotoxic properties of nanoparticles,
which are being increasingly incorporated into nanomedicines and other nanomateri-
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Electrostatic Interactions are Not Sufficient for Protein Sliding
In Chapter II, nanoparticles of various materials and charge densities are tested
for their interactions with microtubules using total internal reflection fluorescence
microscopy (TIRFM) and single particle tracking methods. A previous observation
in the literature that cationic polyacrylamide particles are able to slide along micro-
tubules25 inspired our choice to use microtubules as electrostatic DNA analogs. Like
DNA, microtubules are “linear” biopolymers with an overall negative surface charge.
In addition to electrosatic interactions, microtubules would provide opportunities for
van der Waals interactions with the nanoparticles, but no specific DNA sequence
information.
Neither the polyacrylamide particles (d = 38 or 80 nm; σ = 0.03 or 0.05 (+)/nm2;
Figure 2.1), nor the 2-dimethylaminoethanethiol (DMAET)-stabilized quantum dots
(d = 4.3 nm; σ = 0.3 (+)/nm2; Figure 2.6), that were tested showed any significant
interactions with microtubules. These results are consistent with the findings of Mi-
noura et al.25 that the minimum charge density for polyacrylamide particles to signif-
icantly interact with microtubules is 3.3 (+)/nm2. When generation 5 (G5) polyami-
doamine (PAMAM) dendrimers carrying a surface charge density of 1.4 (+)/nm2 were
tested, it was found that these particles were able to bind microtubules, but not slide
along them (Figure 2.7). The apparent discrepancy between this observation, and
the observation of Minoura et al.25 that particles with charge densities less than 3.3
(+)/nm2 do not significantly interact with microtubules, is likely resolved through
concentration differences (1.67 µM for dendrimers vs. pM range for polyacrylamide
particles).
The only particles that were observed to slide along microtubules were aggregated
polystyrene particles (Figure 2.3), which actually diffused along the microtubule in
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two-dimensions rather than one. That is, the particles seemed to move laterally
across the microtubule surface, rather than just longitudinally. In contrast, individual
polystyrene particles, which were 53 nm in diameter with a surface charge density of
0.13 (+)/nm2, were not observed to slide along microtubules. The diameter of one
sliding aggregate was estimated by measurement from the image, and the Stokes-
Einstein equation (using its measured diffusion coefficient), to be 1 µm. No estimate
of the surface charge density of these aggregates could be obtained due to the probable
high distribution of aggregate sizes present in the sample.
These results suggest that in order for spherical nanoparticles to slide along mi-
crotubules, and presumably by extension, DNA, they must have very high cationic
charge densities, perhaps greater than 3.3 (+)/nm2. There is an apparent discrep-
ancy between these in vitro observations and the biological protein-DNA system:
DNA-binding proteins do not have surface charge densities this high. For example,
T7 RNA polymerase has a cationic charge density of 0.057 (+)/nm2. However, the
cationic charges of DNA-binding proteins are primarily concentrated in their DNA-
binding domains, likely resulting in higher local cationic charge densities. Therefore,
it may be that the shape complementarity of the protein to the DNA, and the charge
juxtaposition within the protein’s DNA binding pocket, are crucial for protein slid-
ing,14,45,46 and that electrostatic interactions alone are not sufficient. Indeed, it is
possible that the reason that some of the polystyrene particle aggregates were able to
slide along microtubules when most other aggregates and all individual nanoparticles
were not, is that the presumably rough surface of these aggregates may have become,
by chance, complementary in shape to the microtubules.
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Paclitaxel-Conjugated PAMAM Dendrimers Adversely Affect Microtubule
Structure through Two Independent Modes of Action
In addition to observing non-specific, electrostatically-driven diffusion along mi-
crotubules by nanoparticles, a target site analog was incorporated into our model
system. For this purpose, paclitaxel was chosen to target the nanoparticles to micro-
tubules. Paclitaxel is known to bind microtubules and stabilize them against depoly-
merization, an action that is cytotoxic in vivo. Naturally, due to this known cyto-
toxic behavior of paclitaxel, it is of interest to test the cytotoxicity of our paclitaxel-
conjugated nanoparticles, which is the subject of Chapter III of this dissertation.
In Chapter III, the interactions between paclitaxel-conjugated G5 PAMAM den-
drimers (Figure 3.1) and microtubules are investigated in vitro, primarily using two
single microtubule imaging techniques: TIRFM and transmission electron microscopy
(TEM). As paclitaxel is known to promote microtubule polymerization, stabilize mi-
crotubules,104 and bundle microtubules,81,112 the paclitaxel-conjugated dendrimers
were tested for the retention of each of these cytotoxic properties. First, we find
that paclitaxel-conjugated dendrimers are able to promote microtubule polymeriza-
tion, although not as efficiently as unconjugated paclitaxel (Figures 3.2 and 3.3),
implying that conjugation of paclitaxel to the dendrimer partially hinders its inter-
action with microtubules. Next, it is found that the conjugates are able to stabilize
microtubules, although once again, not as efficiently as unconjugated paclitaxel (Fig-
ures 3.3 and 3.4). Finally, it is found that the conjugates are able to bundle micro-
tubules (Figure 3.5), although this bundling is not due to the presence of paclitaxel
on the conjugates. This dendrimer-induced bundling was instead dependent on pH
(Figure 3.7). This pH dependence is interpreted to mean that the large number of
protonatable tertiary amines in the dendrimer core (Figure 3.1) were mediating the
observed bundling through electrostatic interactions with the microtubules surface.
The implications of these results are two-fold. First, paclitaxel-conjugated nanopar-
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ticles may be suitable as drug delivery platforms. Even if the paclitaxel-nanoparticle
linker is not cleaved on all particles (assuming they make it into the cell), these par-
ticles will still be able to act upon microtubules and induce cell death. Development
of a water-soluble, targeted delivery strategy for paclitaxel is very desirable due to
the detrimental side effects caused by this hydrophobic untargeted drug, which is
an otherwise successful anti-tumor agent.30 Second, the cytotoxicity of G5 PAMAM
dendrimers warrants further investigation, especially since these nanoparticle have
been of great interest to the field of targeted drug delivery.32,48–51 Chapters IV and
V follow up on these results, investigating the utility of paclitaxel-conjugated gold
nanoparticles for targeted drug delivery, and the cytotoxicity of G5 PAMAM den-
drimers, respectively.
The Fluorescent Dyes Cy5 and TMR Aid Microtubule Bundling
Through Hydrophobic Interactions
In Chapter IV, the cytotoxicity of G5 PAMAM dendrimers is investigated in
order to more precisely determine the cause of the dendrimer-induced microtubule
bundling observed in Chapter III. In doing so, it was determined that in addition to
electrostatic interactions, the observed dendrimer-induced microtubule bundling was
also enhanced by hydrophobic interactions between the fluorescent dyes on the den-
drimers (Cy5) and tubulin (TMR) used for TIRFM imaging (Figures 4.3 and 4.4 and
4.1). These results demonstrate that caution should be used when considering these,
and other hydrophobic compounds, for imaging or therapeutic nanomedicines. How-
ever, it is possible that these dyes may still be safe for use in nanomedical applications
in lower concentrations.
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Paclitaxel-Conjugated Gold Nanoparticles Show Promise as a Targeted
Cancer Drug Delivery Strategy
Gold nanoparticles (AuNPs) have a unique set of physical, chemical, and photonic
properties among nanoparticles that makes them attractive for use in targeted drug
delivery applications.108,109 In addition, they provide multiple options for carrying and
releasing drugs at the target site. For example, thiolated drugs can be conjugated
to the AuNP surface via Au-S bonds. Upon cellular internalization, the reductive
peptide GSH, which is present in high concentrations inside the cell, exchanges with
the drug, thereby freeing the drug for therapeutic action. Since the intracellular
concentrations of GSH are much higher than the extracellular, the selective release
of the drug inside the cell rather than outside is promoted.111
It is this conjugation and delivery strategy that was employed for paclitaxel-
conjugated AuNPs (Figure 5.1). By the same logic used when testing the paclitaxel-
conjugated G5 PAMAM dendrimers, it was decided to test the ability of our paclitaxel-
conjugated AuNPs to promote microtubule polymerization, stabilize microtubules,
and bundle microtubules. Again, TIRFM and TEM were used for these experi-
ments. First, it is found that microtubules are able to polymerize in the absence
of GTP when they are incubated with 20 or 48 nm paclitaxel-conjugated AuNPs
(Figure 5.2). However, no AuNPs could be seen bound to these microtubules, so
it is unknown if the conjugated paclitaxel became separated from the AuNPs, or if
the paclitaxel-conjugated AuNPs were replaced during staining prior to TEM imag-
ing. Next, it is found that 48 nm paclitaxel-conjugated AuNPs were able to bundle
microtubules, while three other distinct paclitaxel-conjugated AuNP samples with di-
ameters ≤ 20 nm were not. In contrast to the dendrimer-mediated bundling observed
in Chapter III, this bundling was dependent on the presence of paclitaxel. Together
the results of this section demonstrate the promise of paclitaxel-conjugated AuNPs
as targeted cancer drug delivery strategies.
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6.2 Future Directions
The nanoparticle-microtubule model system developed in Chapter II is only a
small step toward the overall goal of understanding the mechanisms of protein sliding
along DNA. The results of this chapter suggest that electrostatic interactions alone
are not sufficient to allow proteins to slide along DNA. Considering these results, it
is proposed that specific protein conformational complementarity and a suitable ar-
rangement of cationic charges in the protein’s DNA binding pocket allow proteins to
slide along DNA. Accordingly, future attempts to model protein sliding using cationic
nanoparticles should utilize concave nanoparticles with cationic charges concentrated
in their concavities in order to more closely mimic the conformation and charge ar-
rangements of DNA-binding proteins. For example, Zhao et al.113 and Berkovitch
et al.114 have already synthesized two different types of concave inorganic nanoparti-
cles. However, synthesizing concave nanoparticles on the size scale of DNA-binding
proteins, and preferentially placing cationic charges in the concavity, is still a tech-
nological challenge.
The results of Chapters III and V concerning paclitaxel-conjugated nanoparticles
warrant further investigation into the suitability of these and similar particles as drug
delivery platforms. The experiments presented in this dissertation were all performed
in vitro with purified tubulin. In order to determine the utility of the particles, they
must also be conjugated with some tumor targeting molecule (see Majoros et al.,53 for
example), and tested in vivo with cultured cell lines for cytotoxicity and intracellular
release of their paclitaxel load.
Finally, the results of Chapter IV warrant further investigation into the concen-
tration dependence of microtubule bundling induced by the hydrophobic fluorescent
dyes Cy5 and TMR, on the dendrimer and microtubules, respectively. If these dyes
are found to not induce microtubule bundling at dye:tubulin ratios that could be
expected to be utilized nanomedical imaging applications, then these dyes—and by
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Synthesis and Characterization of
Paclitaxel-Conjugated PAMAM Dendrimers
Synthesis and Characterization of the Paclitaxel Linker
The synthetic scheme of the paclitaxel linker is shown in Figure A.1.
Step 1. To a solution of cystamine dihydrochloride (1; 5.00 g, 22.2 mmol) in water
(15 mL) was added NaOH (2.66 g, 66.6 mmol). The solution was diluted in MeOH
(50 mL) and succinic anhydride was added (2.22 g, 22.2 mmol). The reaction was
stirred at 0 ◦C for 1 h, then room temperature for 7 h. Boc anhydride ((Boc)2O; 7.30
g, 33.3 mmol) was added to the mixture and the resulting mixture was stirred at
room temperature for 12 h. The mixture was concentrated in vacuo, and the aqueous
residue was diluted with water (50 mL), basified with NaHCO3 (5 %) to pH ≈ 9,
extracted with ethyl acetate (150 mL), acidified with 1 M H3PO4 to pH ≈ 5, and
extracted again with ethyl acetate (300 mL). The organic layer was concentrated in
vacuo and purified by flash silica column chromatography (15:85 MeOH:CH2Cl2) to
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Figure A.1: Synthesis of the paclitaxel linker
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Rf (5 % MeOH:CH2Cl2) = 0.29.
1H NMR (400 MHz, CDCl3): δ 3.46-3.44 (t, 2H),
3.33-3.3 (br m, 2H), 2.75-2.74 (t, 2H), 2.72 (t, 2H), 2.69 (t, 2H), 2.43 (br t, 2H), 1.36
(s, 9H) ppm.
Step 2. To a solution of paclitaxel (200 mg, 0.234 mmol) and the N-Boc protected
cystamine-succinic acid (2; 87 mg, 0.246 mmol) in dimethylformamide (DMF; 10 mL)
were added 4-dimethylaminopyridine (DMAP; 31 mg, 0.236 mmol) and 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC; 31 mg, 0.254 mmol). The
mixture was stirred at room temperature for 48 h. The mixture was concentrated in
vacuo and then purified by flash silica column chromatography by eluting with 5-10
% MeOH/CH2Cl2 to yield the N-Boc protected paclitaxel linker derivative (3) as a
pale yellow foam (209 mg, 75 %). Rf (5 % MeOH:CH2Cl2) = 0.46.
1H NMR (400
MHz, CD3OD): δ 8.08-8.05 (m), 7.93 (s), 7.82-7.76 (m), 7.66-7.61 (m), 7.58-7.48 (m),
7.44-7.35 (m), 7.26-7.20 (m), 6.8 (d), 6.41 (s), 6.11 (br t), 6.03 (m), 5.79-5.75 (m),
5.60 (m), 5.42-5.40 (t), 4.97 (d), 4.70 (d), 4.55 (br s), 4.36-4.22 (m), 4.14 (s), 3.79-
3.71 (m), 3.41-3.38 (m), 3.31-3.26 (m), 3.12 (br m), 2.99-2.83 (m), 2.80 (s), 2.77-2.51
(m), 2.45-2.41 (m), 2.36-2.32 (m), 2.19-2.10 (m), 1.88 (d), 1.80-1.70 (m), 1.61 (s),
1.4 (br s), 1.10 (m) ppm. MS (ESI, positive ion mode): m/z (relative intensity, %)
= 1210.4 (100) [M+Na]+. HRMS (ESI) calculated for C60H73N3O18S2Na 1210.4228,
found 1210.4271.
Step 3. To the N-Boc protected paclitaxel derivative (3; 50 mg, 0.042 mmol) was
added a mixture of trifluoroacetic acid and CH2Cl2 (2 mL; 1:1). The mixture was
stirred at room temperature for 20 min and then evaporated to dryness to yield the
paclitaxel linker (4) as pale yellow oil. The 1H NMR analysis indicated the complete
deprotection of the N-Boc protecting group, and the product was used without further
treatment in the next step. Rf (0.5 % Et3N/5 % MeOH:CH2Cl2) = 0.56.
1H NMR
(400 MHz, CD3OD): δ 8.08-8.05 (m), 7.98-7.93 (m), 7.82-7.76 (m), 7.66-7.61 (m),
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7.58-7.48 (m), 7.44-7.35 (m), 7.26-7.20 (m), 6.8 (d), 6.52 (d), 6.41 (s), 6.21 (br d) 6.11
(br t), 6.03 (m), 5.79-5.75 (m), 5.73-5.60 (m), 5.47-5.45 (m), 5.42-5.40(t), 5.29-5.24
(m), 4.97 (d), 4.70 (d), 4.6 (br s), 4.36-4.22 (m), 4.14 (s), 4.10-4.03 (m), 3.79-3.71
(m), 3.59-3.51 (m), 3.41-3.38 (m), 3.31-3.23(m), 3.12 (br m), 2.99-2.83 (m), 2.80 (s),
2.77-2.51 (m), 2.45-2.41 (m), 2.36-2.32 (m), 2.19-2.10 (m), 1.98 (d), 1.92-1.87 (m),
1.80-1.70 (m), 1.61 (s), 1.59-1.53 (m), 1.33 (br s), 1.10 (m), 1.01-0.94 (m), 0.89-0.83
(m) ppm. MS (ESI, positive ion mode): m/z (relative intensity, %) = 1088.4 (100)
[M+H]+. HRMS (ESI) calculated for C55H66N3O6S2 1088.3885, found 1088.3912.
Synthesis and Characterization of PX3Cy2−3OH108-G5
The synthetic scheme of the PX3Cy2−3OH108-G5 synthesis is shown in Figure A.2.
To a solution of G5 PAMAM dendrimers ((NH2)114-G5; 5; 100 mg; 3.7 µmol) in MeOH
(10 mL) was added Cy5-NHS ester (14.2 mg; 18 µmol) and the mixture was stirred
at room temperature for 16 h. To the resulting conjugate, Cy2−3(NH2)108-G5 (6),
was added glutaric anhydride (74 mg; 740 µmol) and the mixture was stirred at room
temperature for 24 h. The mixture was then purified by MWCO 10 kD ultrafiltration
to yield the carboxylated conjugate Cy2−3(COOH)108-G5 (7) as a sticky blue solid (83
mg; 47 %). To the carboxylated conjugate (7; 50 mg; 1.22 µmol) were added 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC; 954 mg; 183 µmol)
and NHS (23 mg; 200 µmol) in DMF (20 mL) and the mixture was stirred at room
temperature for 8 h. To the resulting conjugate (8) was added the paclitaxel linker (4;
13.3 mg; 12.2 µmol) in triethylamine (TEA; 5 µL) and the mixture was stirred at room
temperature for 12 h. To this mixture was added ethanolamine (ETA; 5 µL) and the
mixture was stirred at room temperature for 16 h in order to quench the active NHS
ester and neutralize the dendrimer surface. The resulting mixture was first purified
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Figure A.2: Synthesis of PX3Cy2−3OH108-G5
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Figure A.3: MALDI-TOF mass spectra of PX3Cy2−3OH108-G5 (top panel) and
PX3Cy2−3OH26-G3 (bottom panel).
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Figure A.4: Ultraviolet-visible spectra of PX3Cy2−3OH108-G5 (top panel),
PX3Cy2−3OH26-G3 (middle panel), and Cy5 (bottom panel).
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Figure A.5: 1H NMR spectrum of PX3Cy2−3OH108-G5
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to yield PX3Cy2−3OH108-G5 (9) as a blue solid (48 mg; 82.0 %). MALDI-TOF-
MASS analysis indicated that the PX3Cy2−3OH108-G5 was the expected molecular
weight, 48 kDa (Figure A.3). The number of conjugated Cy5 dyes per dendrimer was
determined to be 2.3, on average, using ultraviolet-visible spectroscopy (Figure A.4),
calibrated to free Cy5. The number of conjugated paclitaxel molecules per dendrimer
was determined to be 3.2 using 1H NMR spectroscopy (Figure A.5). This was
determined as follows. The peaks at δ (ppm) ≈ 7-8 belong to the combination of
three phenyl groups (15 H’s) of paclitaxel and the aromatic groups (8 H’s) of Cy5.
The integration value for these combined signals was corrected to represent only
paclitaxel by subtracting out the integration value calculated for the contribution of
Cy5 molecule. For this correction, other signals at δ (ppm) ≈ 6–6.6, belonging to the
protons in the triene conjugation system of Cy5 (3 H’s), were used as a reference,
and it was assumed that the mean number of Cy5 molecules per dendrimer is 2.3, as
determined earlier by ultraviolet-visible spectroscopy (Figure A.4).
Testing the Stability of Paclitaxel Conjugation to PX3Cy2−3-
OH108-G5
PX3Cy2−3OH108-G5 was tested for stability in water to confirm that the paclitaxel
would not be spontaneously hydrolyzed from the dendrimer carrier at room temper-
ature in the aqueous buffers used in this study over the maximum experimental time
frame, ≤ 6 h. In order to test this, PX3Cy2−3OH108-G5 was dissolved in DI water to a
final concentration of 1 mg/mL. A 200 µL aliquot of this aqueous solution was tested
for the presence of free paclitaxel after 0.17, 1, 2, 3, 6, and 20 h at room temperature.
First, the dendrimers were removed from each aliquot by MWCO 10 kD ultrafiltra-
tion. Then the filtrate, containing any free paclitaxel that may have separated from
the dendrimer during the incubation in water, was collected and the concentration of
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Figure A.6: UPLC spectra of DI H2O (black); (b) paclitaxel (PX) in DI water (red);
or MWCO 10 kD filtrates from PX3Cy2−3OH108-G5 incubated in DI wa-
ter at room temperature for 10 min (green); 6 h (dark blue); or 20 h
(light blue). Note that the first elution peak of the “PX” sample repre-
sents the solvent front while the second peak represents PX. All signals
from the PX3Cy2−3OH108-G5 filtrates are identical to that of water, and
show no significant elution peaks at the time points that free PX elutes,
indicating that the PX linker of PX3Cy2−3OH108-G5 is stable in water at
room temperature for up to 20 h.
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free paclitaxel was measured by ultra performance liquid chromatography (UPLC),
using an Acquity Peptide Mapping System (Waters Corporation; Milford, MA) con-
trolled by Empower 2 software and equipped with an Acquity BEH C4 column and a
photodiode array detector. A gradient elution was used, using a mobile phase rang-
ing from 99:1 - 20:80 (v/v) water:acetonitrile, containing 0.14 % trifluoroacetic acid.
The UPLC spectra show that the paclitaxel linker of PX3Cy2−3OH108-G5 is stable in
water at room temperature for up to 20 h (Figure A.6).
Measuring the pKa of Tertiary Amines in the G5 PAMAM
Dendrimer Core
For this measurement, a G5 PAMAM dendrimer with the same neutralizing
surface modification as PX3Cy2−3OH108-G5 (i.e. its terminal groups are hydroxyl
groups), but with no conjugated Cy5 or paclitaxel, was used. This dendrimer, termed
OH114-G5, according to its surface modifications and stoichiometry, only contains
titratable protons sites in the tertiary amines in the dendrimer core (compare with
the structure of PX3Cy2−3OH108-G5 shown in Figure 1). Potentiometric titration of
OH114-G5 was compared with that of (NH2)114-G5 (Figure A.7). Prior to titration,
10 mg of dendrimer was dissolved in 1 mL of 0.1 N NaCl and the pH of the resulting
solution was adjusted to 2.5. Potentiometric titration was conducted manually with
a MP230 pH meter equipped with an InLab R©Micro pH electrode (Mettler-Toledo;
Columbus, OH). Assuming that both dendrimers have an equivalent titration start
point, the pKa of the tertiary amines in OH114-G5 was calculated as follows: pKa =
0.5 (Endpoint + Startpoint) = 0.5 (9.484 + 3.455) = 6.5 ± 0.2, where the error was







Figure A.7: Potentiometric titration curves of (a) (NH2)114-G5, showing the start
point of titration (start), endpoint of the tertiary amine titration (end 1)
and endpoint of the primary amine titration (end 2); and (b) OH114-G5,
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Figure A.8: Synthesis of PX3Cy2−3OH26-G3
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Synthesis and Characterization of PX3Cy2−3OH26-G3
The synthetic scheme of PX3Cy2−3OH26-G3 is shown in Figure A.8.
G3 PAMAM dendrimers were first purified using a 1 kDa MWCO dialysis membrane,
achieving a relatively monodisperse population (polydispersity index (PDI) = 1.01–
1.05, determined by gel permeation chromatography (GPC)).
To a solution of G3 PAMAM dendrimers ((NH2)32-G3; 11; 20 mg; 2.87 µmol) in
MeOH (5 mL) was added Cy5-NHS ester (11.3 mg; 14.2 µmol) and the mixture was
stirred at room temperature for 16 h. To the resulting conjugate, Cy2−3(NH2)29-G3
(12), was added gluataric anhydride (14.35 mg; 143.5 µmol) and the mixture was
stirred at room temperature for 24 h. The mixture was then purified by MWCO
3 kD ultrafiltration to yield the carboxylated conjugate Cy2−3(COOH)29-G3 (13)
as a sticky blue solid (16.3 mg; 54.7 %). To the carboxylated conjugate (13; 12.4
mg; 1.2 µmol) were added EDC and NHS (6.9 mg; 60 µmol) in DMF (5 mL) and
the mixture was stirred at room temperature for 8 h. To the resulting conjugate
(14) was added the paclitaxel linker (4; 10.9 mg; 10 µmol) in TEA (3 µL) and the
mixture was stirred at room temperature for 12 h. To this mixture was added ETA
(5 µL) and the mixture was stirred at room temperature for 16 h in order to quench
the active NHS ester and neutralize the dendrimer surface. The resulting mixture
was first purified by MWCO 3 kD dialysis against PBS and DI water for 3 runs
each and then lyophilized to yield PX3Cy2−3OH26-G3 (15) as a blue solid (12.3 mg
42 %). MALDI-TOF-MASS analysis indicated that the Cy2−3(NH2)29-G3 was the
expected molecular weight, 10.4 kDa (Figure A.3). The number of conjugated Cy5
dyes per PX3Cy2−3OH26-G3 was determined to be 2-3, on average, using ultraviolet-
visible spectroscopy (Figure A.4), calibrated to free Cy5. The number of conjugated
paclitaxel molecules per PX3Cy2−3OH26-G3 was determined to be 3.2 using
1H NMR
spectroscopy (Figure A.9); by integrating the aromatic peaks located at δ 7-8 and
123
ppm12345678
Figure A.9: 1H NMR spectrum of PX3Cy2−3OH26-G3
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subtracting out the aromatic protons due to the number of conjugated Cy5 molecules
per dendrimer determined by ultraviolet-visible spectroscopy.
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APPENDIX B
Using DNA Curtains to Study DNA-Protein
Interactions
Introduction1
In order to visualize single proteins—or nanoparticles—sliding along DNA in order
to gain information about their dimensionality and speed of movement along DNA—
among other information—single molecule microscopy techniques must be used. As
shown in Chapter II of this dissertation, total internal reflection fluorescence mi-
croscopy (TIRFM) is one technique well suited for this application. In addition to
imaging nanoparticles sliding along DNA as done in this dissertation, TIRFM has
also been used to image proteins sliding along DNA.8,10,12 Previously, in order to
achieve these observations, DNA was randomly adhered to the slide (or coverslip)
surface and stretched and aligned either by flow8,12 or molecular combing.10 While
nonetheless effective, these DNA adherence techniques have a few drawbacks. First,
1Training in DNA curtain technology kindly provided by Eric Greene’s laboratory, primarily by
Feng Wang and Jayil Lee. λ DNA containing a T7 RNA polymerase promoter and biotinylated T7
RNA polymerase constructs were prepared by Feng Wang. All nanofabrication for this project was
performed by Ashwin Panday. This project was conducted in collaboration with Soma Dhakal.
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because the DNA is anchored directly to the surface, either at the end(s) or at inte-
rior points, the normal helical movement of DNA-binding proteins around DNA26–28
is hindered. Second, the placement and orientation of the DNA strands cannot be
precisely controlled.
Recently, a technique has been developed by Eric Greene (Columbia University)
for adhering DNA to surfaces for single molecule observations by TIRFM that ad-
dresses these drawbacks. This technique, termed DNA curtains, involves stringing
DNA molecules across nanofabricated barriers resulting in hundreds of parallel DNA
molecules oriented in the same direction can be viewed in a single field of view (Fig-
ure B.1).115 This allows for hundreds of DNA-protein interactions to be observed in
a single experiment. DNA curtains have been used by Eric Greene and colleagues to
investigate interactions between DNA and multiple DNA-binding proteins.7,116–118
Generally, DNA curtains are formed by creating a fluid lipid bilayer on a slide
surface containing nanofabricated barriers that are raised 25 nm from the surface,
20 nm above the ≈ 5 nm lipid bilayer. λ DNA molecules, labeled on one end with
biotin and on the other end with digoxygenin (DIG), are tethered to the lipid bilayer
through biotin-streptavidin-biotin linkages. Buffer flow pushes the tethered DNA to
the corners of zig-zag nanofabricated barriers and stretches the DNA, allowing it to
anchor to an opposite pentagonal barrier through DIG-anti-DIG linkages (Figure B.1).
Suspending the DNA 20 nm above the lipid bilayer via nanofabricated barriers allows
proteins to access 360 ◦ of the DNA structure, allowing them to move in a helical path
along the DNA. Furthermore, by differentially end-labeling the DNA, each DNA
molecule is oriented in the same direction, allowing for directional observations if
specific DNA sequences are engineered into the λ DNA template.
The motivation for using DNA curtains to address the main goal of this disserta-
tion was to visualize nanoparticle-DNA or protein-DNA interactions during target site


















Figure B.1: (a) Top-down and (b) side views of double-tethered DNA curtain
schematic. A fluid lipid bilayer is created on a slide surface containing
nanofabricated barriers raised 25 nm from the surface, 20 nm above the
≈ 5 nm lipid bilayer. λ DNA molecules, labeled on one end with biotin
and on the other end with digoxygenin (DIG), are tethered to the lipid
bilayer through biotin-streptavidin-biotin linkages. Buffer flow pushes
the tethered DNA to the corners of the zig-zag barriers and stretches it,
allowing it to anchor to the opposite pentagonal barrier through DIG-
anti-DIG linkages. Many copies of these patterns can be fabricated on a
single slide allowing hundreds of observations per experiment.
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should be very advantageous for studying both types of interactions. For example,
my collaborator Shi Yu in Ron Larson’s lab (University of Michigan) has found that
cationic nanoparticles can significantly interact with DNA in solution, but not when
the DNA is attached to the surface via molecular combing, presumably because the
affinity of the nanoparticles for the DNA is not significantly greater than the affinity
to the surface (data not published). DNA curtain technology significantly raises the
DNA above the surface and employs a lipid bilayer to block protein—and presumably
nanoparticle—binding to the surface.
The first aspect of target site searching that was of interest to characterize using
DNA curtains was the ability of bacteriophage T7 RNA polymerase to locate and
recognize promoters (target sites) with varying degrees of sequence mutation. DNA-
binding proteins recognize the unique chemical signature and/or three-dimensional
structure of their DNA target sites. Both of these properties are very sensitive to the
exact sequence of the DNA target site and mutation of even one base can disrupt the
ability of the protein to recognize its target.18 To our knowledge, a characterization
of the effect of promoter mutations on the kinetics of T7 RNA polymerase recognition
using single molecule, real-time observations has never been reported.
The second aspect of target site searching that was of interest to characterize
was the effect of varying DNA roughness landscapes on the sliding kinetics of T7
RNA polymerase. DNA is thought to have different “roughness” landscapes based on
specific sequences. Theory predicts that RNA polymerase will speed up or slow down
upon encountering sequences of different roughness.3 Different degrees of roughness
can be programmed into a DNA strand by changing its sequence using DNA cloning
techniques. Using a model developed by my collaborator Shi Yu (Ron Larson’s lab,
University of Michigan), the diffusion coefficient of RNA polymerase along these
different sequences can be predicted, the diffusion of RNA polymerase in real time
along these sequences can be tracked, the experimental observations to the theoretical
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predictions can be compared. To our knowledge, such a characterization has never
been reported.
Materials and Methods
All protocols were modified from the Eric Greene’s protocols.115
End-labeling Lambda DNA
4 nM of λ DNA (Invitrogen; Grand Island, NY), warmed to 65 ◦C for 10 min be-
fore pipetting with wide bore pipet tips (Mettler-Toledo; Chicago, IL), was incubated
with a 3’ biotinylated oligonucleotide complementary to the single stranded overhangs
on λ DNA and a 5’ DIG-labeled complementary oligonucleotide (both from Exiqon;
Vedbæk, Denmark) in 1x T4 DNA ligase reaction buffer (New England Biolabs; Ip-
swich, MA) at 65 ◦C for 10 min. After the mixture was cooled to room temperature,
4 U/µL of T4 DNA ligase (New England Biolabs; Ipswich, MA) was added and the
resulting mixture was incubated overnight at 42 ◦C. The next day, the ligase was
heat inactivated at 65 ◦C for 10 min.
Next, the ligase was removed from the mixture by phenol-chloroform extraction.
The sample was mixed with one half volume of buffer saturated phenol (MP Biochem-
icals; Santa Ana, CA) and one half volume chloroform (Sigma-Aldrich; St-Louis, MO)
by upturning the sample vial several times. The mixture was then incubated at room
temperature for 1 min prior to centrifugation for 1 min at top speed on a table-top
Eppendorf (Hamburg, Germany) centrifuge. The aqueous (top) layer was transferred
to a new tube and mixed with one volume chloroform by upturning the tube sev-
eral times. The mixture was then incubated at room temperature for 1 min prior to
centrifugation for 1 min at top speed on a table-top centrifuge. The aqueous (top)
layer was again removed to a separate tube, and chloroform extraction was repeated
twice more. The sample (final aqueous layer) was then concentrated in an Eppendorf
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Vacufuge for 30 min. Finally, the labeled DNA was desalted and separated from any
unbound oligonucleotides using illustra MicroSpin S-200 HR columns (GE Healthcare
Life Sciences; Piscataway Township, NJ), according to the manufacturer’s protocol.
The concentration of the resulting end-labeled λ DNA was measured using a Nan-
oDrop2000 spectrometer (Thermo Scientific; Hanover Park, IL), and the integrity of
the DNA (proper length) was confirmed using agarose gel electrophoresis, comparing
to unmodified (λ) DNA.
Preparing Mixed Lipid Stocks
An unused glass test tube was first rinsed with ethanol (Fisher Scientific; Waltham,
MA) and dried in an oven at 120 ◦C for 20 min. Then, using Hamilton (Hamil-
ton Company; Reno, NV) syringes cleaned with chloroform, 1 mL of 20 mg/mL
DOPC (18:1 (9-Cis) PC (DOPC) 1,2-dioleoyl-sn-glycero-3-phosphocholine; Avanti
Polar Lipids; Alabaster, AL), 0.160 mL of 10 mg/mL DOPE-mPEG (18:1 PEG550
PE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-
550]; Avanti Polar Lipids; Alabaster, AL), and 0.010 mL of 10 mg/mL DOPE-biotin
(16:0 Biotinyl Cap PE 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(cap bi-
otinyl); Avanti Polar Lipids; Alabaster, AL) lipid stocks were added to the dried
glass test tube. The chloroform was evaporated from this lipid mixture by carefully
blowing nitrogen gas onto the liquid and then placing the test tube under vacuum
overnight.
The next day, the dried lipid cake was rehydrated by incubation in 2 mL of lipid
buffer (10 mM Tris-HCl (Promega; Fitchberg, WI), pH 7.8, 100 mM NaCl (Sigma-
Aldrich; St-Louis MO) for ≥ 5 h. The hydrated lipid mixture was then resuspended
completely in solution by vortexing for 2 min to yield a milky suspension of large
multilamellar vesicles (LMVs). The LMVs were then broken down into SUVs by
sonication in a water bath sonicator specifically designed for preparation of SUVs
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(in Ari Gafni’s lab, University of Michigan), by sonicating the suspension until its
appearance changed from milky white to nearly clear, but still slightly hazy. The
vesicles were further broken down by a single pass through a 0.22 µm syringe filter
and stored at 4 ◦C for up to 2 weeks. The final lipid concentrations are 10 mg/mL
DOPC with 0.5 % (w/w) DOPE-biotin and 8 % (w/w) DOPE-mPEG.
Nanofabrication of Lipid Diffusion Barriers
All nanofabrication was performed by Ashwin Panday (L. Jay Guo’s lab, Univer-
sity of Michigan). Briefly, glass coverslips (No. 1.5, 24 x 30 mm; VWR; Radnor, PA)
were first spin-coated with a layer of a non-conducting polymer and then a layer of
a conducting polymer. The barrier patterns were then written on the polymer layers
by e-beam lithography. The polymeric coatings were then removed from the patterns
by developing: rinsing with water and then a developing agent. Chromium was then
deposited onto the glass laid bare by developing using e-beam evaporator to achieve
a deposition (i.e., barrier) thickness of ≈ 25 nm. Chromium was then removed from
non-patterned areas (where the polymeric coating remains) using a lift-off protocol
(e.g., utilizing acetone).
Construction of Flowcells
Nanofabricated coverslips (see section ’Nanofabrication of Lipid Diffusion Barri-
ers’) are rinsed in filtered MilliQ water, gently agitated in 2 % Hellmanex cleaning
solution (Sigma-Aldrich; St-Louis MO) for 1 h, rinsed thoroughly in water, soaked
in 1M NaOH (Fisher Scientific; Waltham, MA) for 1 h, and rinsed again with water
and 100 % methanol (Fisher Scientific; Waltham, MA). The coverslips are then dried
under a nitrogen steam and baked at 120 ◦C in an oven for 1 h.
Next, a segment of double-sided tape is masked off with a 30 x 5 mm strip of paper.
This double-sided tape is placed over a glass slide (Fischer Scientific, Waltham, MA),
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cleaned by the same protocol above, with two holes drilled 22 mm apart using a 1.5
mm diamond coated drill bit (Shor International Corporation; Newark, NJ), so that
the paper covers both drilled holes and the chromium barriers. The paper strip is
then cut out of the tape using a razor. The clean and dry patterned coverslip is
then placed over the double-sided tape, and excess tape not covered by the coverslip
is removed with a razor. To melt the tape to achieve a uniform channel depth, the
flowcell is sandwiched between two clean glass microscope slides, even pressure is
applied on the taped area with four small binder clips, and the flowcell is baked in an
oven at 120 ◦C for 45-60 min. NanoPorts (IDEX Corporation; Lake Forest, IL) are
then attached to the slide side of the flowcell assembly with fast-setting Epoxy. The
assembled flowcells are stored at 4 ◦C under vacuum for ≤ 1 week without significant
degradation to the flowcell surface and lipid bilayer fluidity.
Preparation of DNA Curtains
First, a 5 mL syringe full of water is attached to one of the NanoPorts and the
flowcell is rinsed with water, while tapping gently. Tapping the flowcell loosens and
flushes out all air bubbles within the system. Air bubbles must be avoided, as even
a small bubble will ruin the lipid bilayer surface. All subsequent syringes must be
attached to the system by making drop-to-drop Luer lock connections. Next, the
flowcell is washed with 3 ml Lipids Buffer (see section ’Preparing Mixed Lipid Stocks’)
by attaching a 5 ml Luer lock syringe to the second NanoPort (alternating between the
two NanoPorts reduces the chance of injecting air bubbles into the tubing). Next, the
mixed lipid stock (see section ’Preparing Mixed Lipid Stocks’) is diluted 40 µL into
960 µL of Lipid Buffer and injected into the flowcell using a 1 mL syringe as a series of
three injections, incubating 10 min between injections. The unbound lipids are then
removed by rinsing the flowcell with 3 mL Lipid Buffer in a 3 mL syringe. The flowcell
is then incubated for 30 min to promote vesicle fusion and bilayer growth along the
133
silica surface. Next, to block any remaining exposed glass, 1 mL BSA Buffer (40 mM
Tris-Cl, pH 7.8, 0.2 mg/mL BSA (Sigma-Aldrich; St-Louis, MO), 1 mM MgCl2, 1 mM
DTT; prepare this buffer fresh just before use) is injected slowly from a 1 mL syringe
and the flowcell is incubated for 10 min. To allow lipid-biotin-streptavidin-biotin-
DNA linkages, 12 µL of 0.1 mg/mL streptavidin is diluted in 500 µL BSA Buffer and
injected using a 1 mL syringe as a series of two injections, incubating 15 min between
injections. To flush out unbound streptavidin, the flowcell is then rinsed with 3 mL
of BSA buffer. Next, 1 mL of 100 pM end-labeled λ in BSA Buffer is injected into
the flowcell using a 1 mL syringe as a series of three injections, incubating 5 min
between injections to allow for DNA binding to the lipid bilayer surface. The amount
of injected DNA may be adjusted to obtain the desired DNA surface density. Finally,
the unbound DNA is rinsed out of the flowcell with 3 ml BSA Buffer.
Imaging DNA Curtains with TIRFM
The flowcell was transferred to the microscope syringe pump system and 0.5 pM
POPO-3 (Invitrogen Molecular Probes; Eugene, OR) in BSA Buffer was flown onto
the cell at 0.1 mL/min for 5-10 min prior to imaging. Images were taken on an in-
verted fluorescence microscope (model IX81, Olympus, Center Valley, PA) using a 60x
objective lens. Samples were illuminated at 532 nm (type Compass 315M, Coherent
Inc., Santa Clara, CA) at the critical angle, using a cellˆ TIRFTM Illuminator (Olym-
pus, Center Valley, PA). Fluorescent emissions were split into four separate channels
using a QV2 Quad View Imaging System (Photometrics, Tuscon, AZ) and projected
onto an EMCCD camera (model Evolve 512, Photometrics, Tuscon, AZ). Fluorescent
images were viewed using MetaMorph software (Molecular Devices, Sunnyvale, CA).
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Results and Discussion
DNA Does Not Bind Lipids on Coverslip Surface
No DNA curtains were formed, and no DNA was observed bound to lipids on the
coverslip surface, using this protocol. Potential reasons for these technical difficulties
include (1) lipid bilayer is not being formed on coverslip surface; (2) lipid bilayer
is formed on coverslip surface, but is not fluid; and (3) ’end-labeled’ DNA is not
labeled with biotin. Improvements made to the lipid preparation protocol (reflected
in the section ’Preparing Mixed Lipid Stocks’ above), and TIRFM experiments done
by Alex Johnson-Buck and Soma Dhakal (data not shown), show that bilayer fluidity
was an issue initially, but has since been resolved by the improvements to the lipid
preparation protocol. Efforts are now being made by Soma Dhakal to confirm the
biotin labeling of the λ DNA.
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APPENDIX C
A Study of E. coli RNA Polymerase Hydrolysis
Efficiencies of γ-[Fluorescently]Labeled NTPs
Introduction1
Another type of protein-DNA interaction that is investigated in this dissertation
was transcriptional elongation; more specifically, the sequence-specific kinetics of tran-
scriptional elongation. The motivation for this specific goal was riboswitches. Genetic
regulation by riboswitches—RNA domains of complex folds that switch conformation
upon metabolic cues—is one recently discovered paradigm that contributes to the
complex regulatory network employed by the cell. The formation of riboswitches can
either cause the premature termination of transcription or prevent the initiation of
translation.119 Riboswitches regulate several metabolic pathways in bacteria by di-
rectly binding specific metabolites,119,120 and accordingly present a potential target
for novel, highly effective antibiotics, which are much needed.121
An appreciation for the contribution of RNA to genetic regulatory mechanisms
has only recently developed, and therefore, the mechanisms employed by riboswitches
1This project was conducted in collaboration with Krishna Suddhala.
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are not well understood. For example, little is known concerning the kinetics of ri-
boswitching.120 However, due to recent technological advances made by Pacific Bio-
sciences, it is now possible to directly investigate the kinetics of riboswitch forma-
tion in real-time. Pacific Biosciences has successfully developed a technology termed
single-molecule, real-time (SMRTTM) sequencing to monitor DNA replication, a pro-
cess very similar to RNA transcription, with single-nucleotide resolution.122 To this
end, the company developed a fluorescence assay that utilizes deoxyribonucleotides
labeled on the γ-phosphate with four spectrally-distinguishable, fluorescent probes.
In order to obtain background levels low enough to allow single-molecule detection,
they performed the assay in zero-mode waveguides (ZMWs), nanophotonic structures
that confine the fluorescent excitation volume to zeptoliters, and imaged the reaction
using total internal reflection fluorescence microscopy (TIRFM).122
It is plausible that this system may easily be adapted to monitor RNA transcrip-
tion by replacing fluorescently-labeled deoxyribonucleotides with fluorescently-labeled
ribonucleotides and DNA polymerase with RNA polymerase. Binding of a comple-
mentary ribonucleotide to the DNA transcription template within the active site
of RNA polymerase will be signaled by a transient, nucleotide-specific, fluorescence
that ends when the nucleotide is incorporated into the growing RNA strand and the
attached label diffuses into solution (with the cleaved pyrophosphate). Thus, the
resulting records will define the complete, sequence-specific, kinetic information of
RNA polymerase activity, including the rates of nucleotide binding and incorpora-
tion. Consequently, if using a DNA sequence known to code for a riboswitch that
causes the premature termination of transcription, with the addition of the necessary
metabolite, the kinetics of riboswitching and gene regulation could be monitored as
transcription is proceeding. Such a single-molecule approach holds the promise for
the unique dissection of the molecular basis for riboswitch-mediated bacterial gene
regulation.
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As a result of a collaboration with Pacific Biosciences, three different γ-phosphate
labeled ribonucleotides were obtained from this company. In addition, two addi-
tional γ-phosphate labeled ribonucleotides were purchased from alternative commer-
cial sources. Using thin-layer chromatography (TLC), the extent of hydrolysis of
these ribonucleotides by E. coli RNA polymerase was measured, following in vitro
transcription reactions. Preliminary data show that none of the five γ-phosphate
labeled ribonucleotides could be hydrolyzed by E. coli RNA polymerase.
Materials and Methods
Materials
E. coli RNA polymerase core enzyme and Kool NC-45 Universal RNA Polymerase
Template were purchased from Epicentre Biotechnologies (Madison, WI); ATP-hexa-
pentaphosphate, GTP-hexapentaphosphate, and CTP-hexapentaphosphate were pro-
vided by Pacific Biosciences (Menlo Park, CA); γ-[6-Aminohexyl]-ATP-Cy3 from Jena
Biosciences (Jena, Germany); Guanosine 5’-O-(3-thiotriphosphate)BODIPY FL were
purchased from Invitrogen Molecular Probes (Eugene, OR); and Crotalus adamanteus
Phosphodiesterase I from United States Biochemical (Cleveland, OH). TLC plates
and all other chemicals and reagents were purchased from Sigma-Aldrich (St. Louis,
MO).
In vitro Transcription Assays
E. coli core enzyme (0.1 U/µl) was mixed with Kool NC-45 Universal RNA Poly-
merase Template (50 nM), unlabeled ATP, GTP, CTP, and TTP (1 mM each),
dithiothreitol (DTT) (5 mM), MnCl2 (10 mM), and pyrophosphatase (0.01 U/µl) in
transcription buffer (40 mM Tris-HCl, pH 7.5, 150 mM KCl, 10 mM MgCl2, and
0.01 % Triton-X-100). One of the following γ-phosphate labeled ribonucleotides were
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added to a final concentration of 10 µM: (1) ATP-hexapentaphosphate; (2) GTP-
hexapentaphosphate; (3) CTP-hexapentaphosphate; (4) γ-[6-Aminohexyl]-ATP-Cy3;
or (5) Guanosine 5’-O-(3-thiotriphosphate)BODIPY FL. The reaction mixture was
then incubated at 37 ◦C for 3 h. At this point, transcription was halted by the addition
of EDTA to a final concentration of 18 mM.
In vitro Phosphodiesterase Hydrolysis Assays
C. adamanteus Phosphodiesterase I (PDE) was mixed with either: (1) ATP-
hexapentaphosphate; (2) GTP-hexapentaphosphate; (3) CTP-hexapentaphosphate;
(4) γ-[6-Aminohexyl]-ATP-Cy3; or (5) Guanosine 5’-O-(3-thiotriphosphate)BODIPY
FL in PDE reaction buffer (100 mM Tris-HCl, pH 8.9, 100 mM NaCl, and 14 mM
MgCl2). The reaction mixture was then incubated at room temperature for 5 min.
At this point, the hydrolysis reaction was halted by placing the mixture on ice.
Thin-Layer Chromatography (TLC)
Transcription or PDE reaction samples were diluted 1:100 in either transcrip-
tion buffer or PDE reaction buffer, respectively. 0.5 µl of each sample was spotted
onto silica plastic-backed TLC plates containing no fluorescent indicator. The follow-
ing eluent mixture was used, freshly prepared each time (modified from Draganescu
et al.123): 33:33:14:20 of 2-propanol:NH4OH:1,4-dioxane:H2O. Samples were visual-
ized using a Typhoon Scanner (GE Healthcare Life Sciences; Pittsburgh, PA) in
fluorescence mode, using the following excitation/emission combinations for each γ-
phosphate labeled ribonucleotide: (1) 633 nm/670bp30 nm for ATP-hexapentaphos-
phate and CTP-hexapentaphosphate; (2) 532 nm/580bp40 nm for γ-[6-Aminohexyl]-




E. coli RNA Polymerase Does Not Hydrolyze γ-Phosphate Labeled Ri-
bonucleotides
As a first step towards developing a transcription assay capable of real-time, single-
nucleotide resolution using zero-mode waveguide (ZMW) technology, a γ-phosphate
labeled ribonucleotide was sought that could be cleaved by E. coli RNA polymerase
in vitro. For these experiments, five different labeled ribonucleotides were used: (1)
ATP-hexapentaphosphate (FL-ATP); (2) GTP-hexapentaphosphate (FL-GTP); (3)
CTP-hexapentaphosphate (FL-CTP); (4) γ-[6-Aminohexyl]-ATP-Cy3 (Cy3-ATP); and
(5) Guanosine 5’-O-(3-thiotriphosphate)BODIPY FL (GpppBODIPY) (Figure C.1).
Inspired by the methods of Draganescu et al., the hydrolysis efficiency of these
γ-phosphate labeled ribonucleotides by E. coli RNA polymerase was measured using
thin-layer chromatography (TLC).123 In this previous study, the authors used TLC to
monitor the hydrolysis of GpppBODIPY by the polyphosphatase Fhit. As a positive
control, hydrolysis assays using the C. adamanteus phosphodiesterase, which is known
to efficiently hydrolyze GpppBODIPY,124 were run in parallel to all transcription
reactions.
All transcription reactions (Tx+) were run with a transcription negative control
which contained no polymerase (Tx-), a PDE positive control (Px+), and a PDE
negative control, which contained no PDE (Px-), where “x” denotes the number of
labeled ribonucleotide used. The ribonucleotides were numbered as follows: (1) FL-
ATP; (2) FL-GTP; (3) FL-CTP; (4) Cy3-ATP; and (5) GpppBODIPY. Figure C.2
shows TLC plates for all five labeled ribonucleotides. Figures C.2a-c demonstrate
positive ribonucleotide hydrolysis by PDE for ribonucleotides 1-3. For the transcrip-
tion reactions, there is no noticeable difference in the enzyme positive and enzyme




Figure C.1: Chemical structures of γ-[6-Aminohexyl]-ATP-Cy3 (Cy3-ATP) shown on
top and Guanosine 5’-O-(3-thiotriphosphate)BODIPY FL (GpppBOD-
IPY) shown on bottom. Chemical structures of the other three labeled




P1+ P1- T1+ T1- P2+ P2- T2-T2+
T3-T3+P3-P3+ T4+ T4- T5+ T5-
Figure C.2: Cleaved and uncleaved γ-phosphate labeled ribonucleotides separated by
TLC. Samples labeled “P” are run in PDE reaction buffer, samples la-
beled “T” in transcription buffer. Samples labeled “+” include either
PDE or E. coli RNA polymerase, respective of which buffer they were
run in, samples labeled “-” do not include enzyme. γ-phosphate labeled
ribonucleotides are numbered as follows: (1) FL-ATP (a); (2) FL-GTP
(b); (3) FL-CTP (c); (4) Cy3-ATP (d); and (5) GpppBODIPY (e).
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Conclusions
From the TLC separations, it does not appear that E. coli RNA polymerase is
able to hydrolyze any of the five γ-phosphate labeled ribonucleotides used in this
study. Future work should be performed to develop such a sensitive transcription
assay, considering such options as: (1) future optimization of transcription conditions
for hydrolysis of γ-phosphate labeled ribonucleotides by E. coli RNA polymerase; (2)
use of a RNA polymerase from another organism; (3) mutation of RNA polymerase
to better accommodate modified ribonucleotides; or (4) an alternative strategy not
utilizing γ-phosphate labeled ribonucleotides.
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APPENDIX D
MATLAB Code for Quantification of Microtubule
Bundling from TEM Images
% The purpose of this script is to measure microtubule length and diameter from
% TEM images in order to estimate the degree of microtubule bundling in a
% sample.
% The diameter of a microtubule in a user-selected ROI is measured
% at n (sep) pixel intervals. Parameter ’sep’ is defined on line 93. The
% diameter of a unbundled microtubule is pre-defined as the mean of an
% unbundled population within 2 standard deviations (can re-define on line
% 137). This diameter range is assigned a weight of 1. Higher weights,
% representing bundles of microtubules containing x microtubules, are
% assigned as multiples of the 1st diameter range.
% Input is a JPEG image. Output is the array length = [unbundlength
% bundlength totlength]. These parameters represent the total measured





% Read in a JPEG image




im grayscale = rgb2gray(im);
im complement = imcomplement(im grayscale);
% First, morphologically open then adjust contrast of image to correct for
%”dye shadowing” around MT edges (decrease the maximum display value).
%Adjust maxdisp until shadowing can no longer be seen. Adjust mindisp until
%MT object appears solid. Values for mindisp & maxdisp must be between
%[0.0 1.0].
% SE = strel(’ball’,25,25,0);
% bkgnd = imopen(im complement,SE);




con adj im = imadjust(im complement,[mindisp maxdisp],[0 1]);
imshow(con adj im,’InitialMagnification’,25), title(’Contrast Adj’);
s=1;
while s == 1
145
strResponse = input(’Adjust contrast? (y/n)’,’s’);
if strResponse == ’y’
maxdisp = input(’Maxdisp?’);
mindisp = input(’Mindisp?’);
con adj im = imadjust(im complement,[mindisp maxdisp],[0 1]);
imshow(con adj im,’InitialMagnification’,25), title(’Contrast Adj’);
else s = 0;
end
end
% Create a binary version of the image
level = graythresh(con adj im);
bw = im2bw(con adj im,level);
bw comp = imcomplement(bw); imshow(bw comp,’InitialMagnification’,25), title(’Binary’);
% Morphologically transform image so that MTs are solid objects in the bw
% image.
SE = strel(’square’,10);
closed im = imclose(bw comp,SE);
spursgone = bwmorph(closed im,’spur’,10);
imshow(spursgone,’InitialMagnification’,25), title(’Closed’);
%Remove objects that are not MTs
MTs only = bwareaopen(spursgone,10000);
imshow(MTs only,’InitialMagnification’,25),title(’MTs only’);
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%Loop remainder of program until all microtubule sections analyzed.
s = 1;
while s == 1
close all;
%Crop out MT section to be analyzed
disp(’Crop out MT section to be analyzed. Enter when done.’)
cropped = imcrop(MTs only);
disp(’Select MT section to be analyzed. Enter when done.’)
MT = bwselect(cropped);
%Align x axis of MT section with major axis of MT section
d = diameter(MT);
[aligned,∼] = x2majoraxis(d.MajorAxis, MT);
imshow(aligned,’InitialMagnification’,25), title(’Aligned to MajorAxis’);
r=1;
while r == 1
strResponse = input(’Rotate an additional 45 deg cw? (y/n)’,’s’);
if strResponse == ’y’
aligned = imrotate(aligned,-45);










% Subsample boundary, i.e. select points on boundary that are seperated by
% n (sep) pixels, for all MTs, using self-written functions.
sep = 10; MT boundary = B1;
subsampbound = MT boundary(1:sep:length(MT boundary),:);
subsampboundim = bound2im(subsampbound,size(boundim,1),size(boundim,2));
figure, imshow(subsampboundim,’InitialMagnification’,25), title(’Subsampled Bound-
ary’);
%Crop out long edges of MT, so that ends are not included
disp(’Crop out MT section, excluding edges. Double-click to finish.’)
cropped2 = imcrop(subsampboundim);
% Calculate diameter at uniform pixel intervals along the diameter. Pixel
% interval determined by variable ”sep” defined above.
s = size(subsampbound);
h = round(s(1)/2);








% Calculate mean of unbundled MT diameter & remove outliers due to errors
% in measurement routine (these outliers can occur at the MT tip or at
% locations of staining artifacts).
% Define outliers as data points which are further than 2 standard
% deviations from the mean.
mu = mean(dia);
sig = std(dia);




% Calculate diameter weights, based on mean diameter of single, unbundled
% MTs.
w1 = 32.95685423; wts = zeros(s(1),1);
for i = 1:s(1)
if dia(i,1) ≤ w1,
wts(i,1) = 1;
elseif dia(i,1) ≤ 2*w1,
wts(i,1) = 2;
elseif dia(i,1) ≤ 3*w1,
wts(i,1) = 3;
elseif dia(i,1) ≤ 4*w1,
wts(i,1) = 4;
elseif dia(i,1) ≤ 5*w1,
wts(i,1) = 5;
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elseif dia(i,1) ≤ 6*w1,
wts(i,1) = 6;
elseif dia(i,1) ≤ 7*w1,
wts(i,1) = 7;
elseif dia(i,1) ≤ 8*w1,
wts(i,1) = 8;
elseif dia(i,1) ≤ 9*w1,
wts(i,1) = 9;
elseif dia(i,1) ≤ 10*w1,
wts(i,1) = 10;
elseif dia(i,1) ≤ 11*w1,
wts(i,1) = 11;
elseif dia(i,1) ≤ 12*w1,
wts(i,1) = 12;
elseif dia(i,1) ≤ 13*w1,
wts(i,1) = 13;
elseif dia(i,1) ≤ 14*w1,
wts(i,1) = 14;
elseif dia(i,1) ≤ 15*w1,
wts(i,1) = 15;
elseif dia(i,1) ≤ 16*w1,
wts(i,1) = 16;
elseif dia(i,1) ≤ 17*w1,
wts(i,1) = 17;
elseif dia(i,1) ≤ 18*w1,
wts(i,1) = 18;
elseif dia(i,1) ≤ 19*w1,
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wts(i,1) = 19;
elseif dia(i,1) ≤ 20*w1,
wts(i,1) = 20;
elseif dia(i,1) ≤ 21*w1,
wts(i,1) = 21;
elseif dia(i,1) ≤ 22*w1,
wts(i,1) = 22;
elseif dia(i,1) ≤ 23*w1,
wts(i,1) = 23;
elseif dia(i,1) ≤ 24*w1,
wts(i,1) = 24;
elseif dia(i,1) ≤ 25*w1,
wts(i,1) = 25;
elseif dia(i,1) ≤ 26*w1,
wts(i,1) = 26;
elseif dia(i,1) ≤ 27*w1,
wts(i,1) = 27;
elseif dia(i,1) ≤ 28*w1,
wts(i,1) = 28;
elseif dia(i,1) ≤ 29*w1,
wts(i,1) = 29;
elseif dia(i,1) ≤ 30*w1,
wts(i,1) = 30;




% Calculate weighted bundled & unbundled length, in pixels.
totwtlength = sum(sep*wts);
undia = zeros(s(1),1); for i = 1:s(1),







bundlength = totwtlength - unbundlength;
totlength = length(wts)*sep;
lengths = [unbundlength bundlength totlength];
findr = input(’Do you want to analyze another MT? (y/n)’,’s’);








MATLAB Code for Quantification of Microtubule
Bundling from TIRFM Images
%This script takes multiple lines scans at a set pixel interval across the
%x-dimension of a rectangular ROI, which the user has defined to include a
%single microtubule. These lines scans are then fit with Gaussian functions
%to find the axis of the microtubule. The axis is then used to rotate the
%image so that the x-axis is aligned with the microtubule axis. Line scans
%are then taken again and fit with Gaussians which are then integrated to
%determine the total cross-sectional fluorescence intensity.
%Input in TIFF image (image file name on line 22).
%Output is matrix ”MT stats”, see script for details.




%User-defined parameters; to be inputted before running script.
px = 5; %Input desired pixel interval between line scans
r2 = 0.80; %R2 threshold for acceptance of Gaussian fits when determining MT axis
endpts
res = 0.267; %Resolution of image in um/px
w1 = 1.899962; %mean diameter of 20 single MTs minus 1 standard deviation
range = 1.61836; %2*SD
imagename = ’110105 MTs 3fM 80nmPAANPs 600ms 488 3.tif’;
frame = 1;
%Read in a TIFF image; index = frame #
im = imread(imagename,’Index’,frame);
%Crop to only include MT(TMR/Cy3) channel.
MTchannel = imcrop(im,[257 1 255 255]);
%Correct non-uniform background with morphological opening; structuring




bkgndcorrected = imadjust(MTchannel - bkgnd);
J = imadjust(bkgndcorrected,[0.4;1.0],[0;1.0]);









%If the MT is mostly vertical, it will be rotated 90 deg.
disp(’Crop out MT section to be analyzed. Press enter when done.’)
MTcrop = imcrop(J,pos);








%Number of line scans taken
num ls = floor(width/px);
%120601 Take line scans at ’px’ pixel intervals along the x-axis of the
%cropped image
%120618 Determine points of MT axis by fitting intensity vectors with
%Gaussian functions
cx = zeros(height-1,num ls);
cy = zeros(height-1,num ls);
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c = zeros(height-1,num ls);
MTaxis = zeros(num ls,2);
for n = 1:num ls
[cx(:,n),cy(:,n),c(:,n)] = improfile(MTcrop,[(5*n)-4 (5*n)-4],[1 height-1]);
[gaussfit,gof] = fit(cy(:,n),c(:,n),’gauss1’);





%Determine endpts of MT axis
for n = 1:num ls
if all(MTaxis(n,:))== 1




MTaxis flipped = flipud(MTaxis);
for n = 1:num ls
if all(MTaxis flipped(n,:))== 1





%Rotate image so that MT axis aligns with x-axis of image.






%Number of line scans to take for image of rotated MT
num ls 2 = floor(width/px);
%Take line scans of the rotated MT, again at ’px’ pixel intervals along the
%x-axis.
%120618 Normalize intensity matrix c 2 to c 2 norm. Normalize by highest
%intensity possible for # bits in image.
%Fit Gaussian functions to each line scan. Store the xmin, ymin, width, and
%height of the original, user selected ROI into columns 1-4, respectively,
%of the matrix,MT stats. Store the R2, mean, standard error, and area
%under curve of the 2nd round of Gaussian fits in columns 5-8,
%respectively, of MT stats.
info = imfinfo(imagename);
bits = info.BitsPerSample;
int max = (2∧bits)-1;
cx 2 = zeros(height-1,num ls 2-1);
cy 2 = zeros(height-1,num ls 2-1);
c 2 = zeros(height-1,num ls 2-1);
MT stats = zeros(num ls 2-1,9);
157
MT stats(1,1:4) = [pos(1) pos(2) pos(3) pos(4)];
for i = 1:2
for n = 2:num ls 2
[cx 2(:,n),cy 2(:,n),c 2(:,n)] = improfile(MTrotate,[(5*n)-4 (5*n)-4],[1 height-1]);
c 2 norm = c 2/int max;
[gaussfit,gof] = fit(cy 2(:,n),c 2 norm(:,n),’gauss1’);
int = integrate(gaussfit,cx 2(1,:),cx 2(1,1));
area = int(num ls 2-1)-int(1);
% Calculate diameter weights, based on mean diameter of single, unbundled
% MTs.
if area ≤ w1,
wt = 0;
elseif area ≤ range+w1,
wt = 1;
elseif area ≤ (2*range)+w1,
wt = 2;
elseif area ≤ (3*range)+w1,
wt = 3;
elseif area ≤ (4*range)+w1,
wt = 4;
elseif area ≤ (5*range)+w1,
wt = 5;
elseif area ≤ (6*range)+w1,
wt = 6;
elseif area ≤ (7*range)+w1,
wt = 7;
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elseif area ≤ (8*range)+w1,
wt = 8;
elseif area ≤ (9*range)+w1,
wt = 9;
elseif area ≤ (10*range)+w1,
wt = 10;
elseif area ≤ (11*range)+w1,
wt = 11;
elseif area ≤ (12*range)+w1,
wt = 12;
elseif area ≤ (13*range)+w1,
wt = 13;
elseif area ≤ (14*range)+w1,
wt = 14;
elseif area ≤ (15*range)+w1,
wt = 15;
elseif area ≤ (16*range)+w1,
wt = 16;
elseif area ≤ (17*range)+w1,
wt = 17;
elseif area ≤ (18*range)+w1,
wt = 18;
elseif area ≤ (19*range)+w1,
wt = 19;
elseif area ≤ (20*range)+w1,
wt = 20;
elseif area ≤ (21*range)+w1,
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wt = 21;
elseif area ≤ (22*range)+w1,
wt = 22;
elseif area ≤ (23*range)+w1,
wt = 23;
elseif area ≤ (24*range)+w1,
wt = 24;
elseif area ≤ (25*range)+w1,
wt = 25;
elseif area ≤ (26*range)+w1,
wt = 26;
elseif area ≤ (27*range)+w1,
wt = 27;
elseif area ≤ (28*range)+w1,
wt = 28;
elseif area ≤ (29*range)+w1,
wt = 29;
else disp(’Need to create another weight level’)
end
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